# ESC Guidelines: Hypertension (2024)

**Source**: `2024_Hypertension.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 107

---

## Table of Contents

- [2024 ESC Guidelines for the management of elevated blood pressure and hypertension](#2024-esc-guidelines-for-the-management-of-elevated) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 9)*
  - [3. Pathophysiology of elevated blood pressure and hypertension](#3-pathophysiology-of-elevated-blood-pressure-and-h) *(p. 17)*
  - [4. Clinical consequences of elevated blood pressure and hypertension](#4-clinical-consequences-of-elevated-blood-pressure) *(p. 17)*
  - [5. Measuring blood pressure](#5-measuring-blood-pressure) *(p. 18)*
    - [5.1. Introduction and pertinent definitions](#51-introduction-and-pertinent-definitions) *(p. 18)*
    - [5.2. Practical recommendations for measuring blood pressure](#52-practical-recommendations-for-measuring-blood-p) *(p. 19)*
      - [5.2.1. Clinical validation of equipment for measuring blood pressure](#521-clinical-validation-of-equipment-for-measuring) *(p. 19)*
      - [5.2.2. Office blood pressure measurement](#522-office-blood-pressure-measurement) *(p. 19)*
      - [5.2.3. Home blood pressure measurement](#523-home-blood-pressure-measurement) *(p. 20)*
      - [5.2.4. Ambulatory blood pressure measurement](#524-ambulatory-blood-pressure-measurement) *(p. 22)*
      - [5.2.5. Comparison of home and ambulatory blood pressure monitoring](#525-comparison-of-home-and-ambulatory-blood-pressu) *(p. 23)*
    - [5.3. What is the best method for measuring blood pressure to diagnose hypertension?](#53-what-is-the-best-method-for-measuring-blood-pre) *(p. 23)*
      - [5.3.1. Blood pressure measurement for hypertension screening](#531-blood-pressure-measurement-for-hypertension-sc) *(p. 23)*
      - [5.3.2. Blood pressure measurement for diagnosing hypertension](#532-blood-pressure-measurement-for-diagnosing-hype) *(p. 23)*
    - [5.4. What is the best method for measuring blood pressure for long-term management of hypertension?](#54-what-is-the-best-method-for-measuring-blood-pre) *(p. 23)*
      - [5.4.1. Home monitoring](#541-home-monitoring) *(p. 23)*
      - [5.4.2. Ambulatory monitoring](#542-ambulatory-monitoring) *(p. 23)*
    - [5.5. Measuring blood pressure in selected groups](#55-measuring-blood-pressure-in-selected-groups) *(p. 24)*
      - [5.5.1. Pregnancy](#551-pregnancy) *(p. 24)*
      - [5.5.2. Atrial fibrillation](#552-atrial-fibrillation) *(p. 24)*
      - [5.5.3. Orthostatic hypotension](#553-orthostatic-hypotension) *(p. 24)*
    - [5.6. Novel methods of measuring blood pressure](#56-novel-methods-of-measuring-blood-pressure) *(p. 24)*
  - [6. Definition and classification of elevated blood pressure and hypertension, and cardiovascular disease risk assessment](#6-definition-and-classification-of-elevated-blood-) *(p. 25)*
    - [6.1. Definition and classification of elevated blood pressure and hypertension](#61-definition-and-classification-of-elevated-blood) *(p. 25)*
    - [6.2. Principles of a risk-based approach for managing blood pressure and preventing cardiovascular disease](#62-principles-of-a-risk-based-approach-for-managin) *(p. 25)*
      - [6.2.1. Role of cardiovascular disease risk assessment](#621-role-of-cardiovascular-disease-risk-assessment) *(p. 25)*
    - [6.3. Predicting cardiovascular disease risk](#63-predicting-cardiovascular-disease-risk) *(p. 26)*
      - [6.3.1. 10-year cardiovascular disease risk-prediction models](#631-10-year-cardiovascular-disease-risk-prediction) *(p. 27)*
    - [6.4. Refining cardiovascular disease risk estimation beyond risk models](#64-refining-cardiovascular-disease-risk-estimation) *(p. 28)*
      - [6.4.1. Sex-specific non-traditional cardiovascular disease risk modifiers](#641-sex-specific-non-traditional-cardiovascular-di) *(p. 28)*
      - [6.4.2. Non-traditional cardiovascular disease risk modifiers shared by men and women](#642-non-traditional-cardiovascular-disease-risk-mo) *(p. 29)*
      - [6.4.3. Additional risk decision tests](#643-additional-risk-decision-tests) *(p. 30)*
    - [6.5. Summary of the cardiovascular disease risk stratification approach for allocating blood pressure treatment](#65-summary-of-the-cardiovascular-disease-risk-stra) *(p. 30)*
  - [7. Diagnosing hypertension and investigating underlying causes](#7-diagnosing-hypertension-and-investigating-underl) *(p. 32)*
    - [7.1. Screening for hypertension](#71-screening-for-hypertension) *(p. 32)*
    - [7.2. Confirming the diagnosis of hypertension](#72-confirming-the-diagnosis-of-hypertension) *(p. 32)*
    - [7.3. Communicating the diagnosis](#73-communicating-the-diagnosis) *(p. 33)*
    - [7.4. Baseline assessment and diagnostic approach](#74-baseline-assessment-and-diagnostic-approach) *(p. 33)*
      - [7.4.1. Medical history, medication history, and physical examination](#741-medical-history,-medication-history,-and-physi) *(p. 33)*
      - [7.4.2. Drug adherence and persistence with treatment](#742-drug-adherence-and-persistence-with-treatment) *(p. 34)*
      - [7.4.3. Routine and optional tests](#743-routine-and-optional-tests) *(p. 34)*
        - [7.4.3.1. The kidneys](#7431-the-kidneys) *(p. 36)*
        - [7.4.3.2. The heart](#7432-the-heart) *(p. 36)*
        - [7.4.3.3. The arteries](#7433-the-arteries) *(p. 37)*
      - [7.4.4. Genetic testing](#744-genetic-testing) *(p. 37)*
    - [7.5. Resistant hypertension: definition and diagnosis](#75-resistant-hypertension:-definition-and-diagnosi) *(p. 37)*
    - [7.6. Secondary hypertension: when to screen/further investigations](#76-secondary-hypertension:-when-to-screen/further-) *(p. 39)*
      - [7.6.1. General considerations](#761-general-considerations) *(p. 39)*
      - [7.6.2. Primary aldosteronism](#762-primary-aldosteronism) *(p. 39)*
      - [7.6.3. Renovascular hypertension](#763-renovascular-hypertension) *(p. 40)*
      - [7.6.4. Obstructive sleep apnoea syndrome](#764-obstructive-sleep-apnoea-syndrome) *(p. 40)*
      - [7.6.5. Phaeochromocytoma/paraganglioma](#765-phaeochromocytoma/paraganglioma) *(p. 43)*
  - [8. Preventing and treating elevated blood pressure and hypertension](#8-preventing-and-treating-elevated-blood-pressure-) *(p. 43)*
    - [8.1. Prevention strategies in early life](#81-prevention-strategies-in-early-life) *(p. 43)*
    - [8.2. Non-pharmacological interventions](#82-non-pharmacological-interventions) *(p. 43)*
      - [8.2.1. Dietary sodium and potassium intake](#821-dietary-sodium-and-potassium-intake) *(p. 43)*
        - [8.2.1.1. Sodium](#8211-sodium) *(p. 43)*
        - [8.2.1.2. Potassium](#8212-potassium) *(p. 44)*
      - [8.2.2. Physical activity and exercise](#822-physical-activity-and-exercise) *(p. 45)*
      - [8.2.3. Weight reduction and diet](#823-weight-reduction-and-diet) *(p. 46)*
      - [8.2.4. Alcohol, coffee, and soft drinks](#824-alcohol,-coffee,-and-soft-drinks) *(p. 46)*
      - [8.2.5. Smoking](#825-smoking) *(p. 46)*
    - [8.3. Pharmacological interventions](#83-pharmacological-interventions) *(p. 47)*
      - [8.3.1. Treatment strategy to reduce adverse cardiovascular disease outcomes](#831-treatment-strategy-to-reduce-adverse-cardiovas) *(p. 47)*
      - [8.3.2. Drug classes with evidence on clinical outcomes in the target population](#832-drug-classes-with-evidence-on-clinical-outcome) *(p. 47)*
      - [8.3.3. New therapies with blood pressure-lowering properties that await supportive evidence from cardiovascular outcomes trials prior to guideline endorsement and routine use in hypertension](#833-new-therapies-with-blood-pressure-lowering-pro) *(p. 48)*
      - [8.3.4. Drug combinations and up-titrating strategies](#834-drug-combinations-and-up-titrating-strategies) *(p. 48)*
      - [8.3.5. A practical algorithm for intensive, effective, and tolerable blood pressure lowering with drug therapy, including considerations around single-pill combinations](#835-a-practical-algorithm-for-intensive,-effective) *(p. 48)*
      - [8.3.6. Timing of blood pressure-lowering drug treatment](#836-timing-of-blood-pressure-lowering-drug-treatme) *(p. 51)*
    - [8.4. Selecting patients for pharmacological blood pressure-lowering treatment](#84-selecting-patients-for-pharmacological-blood-pr) *(p. 51)*
    - [8.5. Intensity of blood pressure-lowering therapy and ideal treatment targets](#85-intensity-of-blood-pressure-lowering-therapy-an) *(p. 53)*
      - [8.5.1. Expected degree of blood pressure reduction with approved drugs](#851-expected-degree-of-blood-pressure-reduction-wi) *(p. 53)*
      - [8.5.2. The ideal target of blood pressure-lowering treatment](#852-the-ideal-target-of-blood-pressure-lowering-tr) *(p. 53)*
      - [8.5.3. Personalizing treatment strategies](#853-personalizing-treatment-strategies) *(p. 54)*
      - [8.5.4. Duration and monitoring of drug therapy](#854-duration-and-monitoring-of-drug-therapy) *(p. 55)*
    - [8.6. Device-based blood pressure lowering](#86-device-based-blood-pressure-lowering) *(p. 55)*
      - [8.6.1. Catheter-based renal denervation](#861-catheter-based-renal-denervation) *(p. 55)*
      - [8.6.2. Other devices](#862-other-devices) *(p. 57)*
    - [8.7. Unintended and potentially harmful consequences of blood pressure lowering and implications for treatment targets](#87-unintended-and-potentially-harmful-consequences) *(p. 57)*
      - [8.7.1. Adverse effects of blood pressure-lowering medications](#871-adverse-effects-of-blood-pressure-lowering-med) *(p. 57)*
        - [8.7.1.1. Symptomatic adverse effects](#8711-symptomatic-adverse-effects) *(p. 57)*
        - [8.7.1.2. Renal effects](#8712-renal-effects) *(p. 57)*
        - [8.7.1.3. Erectile dysfunction](#8713-erectile-dysfunction) *(p. 57)*
      - [8.7.2. Pill burden and non-adherence](#872-pill-burden-and-non-adherence) *(p. 57)*
      - [8.7.3. Potentially harmful consequences of blood pressure lowering for frail older people](#873-potentially-harmful-consequences-of-blood-pres) *(p. 57)*
      - [8.7.4. Clinical inertia in blood pressure lowering](#874-clinical-inertia-in-blood-pressure-lowering) *(p. 57)*
  - [9. Managing specific patient groups or circumstances](#9-managing-specific-patient-groups-or-circumstance) *(p. 58)*
    - [9.1. Young adulthood (18–40 years)](#91-young-adulthood-(18–40 years)) *(p. 58)*
      - [9.1.1. Definition and epidemiology](#911-definition-and-epidemiology) *(p. 58)*
      - [9.1.2. Secondary hypertension in young adulthood](#912-secondary-hypertension-in-young-adulthood) *(p. 58)*
      - [9.1.3. Measurement and management of blood pressure in young adults](#913-measurement-and-management-of-blood-pressure-i) *(p. 58)*
    - [9.2. Pregnancy](#92-pregnancy) *(p. 58)*
      - [9.2.1. Definition and epidemiology](#921-definition-and-epidemiology) *(p. 58)*
      - [9.2.2. Classifying hypertension in pregnancy](#922-classifying-hypertension-in-pregnancy) *(p. 58)*
      - [9.2.3. Measuring blood pressure in pregnancy](#923-measuring-blood-pressure-in-pregnancy) *(p. 59)*
      - [9.2.4. Investigating hypertension in pregnancy](#924-investigating-hypertension-in-pregnancy) *(p. 59)*
      - [9.2.5. Preventing hypertension and pre-eclampsia](#925-preventing-hypertension-and-pre-eclampsia) *(p. 59)*
      - [9.2.6. Treatment initiation and blood pressure targets](#926-treatment-initiation-and-blood-pressure-target) *(p. 59)*
      - [9.2.7. Managing mild hypertension in pregnancy (office blood pressure 140–159/90–109 mmHg)](#927-managing-mild-hypertension-in-pregnancy-(offic) *(p. 59)*
      - [9.2.8. Managing severe hypertension in pregnancy (≫160/110 mmHg)](#928-managing-severe-hypertension-in-pregnancy-(≫16) *(p. 60)*
      - [9.2.9. Managing blood pressure post-partum](#929-managing-blood-pressure-post-partum) *(p. 60)*
      - [9.2.10. Risk of recurrence of hypertensive disorders in a subsequent pregnancy](#9210-risk-of-recurrence-of-hypertensive-disorders-) *(p. 60)*
    - [9.3. Very old age (≧85 years), frailty, multimorbidity, and polypharmacy](#93-very-old-age-(≧85 years),-frailty,-multimorbidi) *(p. 60)*
      - [9.3.1. Definition of frailty](#931-definition-of-frailty) *(p. 60)*
      - [9.3.2. Randomized controlled trials of blood pressure lowering in frail older patients](#932-randomized-controlled-trials-of-blood-pressure) *(p. 61)*
      - [9.3.3. Starting blood pressure-lowering treatment in very old or frail patients](#933-starting-blood-pressure-lowering-treatment-in-) *(p. 62)*
      - [9.3.4. Maintaining blood pressure lowering in very old or frail patients](#934-maintaining-blood-pressure-lowering-in-very-ol) *(p. 62)*
    - [9.4. Isolated systolic and diastolic hypertension](#94-isolated-systolic-and-diastolic-hypertension) *(p. 62)*
      - [9.4.1. Definition of isolated systolic hypertension](#941-definition-of-isolated-systolic-hypertension) *(p. 62)*
      - [9.4.2. Isolated systolic hypertension, risk factors, and ageing](#942-isolated-systolic-hypertension,-risk-factors,-) *(p. 62)*
      - [9.4.3. Isolated systolic hypertension in young adults](#943-isolated-systolic-hypertension-in-young-adults) *(p. 63)*
      - [9.4.4. Isolated diastolic hypertension](#944-isolated-diastolic-hypertension) *(p. 63)*
    - [9.5. Orthostatic hypotension with supine hypertension](#95-orthostatic-hypotension-with-supine-hypertensio) *(p. 63)*
    - [9.6. Diabetes](#96-diabetes) *(p. 64)*
      - [9.6.1. Diabetes and elevated blood pressure/hypertension](#961-diabetes-and-elevated-blood-pressure/hypertens) *(p. 64)*
      - [9.6.2. J-shaped curve of blood pressure and risk of cardiovascular disease in patients with diabetes](#962-j-shaped-curve-of-blood-pressure-and-risk-of-c) *(p. 64)*
      - [9.6.3. Managing blood pressure in diabetes](#963-managing-blood-pressure-in-diabetes) *(p. 64)*
    - [9.7. Chronic kidney disease](#97-chronic-kidney-disease) *(p. 64)*
      - [9.7.1. Relationship between hypertension and chronic kidney disease](#971-relationship-between-hypertension-and-chronic-) *(p. 64)*
      - [9.7.2. Blood pressure lowering in chronic kidney disease](#972-blood-pressure-lowering-in-chronic-kidney-dise) *(p. 65)*
      - [9.7.3. Managing blood pressure in chronic kidney disease](#973-managing-blood-pressure-in-chronic-kidney-dise) *(p. 65)*
      - [9.7.4. Blood pressure targets in chronic kidney disease](#974-blood-pressure-targets-in-chronic-kidney-disea) *(p. 65)*
    - [9.8. Cardiac disease](#98-cardiac-disease) *(p. 65)*
      - [9.8.1. Blood pressure thresholds and targets in patients with cardiac disease](#981-blood-pressure-thresholds-and-targets-in-patie) *(p. 65)*
      - [9.8.2. Coronary artery disease with particular reference to the blood pressure J-curve](#982-coronary-artery-disease-with-particular-refere) *(p. 66)*
      - [9.8.3. Valvular heart disease](#983-valvular-heart-disease) *(p. 66)*
      - [9.8.4. Heart failure](#984-heart-failure) *(p. 66)*
      - [9.8.5. Heart rhythm disease (including AF)](#985-heart-rhythm-disease-(including-af)) *(p. 67)*
    - [9.9. Chronic cerebrovascular disease and/or cognitive impairment](#99-chronic-cerebrovascular-disease-and/or-cogniti) *(p. 67)*
      - [9.9.1. Role of hypertension in chronic cerebrovascular disease](#991-role-of-hypertension-in-chronic-cerebrovascula) *(p. 67)*
      - [9.9.2. Treatment in patients with history of prior stroke or transient ischaemic attack](#992-treatment-in-patients-with-history-of-prior-st) *(p. 67)*
      - [9.9.3. Treatment in patients with chronic cerebrovascular disease and cognitive impairment](#993-treatment-in-patients-with-chronic-cerebrovasc) *(p. 67)*
    - [9.10. Aortopathy](#910-aortopathy) *(p. 68)*
      - [9.10.1. Coarctation of the aorta](#9101-coarctation-of-the-aorta) *(p. 68)*
      - [9.10.2. Bicuspid aortic valve-related aortopathy](#9102-bicuspid-aortic-valve-related-aortopathy) *(p. 68)*
      - [9.10.3. Preventing aortic dilation and dissection in high-risk patients](#9103-preventing-aortic-dilation-and-dissection-in-) *(p. 68)*
    - [9.11. Different ethnic groups](#911-different-ethnic-groups) *(p. 68)*
    - [9.12. Nocturnal hypertension](#912-nocturnal-hypertension) *(p. 68)*
      - [9.12.1. Definition](#9121-definition) *(p. 68)*
      - [9.12.2. Epidemiology](#9122-epidemiology) *(p. 69)*
      - [9.12.3. Night-time blood pressure as a cardiovascular disease risk factor](#9123-night-time-blood-pressure-as-a-cardiovascular) *(p. 69)*
      - [9.12.4. Treatment of nocturnal hypertension](#9124-treatment-of-nocturnal-hypertension) *(p. 69)*
    - [9.13. Resistant hypertension](#913-resistant-hypertension) *(p. 69)*
      - [9.13.1. Definition of resistant hypertension](#9131-definition-of-resistant-hypertension) *(p. 69)*
      - [9.13.2. Non-pharmacological interventions](#9132-non-pharmacological-interventions) *(p. 69)*
      - [9.13.3. Pharmacological interventions](#9133-pharmacological-interventions) *(p. 69)*
      - [9.13.4. Devices for blood pressure lowering](#9134-devices-for-blood-pressure-lowering) *(p. 70)*
    - [9.14. Management of specific causes of secondary hypertension](#914-management-of-specific-causes-of-secondary-hyp) *(p. 71)*
      - [9.14.1. General considerations](#9141-general-considerations) *(p. 71)*
      - [9.14.2. Primary aldosteronism](#9142-primary-aldosteronism) *(p. 71)*
      - [9.14.3. Renovascular hypertension](#9143-renovascular-hypertension) *(p. 71)*
      - [9.14.4. Phaeochromocytoma/paraganglioma](#9144-phaeochromocytoma/paraganglioma) *(p. 72)*
      - [9.14.5. Obstructive sleep apnoea syndrome](#9145-obstructive-sleep-apnoea-syndrome) *(p. 72)*
      - [9.14.6. Drug-induced hypertension](#9146-drug-induced-hypertension) *(p. 72)*
        - [9.14.6.1. Anticancer drug-induced hypertension](#91461-anticancer-drug-induced-hypertension) *(p. 72)*
      - [9.14.7. Other forms of secondary hypertension](#9147-other-forms-of-secondary-hypertension) *(p. 72)*
  - [10. Acute and short-term lowering of blood pressure](#10-acute-and-short-term-lowering-of-blood-pressure) *(p. 72)*
    - [10.1. Acute blood pressure management in hypertensive emergencies](#101-acute-blood-pressure-management-in-hypertensiv) *(p. 72)*
      - [10.1.1. Definition and characteristics of hypertensive emergencies](#1011-definition-and-characteristics-of-hypertensiv) *(p. 72)*
      - [10.1.2. Acute management of hypertensive emergencies](#1012-acute-management-of-hypertensive-emergencies) *(p. 73)*
      - [10.1.3. Prognosis and follow-up](#1013-prognosis-and-follow-up) *(p. 73)*
    - [10.2. Acute blood pressure management in acute intracerebral haemorrhage](#102-acute-blood-pressure-management-in-acute-intra) *(p. 73)*
    - [10.3. Acute blood pressure management in acute ischaemic stroke](#103-acute-blood-pressure-management-in-acute-ischa) *(p. 73)*
    - [10.4. Acute blood pressure management in pre-eclampsia and severe hypertension in pregnancy](#104-acute-blood-pressure-management-in-pre-eclamps) *(p. 74)*
      - [10.4.1. Pre-eclampsia](#1041-pre-eclampsia) *(p. 74)*
      - [10.4.2. Severe acute hypertension in pregnancy](#1042-severe-acute-hypertension-in-pregnancy) *(p. 74)*
    - [10.5. Peri-operative acute management of elevated blood pressure](#105-peri-operative-acute-management-of-elevated-bl) *(p. 74)*
      - [10.5.1. Blood pressure-lowering drugs in the peri-operative phase](#1051-blood-pressure-lowering-drugs-in-the-peri-ope) *(p. 74)*
  - [11. Patient-centred care in hypertension](#11-patient-centred-care-in-hypertension) *(p. 75)*
    - [11.1. Definition](#111-definition) *(p. 75)*
    - [11.2. Communicating consequences of treatment](#112-communicating-consequences-of-treatment) *(p. 75)*
    - [11.3. Self-measuring and monitoring](#113-self-measuring-and-monitoring) *(p. 76)*
    - [11.4. Facilitating medication adherence and persistence](#114-facilitating-medication-adherence-and-persiste) *(p. 76)*
    - [11.5. Multidisciplinary management](#115-multidisciplinary-management) *(p. 76)*
  - [12. Key messages](#12-key-messages) *(p. 77)*
  - [13. Gaps in the evidence](#13-gaps-in-the-evidence) *(p. 78)*
  - [14. ‘What to do’ and ‘what not to do’ messages from the guidelines](#14-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 78)*
  - [15. Evidence tables](#15-evidence-tables) *(p. 82)*
  - [16. Data availability statement](#16-data-availability-statement) *(p. 82)*
  - [17. Author information](#17-author-information) *(p. 82)*
  - [Appendix](#appendix) *(p. 82)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2024 ESC Guidelines for the management of 
elevated blood pressure and hypertension
Developed by the task force on the management of elevated blood pressure and 
hypertension of the European Society of Cardiology (ESC) and endorsed by the 
European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)
Authors/Task Force Members: John William McEvoy  *†, (Chairperson) (Ireland), 
Cian P. McCarthy  
‡, (Task Force Co-ordinator) (United States of America), 
Rosa Maria Bruno  
‡, (Task Force Co-ordinator) (France), Sofie Brouwers  
(Belgium), Michelle D. Canavan  
(Ireland), Claudio Ceconi  
(Italy), 
Ruxandra Maria Christodorescu  
(Romania), Stella S. Daskalopoulou  
(Canada), 
Charles J. Ferro  
1 (United Kingdom), Eva Gerdts  
(Norway), Henner Hanssen  
(Switzerland), Julie Harris (United Kingdom), Lucas Lauder  
(Switzerland/Germany), Richard J. McManus  
(United Kingdom), Gerard J. Molloy  
(Ireland), Kazem Rahimi  
(United Kingdom), Vera Regitz-Zagrosek (Germany), 
Gian Paolo Rossi  
2 (Italy), Else Charlotte Sandset  
3 (Norway), Bart Scheenaerts 
(Belgium), Jan A. Staessen  
(Belgium), Izabella Uchmanowicz  
(Poland), 
Maurizio Volterrani  
(Italy), Rhian M. Touyz  *†, (Chairperson) (Canada), 
and ESC Scientific Document Group
*  Corresponding authors: John William McEvoy, Department of Cardiology, University of Galway School of Medicine, Galway, Ireland, and National Institute for Prevention and 
Cardiovascular Health, Galway, Ireland. Tel: +353 91 544310, E-mail: johnwilliam.mcevoy@universityofgalway.ie; and Rhian M. Touyz, Department of Medicine, McGill University, 
Montreal, Canada, Department of Family Medicine, McGill University, Montreal, Canada, and the Research Institute of the McGill University Health Centre, McGill University, Montreal, 
Canada. Tel: +1 514 934 1934 ext 71608, E-mail: Rhian.touyz@mcgill.ca
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1Representing the European Renal Association (ERA), 2Representing the European Society of Endocrinology (ESE), 3Representing the European Stroke Organisation (ESO), 4Representing the 
European Geriatric Medicine Society (EuGMS).
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous 
Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Hypertension, Council on Stroke.
Working Groups: Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, E-Cardiology.
Patient Forum
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guide­
lines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines 
fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC 
Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health 
condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full 
and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the 
scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating 
to drugs and medical devices at the time of prescription. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of 
the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com
https://doi.org/10.1093/eurheartj/ehae178
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Ana Abreu, (CPG Review Co-ordinator) (Portugal), Michael Hecht Olsen, (CPG Review 
Co-ordinator) (Denmark), Marco Ambrosetti (Italy), Emmanuel Androulakis (United Kingdom), Lia Evi Bang 
(Denmark), Jesper Nørgaard Bech (Denmark), Michael A. Borger (Germany), Pierre Boutouyrie (France), 
Luís Bronze (Portugal), Sergio Buccheri (Sweden), Regina Dalmau (Spain), Maria Carmen De Pablo Zarzosa (Spain), 
Christian Delles (United Kingdom), Maria Manuela Fiuza (Portugal), Rahima Gabulova (Azerbaijan), 
Bjørn Olav Haugen (Norway), Christian Heiss (United Kingdom), Borja Ibanez (Spain), Stefan James (Sweden), 
Vikas Kapil (United Kingdom), Meral Kayikçioglu (Turkey), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), Emanuela Teresa Locati (Italy), Sharon MacDonald (United Kingdom), Anastasia S. Mihailidou 
(Australia), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), 
Martin Bodtker Mortensen (Denmark), Sandor Nardai (Hungary), Lis Neubeck (United Kingdom), 
Jens Cosedis Nielsen (Denmark), Peter M. Nilsson (Sweden), Agnes A. Pasquet (Belgium), Mónica Mendes Pedro 
(Portugal), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Ernst Rietzschel (Belgium), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Jean-Paul Schmid (Switzerland), Eduard Shantsila (United Kingdom), 
Isabella Sudano (Switzerland), Ana Teresa Timóteo (Portugal), Georgios Tsivgoulis3 (Greece), Andrea Ungar4 
(Italy), Ilonca Vaartjes (Netherlands), Frank Visseren (Netherlands), Heinz Voeller (Germany), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), Maria-Christina Zennaro2 (France), 
and Katja Zeppenfeld (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest, 
which are reported in a supplementary document to the guidelines. See the European Heart Journal online or 
www.escardio.org/Guidelines for supplementary documents, as well as evidence tables.
Click here to access the corresponding ESC CardioMed chapters.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords 
Guidelines • Blood pressure • Hypertension • Hypertension-mediated organ damage • Blood pressure measurement 
• Ambulatory blood pressure monitoring • Home blood pressure monitoring • Antihypertensive medication • 
Hypertension treatment • Hypertension targets • Secondary hypertension • Cardiovascular disease risk estimation • 
Cardiovascular disease prevention • Resistant hypertension • Hypertension screening
Table of contents
1. Preamble .............................................................................................................. 3918
2. Introduction ....................................................................................................... 3919
2.1. What is new .............................................................................................
3920
3. Pathophysiology of elevated blood pressure and hypertension .. 3928
4. Clinical consequences of elevated blood pressure  
and hypertension ................................................................................................... 3928
5. Measuring blood pressure ............................................................................ 3929
5.1. Introduction and pertinent definitions ..........................................
3929
5.2. Practical recommendations for measuring blood pressure .
3930
5.2.1. Clinical validation of equipment for measuring blood 
pressure .......................................................................................................... 3930
5.2.2. Office blood pressure measurement ..................................... 3930
5.2.3. Home blood pressure measurement ..................................... 3931
5.2.4. Ambulatory blood pressure measurement ......................... 3933
5.2.5. Comparison of home and ambulatory blood pressure 
monitoring ...................................................................................................... 3934
5.3. What is the best method for measuring blood pressure to 
diagnose hypertension? ................................................................................
3934
5.3.1. Blood pressure measurement for hypertension 
screening ......................................................................................................... 3934
5.3.2. Blood pressure measurement for diagnosing 
hypertension ................................................................................................. 3934
5.4. What is the best method for measuring blood pressure for 
long-term management of hypertension? ............................................
3934
5.4.1. Home monitoring ........................................................................... 3934
5.4.2. Ambulatory monitoring ............................................................... 3934
5.5. Measuring blood pressure in selected groups ...........................
3935
5.5.1. Pregnancy ........................................................................................... 3935
5.5.2. Atrial fibrillation ............................................................................... 3935
5.5.3. Orthostatic hypotension ............................................................. 3935
5.6. Novel methods of measuring blood pressure ...........................
3935
6. Definition and classification of elevated blood pressure and 
hypertension, and cardiovascular disease risk assessment .................. 3936
6.1. Definition and classification of elevated blood pressure and 
hypertension .....................................................................................................
3936
6.2. Principles of a risk-based approach for managing blood 
pressure and preventing cardiovascular disease ................................
3936
6.2.1. Role of cardiovascular disease risk assessment ................. 3936
6.3. Predicting cardiovascular disease risk ............................................
3937
6.3.1. 10-year cardiovascular disease risk-prediction models .. 3938
6.4. Refining cardiovascular disease risk estimation beyond risk 
models .................................................................................................................


<!-- PAGE 3 -->

### Page 3

6.4.1. Sex-specific non-traditional cardiovascular disease risk 
modifiers ......................................................................................................... 3939
6.4.2. Non-traditional cardiovascular disease risk modifiers 
shared by men and women .................................................................... 3940
6.4.3. Additional risk decision tests ..................................................... 3941
6.5. Summary of the cardiovascular disease risk stratification 
approach for allocating blood pressure treatment ..........................
3941
7. Diagnosing hypertension and investigating underlying causes ...... 3943
7.1. Screening for hypertension ................................................................
3943
7.2. Confirming the diagnosis of hypertension ..................................
3943
7.3. Communicating the diagnosis ...........................................................
3944
7.4. Baseline assessment and diagnostic approach ...........................
3944
7.4.1. Medical history, medication history, and physical 
examination ................................................................................................... 3944
7.4.2. Drug adherence and persistence with treatment ............ 3945
7.4.3. Routine and optional tests .......................................................... 3945
7.4.3.1. The kidneys ...............................................................................
3947
7.4.3.2. The heart ...................................................................................
3947
7.4.3.3. The arteries ..............................................................................
3948
7.4.4. Genetic testing ................................................................................. 3948
7.5. Resistant hypertension: definition and diagnosis ......................
3948
7.6. Secondary hypertension: when to screen/further 
investigations .....................................................................................................
3950
7.6.1. General considerations ................................................................ 3950
7.6.2. Primary aldosteronism ................................................................. 3950
7.6.3. Renovascular hypertension ........................................................ 3951
7.6.4. Obstructive sleep apnoea syndrome ..................................... 3951
7.6.5. Phaeochromocytoma/paraganglioma ..................................... 3954
8. Preventing and treating elevated blood pressure and 
hypertension ........................................................................................................... 3954
8.1. Prevention strategies in early life .....................................................
3954
8.2. Non-pharmacological interventions ...............................................
3954
8.2.1. Dietary sodium and potassium intake ................................... 3954
8.2.1.1. Sodium ........................................................................................
3954
8.2.1.2. Potassium ...................................................................................
3955
8.2.2. Physical activity and exercise ..................................................... 3956
8.2.3. Weight reduction and diet ......................................................... 3957
8.2.4. Alcohol, coffee, and soft drinks ................................................ 3957
8.2.5. Smoking ............................................................................................... 3957
8.3. Pharmacological interventions ..........................................................
3958
8.3.1. Treatment strategy to reduce adverse cardiovascular 
disease outcomes ........................................................................................ 3958
8.3.2. Drug classes with evidence on clinical outcomes in the 
target population ......................................................................................... 3958
8.3.3. New therapies with blood pressure-lowering properties 
that await supportive evidence from cardiovascular outcomes 
trials prior to guideline endorsement and routine use in 
hypertension ................................................................................................. 3959
8.3.4. Drug combinations and up-titrating strategies .................. 3959
8.3.5. A practical algorithm for intensive, effective, and tolerable 
blood pressure lowering with drug therapy, including 
considerations around single-pill combinations ............................. 3959
8.3.6. Timing of blood pressure-lowering drug treatment ....... 3962
8.4. Selecting patients for pharmacological blood pressure- 
lowering treatment ........................................................................................
3962
8.5. Intensity of blood pressure-lowering therapy and ideal 
treatment targets ............................................................................................
3964
8.5.1. Expected degree of blood pressure reduction with 
approved drugs ............................................................................................ 3964
8.5.2. The ideal target of blood pressure-lowering treatment
3964
8.5.3. Personalizing treatment strategies .......................................... 3965
8.5.4. Duration and monitoring of drug therapy ........................... 3966
8.6. Device-based blood pressure lowering ........................................
3966
8.6.1. Catheter-based renal denervation .......................................... 3966
8.6.2. Other devices ................................................................................... 3968
8.7. Unintended and potentially harmful consequences of blood 
pressure lowering and implications for treatment targets ...........
3968
8.7.1. Adverse effects of blood pressure-lowering medications
3968
8.7.1.1. Symptomatic adverse effects ............................................
3968
8.7.1.2. Renal effects .............................................................................
3968
8.7.1.3. Erectile dysfunction ...............................................................
3968
8.7.2. Pill burden and non-adherence ................................................. 3968
8.7.3. Potentially harmful consequences of blood pressure 
lowering for frail older people .............................................................. 3968
8.7.4. Clinical inertia in blood pressure lowering .......................... 3968
9. Managing specific patient groups or circumstances .......................... 3969
9.1. Young adulthood (18–40 years) ......................................................
3969
9.1.1. Definition and epidemiology ...................................................... 3969
9.1.2. Secondary hypertension in young adulthood ..................... 3969
9.1.3. Measurement and management of blood pressure in 
young adults .................................................................................................. 3969
9.2. Pregnancy ...................................................................................................
3969
9.2.1. Definition and epidemiology ...................................................... 3969
9.2.2. Classifying hypertension in pregnancy ................................... 3969
9.2.3. Measuring blood pressure in pregnancy ............................... 3970
9.2.4. Investigating hypertension in pregnancy ............................... 3970
9.2.5. Preventing hypertension and pre-eclampsia ....................... 3970
9.2.6. Treatment initiation and blood pressure targets .............. 3970
9.2.7. Managing mild hypertension in pregnancy (office blood 
pressure 140–159/90–109 mmHg) ..................................................... 3970
9.2.8. Managing severe hypertension in pregnancy (>160/110  
mmHg) ............................................................................................................. 3971
9.2.9. Managing blood pressure post-partum ................................. 3971
9.2.10. Risk of recurrence of hypertensive disorders in a 
subsequent pregnancy .............................................................................. 3971
9.3. Very old age (≥85 years), frailty, multimorbidity, and 
polypharmacy ....................................................................................................
3971
9.3.1. Definition of frailty ......................................................................... 3971
9.3.2. Randomized controlled trials of blood pressure lowering 
in frail older patients .................................................................................. 3972
9.3.3. Starting blood pressure-lowering treatment in very old or 
frail patients ................................................................................................... 3973
9.3.4. Maintaining blood pressure lowering in very old or frail 
patients ............................................................................................................ 3973
9.4. Isolated systolic and diastolic hypertension ................................
3973
9.4.1. Definition of isolated systolic hypertension ........................ 3973
9.4.2. Isolated systolic hypertension, risk factors, and ageing .. 3973
9.4.3. Isolated systolic hypertension in young adults ................... 3974
9.4.4. Isolated diastolic hypertension .................................................. 3974
9.5. Orthostatic hypotension with supine hypertension ...............
3974


<!-- PAGE 4 -->

### Page 4

9.6. Diabetes .....................................................................................................
3975
9.6.1. Diabetes and elevated blood pressure/hypertension ..... 3975
9.6.2. J-shaped curve of blood pressure and risk of 
cardiovascular disease in patients with diabetes ........................... 3975
9.6.3. Managing blood pressure in diabetes ..................................... 3975
9.7. Chronic kidney disease ........................................................................
3975
9.7.1. Relationship between hypertension and chronic kidney 
disease .............................................................................................................. 3975
9.7.2. Blood pressure lowering in chronic kidney disease ......... 3976
9.7.3. Managing blood pressure in chronic kidney disease ........ 3976
9.7.4. Blood pressure targets in chronic kidney disease ............ 3976
9.8. Cardiac disease ........................................................................................
3976
9.8.1. Blood pressure thresholds and targets in patients with 
cardiac disease .............................................................................................. 3976
9.8.2. Coronary artery disease with particular reference to the 
blood pressure J-curve ............................................................................. 3977
9.8.3. Valvular heart disease ................................................................... 3977
9.8.4. Heart failure ...................................................................................... 3977
9.8.5. Heart rhythm disease (including AF) ...................................... 3978
9.9. Chronic cerebrovascular disease  
and/or cognitive impairment ......................................................................
3978
9.9.1. Role of hypertension in chronic cerebrovascular disease
3978
9.9.2. Treatment in patients with history of prior stroke or 
transient ischaemic attack ....................................................................... 3978
9.9.3. Treatment in patients with chronic cerebrovascular 
disease and cognitive impairment ........................................................ 3978
9.10. Aortopathy .............................................................................................
3979
9.10.1. Coarctation of the aorta ........................................................... 3979
9.10.2. Bicuspid aortic valve-related aortopathy ........................... 3979
9.10.3. Preventing aortic dilation and dissection in high-risk 
patients ............................................................................................................ 3979
9.11. Different ethnic groups .....................................................................
3979
9.12. Nocturnal hypertension ....................................................................
3979
9.12.1. Definition ......................................................................................... 3979
9.12.2. Epidemiology .................................................................................. 3980
9.12.3. Night-time blood pressure as a cardiovascular disease 
risk factor ....................................................................................................... 3980
9.12.4. Treatment of nocturnal hypertension ................................ 3980
9.13. Resistant hypertension ......................................................................
3980
9.13.1. Definition of resistant hypertension .................................... 3980
9.13.2. Non-pharmacological interventions ..................................... 3980
9.13.3. Pharmacological interventions ................................................ 3980
9.13.4. Devices for blood pressure lowering .................................. 3981
9.14. Management of specific causes of secondary hypertension
3982
9.14.1. General considerations .............................................................. 3982
9.14.2. Primary aldosteronism ............................................................... 3982
9.14.3. Renovascular hypertension ...................................................... 3982
9.14.4. Phaeochromocytoma/paraganglioma .................................. 3983
9.14.5. Obstructive sleep apnoea syndrome ................................... 3983
9.14.6. Drug-induced hypertension ..................................................... 3983
9.14.6.1. Anticancer drug-induced hypertension ......................
3983
9.14.7. Other forms of secondary hypertension ........................... 3983
10. Acute and short-term lowering of blood pressure ........................ 3983
10.1. Acute blood pressure management in hypertensive 
emergencies .......................................................................................................
3983
10.1.1. Definition and characteristics of hypertensive 
emergencies ................................................................................................... 3983
10.1.2. Acute management of hypertensive emergencies ......... 3984
10.1.3. Prognosis and follow-up ........................................................... 3984
10.2. Acute blood pressure management in acute intracerebral 
haemorrhage .....................................................................................................
3984
10.3. Acute blood pressure management in acute ischaemic 
stroke ...................................................................................................................
3984
10.4. Acute blood pressure management in pre-eclampsia and 
severe hypertension in pregnancy ...........................................................
3985
10.4.1. Pre-eclampsia ................................................................................. 3985
10.4.2. Severe acute hypertension in pregnancy ........................... 3985
10.5. Peri-operative acute management of elevated blood 
pressure ..............................................................................................................
3985
10.5.1. Blood pressure-lowering drugs in the peri-operative 
phase ................................................................................................................ 3985
11. Patient-centred care in hypertension ................................................... 3986
11.1. Definition ................................................................................................
3986
11.2. Communicating consequences of treatment ..........................
3986
11.3. Self-measuring and monitoring ......................................................
3987
11.4. Facilitating medication adherence and persistence ...............
3987
11.5. Multidisciplinary management ........................................................
3987
12. Key messages .................................................................................................. 3988
13. Gaps in the evidence ................................................................................... 3989
14. ‘What to do’ and ‘what not to do’ messages from the guidelines
3989
15. Evidence tables ............................................................................................... 3993
16. Data availability statement ......................................................................... 3993
17. Author information ...................................................................................... 3993
18. Appendix ........................................................................................................... 3993
Tables of Recommendations
Recommendation Table 1 — Recommendations for measuring 
blood pressure (see Evidence Tables 1–8) ................................................ 3935
Recommendation Table 2 — Recommendations for categorizing 
blood pressure (see Evidence Table 9) ....................................................... 3936
Recommendation Table 3 — Recommendations for assessing 
cardiovascular disease risk among individuals with elevated blood 
pressure (office systolic blood pressure 120–139 mmHg or diastolic 
blood pressure 70–89 mmHg) (see Evidence Tables 10 and 11) .... 3939
Recommendation Table 4 — Recommendations for refining 
cardiovascular disease risk (see Evidence Tables 12–14) .................... 3941
Recommendation Table 5 — Recommendations for blood pressure 
screening (see Evidence Table 15) ................................................................ 3943
Recommendation Table 6 — Recommendations for confirming 
hypertension diagnosis ........................................................................................ 3943
Recommendation Table 7 — Recommendations for assessing 
adherence and persistence with treatment  (see Evidence Table 16)
3945
Recommendation Table 8 — Recommendations for assessing renal 
hypertension-mediated organ damage ........................................................ 3947
Recommendation Table 9 — Recommendations for assessing 
cardiac hypertension-mediated organ damage ........................................ 3947
Recommendation Table 10 — Recommendations for assessing 
vascular hypertension-mediated organ damage (see Evidence 
Table 17) ................................................................................................................... 3948
Recommendation Table 11 — Recommendations for genetic testing 
in hypertension management .......................................................................... 3948
Recommendation Table 12 — Recommendations for resistant 
hypertension work-up (see Evidence Table 18) ...................................... 3950
ESC Guidelines                                                                                                                                                                                          3915


<!-- PAGE 5 -->

### Page 5

Recommendation Table 13 — Recommendations for screening for 
secondary hypertension (see Evidence Tables 19 and 20) ................. 3954
Recommendation Table 14 — Recommendations for screening for 
hypertension in children and adolescents (see Evidence Table 21)
3954
Recommendation Table 15 — Recommendations for 
non-pharmacological treatment of blood pressure and cardiovascular 
risk reduction (see Evidence Tables 22–26) .................................................
3958
Recommendation Table 16 — Recommendations for 
pharmacological treatment of hypertension (see Evidence Tables 27, 
28, and 29) ............................................................................................................... 3962
Recommendation Table 17 — Recommendations for initiating 
blood pressure-lowering treatment (see Evidence Tables 30–32) . 3963
Recommendation Table 18 — Recommendations for blood 
pressure targets with treatment (see Evidence Table 34) .................. 3966
Recommendation Table 19 — Recommendations for follow-up in 
patients with treated hypertension (see Evidence Table 33) ............ 3966
Recommendation Table 20 — Recommendations for device-based 
treatment of hypertension (see Evidence Table 35) ............................. 3967
Recommendation Table 21 — Recommendations for managing 
hypertension in young adults (see Evidence Tables 36 and 37) ....... 3969
Recommendation Table 22 — Recommendations for managing 
hypertension in pregnancy (see Evidence Tables 38–40) ................... 3971
Recommendation Table 23 — Recommendations for managing 
hypertension in patients who are very old or frail (see Evidence 
Table 41) ................................................................................................................... 3973
Recommendation Table 24 — Recommendations for managing 
hypertension in patients with orthostatic hypotension ....................... 3975
Recommendation Table 25 — Recommendations for managing 
hypertension in patients with diabetes ........................................................ 3975
Recommendation Table 26 — Recommendations for managing 
hypertension in patients with chronic kidney disease ........................... 3976
Recommendation Table 27 — Recommendations for managing 
hypertension in patients with cardiac disease .......................................... 3978
Recommendation Table 28 — Recommendations for managing 
hypertension in patients with chronic cerebrovascular disease and 
cognitive impairment ........................................................................................... 3979
Recommendation Table 29 — Recommendations for managing 
hypertension in different ethnic groups ...................................................... 3979
Recommendation Table 30 — Recommendations for treating 
resistant hypertension (see Evidence Tables 42 and 43) .................... 3981
Recommendation Table 31 — Recommendations for managing 
hypertension in patients with renovascular hypertension (see 
Evidence Tables 44 and 45) .............................................................................. 3982
Recommendation Table 32 — Recommendations for acutely 
managing blood pressure in patients with intracerebral haemorrhage 
or acute ischaemic stroke ................................................................................. 3984
Recommendation Table 33 — Recommendations for acutely 
managing blood pressure in patients with severe hypertension in 
pregnancy and pre-eclampsia (see Evidence Table 46) ........................ 3985
Recommendation Table 34 — Recommendations for 
communicating consequences of treatment (see Evidence 
Table 47) ................................................................................................................... 3987
Recommendation Table 35 — Recommendations for self-measuring 
and monitoring blood pressure (see Evidence Table 48) ................... 3987
Recommendation Table 36 — Recommendations for multi/ 
interdisciplinary blood pressure management (see Evidence 
Table 49) ................................................................................................................... 3987
List of tables
Table 1 Classes of recommendations .......................................................... 3918
Table 2 Levels of evidence ................................................................................ 3919
Table 3 New recommendations .................................................................... 3920
Table 4 Revised recommendations ............................................................... 3923
Table 5 Comparison of office, home, and ambulatory blood pressure 
measurement thresholds for elevated blood pressure and 
hypertension .....................................................................................................................
3933
Table 6 Comparison of ambulatory and home blood pressure 
monitoring ..................................................................................................................
3934
Table 7 Key illness representations and treatment beliefs: how these 
apply to communicating a hypertension diagnosis to the patient 
(note that gender influences these representations) ............................ 3945
Table 8 Routine tests recommended in the initial work-up of a 
patient with elevated blood pressure or hypertension ........................ 3946
Table 9 Optional tests that may be used as clinically indicated in the initial 
work-up of a patient with elevated blood pressure or hypertension to 
assess hypertension-mediated organ damage or established 
cardiovascular disease ...................................................................................................... 3947
Table 10 Current definition of resistant hypertension ........................ 3950
Table 11 Conditions found to cause pseudo-resistance or resistance 
to blood pressure-lowering treatment ........................................................ 3950
Table 12 Drugs and conditions that affect aldosterone, renin, and 
aldosterone-to-renin ratio ................................................................................ 3951
Table 13 Optional tests that should be used to screen for secondary 
hypertension in the presence of suggestive signs, symptoms, or 
medical history ....................................................................................................... 3952
Table 14 Initiation of blood pressure-lowering treatment based on 
confirmed blood pressure category and cardiovascular disease risk
3963
Table 15 What to do and what not to do ................................................ 3989
List of figures
Figure 1 Pathophysiology of elevated blood pressure and 
hypertension ........................................................................................................... 3928
Figure 2 Persistently elevated blood pressure and hypertension lead to 
hypertension-mediated organ damage and cardiovascular disease .....
3929
Figure 3 Summary of office blood pressure measurement ................ 3931
Figure 4 Summary of home blood pressure measurement ................ 3932
Figure 5 Summary of ambulatory blood pressure measurement .... 3933
Figure 6 Blood pressure categories .............................................................. 3937
Figure 7 Sufficiently high cardiovascular risk conditions that warrant 
blood pressure-lowering treatment among adults with elevated 
blood pressure ....................................................................................................... 3938
Figure 8 Cardiovascular disease risk modifiers to consider for 
up-classification of risk ........................................................................................ 3940
Figure 9 Summary of cardiovascular disease risk-stratification 
approach for blood pressure treatment in adults with elevated 
blood pressure ....................................................................................................... 3942
Figure 10 Protocol for confirming hypertension diagnosis ................. 3944
Figure 11 Definitions, assessments, and potential interventions for 
the three phases of adherence to BP-lowering medications ............. 3946
Figure 12 Tests and criteria for defining hypertension-mediated 
organ damage and considerations for their use in clinical practice
3949
Figure 13 Summary of primary aldosteronism as a common form of 
secondary hypertension ..................................................................................... 3952


<!-- PAGE 6 -->

### Page 6

Figure 14 Summary of renovascular disease as a common form of 
secondary hypertension ..................................................................................... 3953
Figure 15 Summary of obstructive sleep apnoea as a common form 
of secondary hypertension ............................................................................... 3953
Figure 16 Physical activity according to different types of exercise 
and reduction of blood pressure and overall cardiovascular disease 
risk ............................................................................................................................... 3955
Figure 17 Effects of main lifestyle factors on blood pressure and 
cardiovascular risk reduction ........................................................................... 3956
Figure 18 Practical algorithm for pharmacological blood pressure 
lowering .................................................................................................................... 3960
Figure 19 Central Illustration ........................................................................... 3961
Figure 20 Systolic blood pressure categories and treatment target 
range ........................................................................................................................... 3965
Figure 21 Frailty assessment in the management of blood pressure
3972
Figure 22 Management of resistant hypertension .................................. 3981
Figure 23 Patient-centred care ....................................................................... 3986
Figure 24 The five dimensions of adherence (WHO, 2003) applied 
to hypertension ..................................................................................................... 3988
Abbreviations and acronyms
ABI
Ankle–brachial index
ABPM
Ambulatory blood pressure monitoring
ACCORD
Action to Control Cardiovascular Risk in Diabetes
ACE
Angiotensin-converting enzyme
ACR
Albumin:creatinine ratio
AF
Atrial fibrillation
AHI
Apnoea–hypopnoea index
ALARA
As low as reasonably achievable
ALLHAT
Antihypertensive and Lipid-Lowering Treatment 
to Prevent Heart Attack
AOBP
Automated office blood pressure (measurement)
ARB
Angiotensin receptor blocker
ARNi
Angiotensin receptor-neprilysin inhibitor
ARR
Aldosterone-to-renin ratio
ASCVD
Atherosclerotic cardiovascular disease
BMI
Body mass index
BP
Blood pressure
BSA
Body surface area
CAC
Coronary artery calcium
CAD
Coronary artery disease
CCB
Calcium channel blocker
CHAP
Chronic Hypertension and Pregnancy
CI
Confidence interval
CKD
Chronic kidney disease
CKD-EPI
Chronic Kidney Disease Epidemiology 
Collaboration
COVID-19
Coronavirus disease 2019
CPAP
Continuous positive airway pressure
CPG
Clinical Practice Guidelines
CT
Computed tomography
CVD
Cardiovascular disease
DASH
Dietary Approaches to Stop Hypertension
DBP
Diastolic blood pressure
DECIDE-Salt
Diet, ExerCIse and carDiovascular hEalth–Salt
EACTS
European Association for Cardio-Thoracic Surgery
ECG
Electrocardiogram eGFR
Estimated glomerular filtration rate
EPIC
European Prospective Investigation into Cancer 
and Nutrition
ESC
European Society of Cardiology
ESH
European Society of Hypertension
ESPRIT
Effects of intensive Systolic blood Pressure lowering 
treatment in reducing RIsk of vascular evenTs
FMD-RVH
Fibromuscular dysplasia-induced renovascular 
hypertension
GFR
Glomerular filtration rate
GLP-1
Glucagon-like peptide-1
GP
General practitioner
HbA1c
Glycated haemoglobin
HBPM
Home blood pressure monitoring
HDL
High-density lipoprotein
HFpEF
Heart failure with preserved ejection fraction
HF(m)rEF
Heart failure with (mildly) reduced ejection 
fraction
HIV
Human immunodeficiency virus
HMOD
Hypertension-mediated organ damage i.m.
Intramuscular i.v.
Intravenous
KDIGO
Kidney Disease: Improving Global Outcomes
LA
Left atrial
LDL
Low-density lipoprotein
LV
Left ventricular
LVH
Left ventricular hypertrophy
MRA
Mineralocorticoid receptor antagonist
MRI
Magnetic resonance imaging
NNT
Number needed to treat
NT-proBNP
N-terminal pro-brain natriuretic peptide
OSAS
Obstructive sleep apnoea syndrome
PPGL
Phaeochromocytoma/paraganglioma
PREOP-ACEI
Prospective Randomized Evaluation of Preoperative 
Angiotensin-Converting Enzyme Inhibition
PREMs
Patient-Reported Experience Measures
PROMS
Patient-Reported Outcome Measures
PTRA
Percutaneous transluminal renal angioplasty
PWV
Pulse wave velocity
RAAS
Renin-angiotensin-aldosterone system
RADIANCE-HTN
A Study of the Recor Medical Paradise System in 
Clinical Hypertension
RAS
Renin–angiotensin system
RCT
Randomized controlled trial
RVH
Renovascular hypertension
RWT
Relative wall thickness
SBP
Systolic blood pressure
SCORE2
Systematic COronary Risk Evaluation 2
SCORE2-OP
Systematic COronary Risk Evaluation 2–Older 
Persons
SGLT2
Sodium–glucose co-transporter 2
SNP
Single-nucleotide polymorphism
SNS
Sympathetic nervous system
SPC
Single-pill combination
SPRINT
Systolic Blood Pressure Intervention Trial
SSaSS
Salt Substitute and Stroke Study
STEP
Strategy of Blood Pressure Intervention in Elderly 
Hypertensive Patients
STEP-1
Semaglutide Treatment Effect in People with 
Obesity
ESC Guidelines                                                                                                                                                                                          3917


<!-- PAGE 7 -->

### Page 7

TIA
Transient ischaemic attack
TRIUMPH
Treating Resistant Hypertension Using Lifestyle 
Modification to Promote Health
TSH
Thyroid-stimulating hormone
WHO
World Health Organization
WML
White matter lesion
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeut­
ic approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals and the European Society of 
Cardiology (ESC) makes its guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription and to respect the ethical rules of their profession.
ESC Guidelines represent the official position of the ESC on a given topic 
and are regularly updated when warranted by new evidence. ESC Policies 
and Procedures for formulating and issuing ESC Guidelines can be 
found on the ESC website (https://www.escardio.org/Guidelines/Clinical- 
Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). 
This guideline version updates and replaces the previous version 
from 2018.
The Members of this task force were selected by the ESC to include 
professionals involved in the medical care of patients with this path­
ology, as well as patient representatives and methodologists. The se­
lection procedure included an open call for authors and aimed to 
include members from across the whole of the ESC region and 
from relevant ESC Subspecialty Communities. Consideration was gi­
ven to diversity and inclusion, notably with respect to gender and 
country of origin. The task force performed a critical review and 
evaluation of the published literature on diagnostic and therapeutic 
approaches including assessment of the risk-benefit ratio. The strength 
of every recommendation and the level of evidence supporting them 
were weighed and scored according to predefined scales as outlined in 
Tables 1 and 2 below. Patient-Reported Outcome Measures (PROMs) 
and Patient-Reported Experience Measures (PREMs) were also evaluated 
as the basis for recommendations and/or discussion in these guidelines. 
The task force followed ESC voting procedures and all approved recom­
mendations were subject to a vote and achieved at least 75% agreement 
among voting members. Members of the task force with declared inter­
ests on specific topics were asked to abstain from voting on related 
recommendations.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules, 
which can be found on the ESC website (http://www.escardio.org/ 
guidelines) and have been compiled in a report published in a supple­
mentary document with the guidelines. Funding for the development 
of ESC Guidelines is derived entirely from the ESC with no involvement 
of the healthcare industry.
Table 1 Classes of recommendations
©ESC 2024
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2024


<!-- PAGE 8 -->

### Page 8

The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible 
for the approval process. In addition to review by the CPG 
Committee, ESC Guidelines undergo multiple rounds of double-blind 
peer review by external experts, including members from across the 
whole of the ESC region, all National Cardiac Societies of the ESC 
and from relevant ESC Subspecialty Communities. After appropriate 
revisions, the guidelines are signed off by all the experts in the task 
force. The finalized document is signed off by the CPG Committee 
for publication in the European Heart Journal.
ESC Guidelines are based on analyses of published evidence, chiefly 
on clinical trials and meta-analyses of trials, but potentially including 
other types of studies. Evidence tables summarizing key information 
from relevant studies are generated early in the guideline development 
process to facilitate the formulation of recommendations, to enhance 
comprehension of recommendations after publication, and reinforce 
transparency in the guidelines development process. The tables are 
published in their own section of ESC Guidelines and reference specific 
recommendation tables.
Off-label use of medication may be presented in these guidelines if a 
sufficient level of evidence shows that it can be considered medically ap­
propriate for a given condition. However, the final decisions concerning 
an individual patient must be made by the responsible health profes­
sional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent;
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
This 2024 document updates the 2018 ESC/European Society of 
Hypertension (ESH) Guidelines on the management of arterial hyper­
tension.1 While the current document builds on prior guidelines, it 
also incorporates important updates and new recommendations based 
on current evidence. For example: 
(1) The title has changed from ‘Guidelines on the management of ar­
terial hypertension’ to ‘Guidelines on the management of elevated 
blood pressure and hypertension’. This is based on evidence that 
the risk for cardiovascular disease (CVD) attributable to blood 
pressure (BP) is on a continuous exposure scale, not a binary scale 
of normotension vs. hypertension.2,3 Updated evidence also in­
creasingly demonstrates the benefit on CVD outcomes of 
BP-lowering medications among persons with high CVD risk and 
BP levels that are elevated but that do not meet traditional thresh­
olds used to define hypertension. The term ‘arterial’ is removed 
from the title of the 2024 Guidelines, as arterial hypertension can 
also occur in the pulmonary arteries, which is not a focus here.
(2) The 2024 Guidelines continue to define hypertension as office sys­
tolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg. However, a 
new BP category called ‘Elevated BP’ is introduced. Elevated BP is 
defined as an office systolic BP of 120–139 mmHg or diastolic BP 
of 70–89 mmHg.
(3) A major, evidence-based change in the 2024 Guidelines is the rec­
ommendation to pursue a target systolic BP of 120–129 mmHg 
among adults receiving BP-lowering medications. There are several 
important caveats to this recommendation, including: (i) the re­
quirement that treatment to this BP target is well tolerated by 
the patient, (ii) the fact that more lenient BP targets can be consid­
ered in persons with symptomatic orthostatic hypotension, those 
aged 85 years or over, or those with moderate-to-severe frailty 
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2024
© ESC 2024
ESC Guidelines                                                                                                                                                                                          3919


<!-- PAGE 9 -->

### Page 9

or limited life expectancy, and (iii) a strong emphasis on 
out-of-office BP measurement to confirm the systolic BP target 
of 120–129 mmHg is achieved. For those selected individual cases 
where a target systolic BP of 120–129 mmHg is not pursued, either 
due to intolerance or the existence of conditions that favour a 
more lenient BP target, we recommend targeting a BP that is as 
low as reasonably achievable. Personalized clinical decision-making 
and shared decisions with the patient are also emphasized.
(4) Another important change in the 2024 Guidelines compared with 
earlier versions is the increased focus on evidence related to fatal 
and non-fatal CVD outcomes rather than surrogate outcomes such 
as BP lowering alone. Except for lifestyle interventions and low-risk 
non-pharmacological interventions aimed at implementation or care 
delivery, the current guidelines require that, for a Class I recommen­
dation to be made for a drug or procedural intervention, the evidence 
must show benefit on CVD outcomes and not only BP lowering.
(5) The task force comprised of a balanced representation of males 
and females.
(6) The present guidelines consider sex and gender as an integral com­
ponent throughout the document, rather than in a separate section 
at the end. In this document, sex is the biological condition of being 
female or male from conception, based on genes, and gender is the 
socio-cultural dimension of being a woman or a man in a given soci­
ety, based on gender roles, gender norms, gender identity, and gen­
der relations valid in the respective society at a given timepoint.4,5
(7) The 2024 Guidelines are written to make them more ‘user friendly’. 
Input from general practitioners (GPs) was obtained in this regard, 
and one task force member is a GP. Given the ageing population in 
Europe, there was also a focus on tailoring treatment with respect to 
frailty and into older age, which is addressed in multiple sections. 
Moreover, patient input and their lived experiences are considered 
throughout. We also now include evidence tables in the 
Supplementary section to provide improved transparency regarding 
our recommendations. As appropriate, readers who wish to seek add­
itional details and information are referred to the Supplementary data 
online and to the 
ESC CardioMed.6
(8) The task force recognized that a major challenge in guideline usage 
is poor implementation. This likely contributes to suboptimal con­
trol of hypertension.7–9 To address this, a dedicated section on im­
plementation is included in the Supplementary data online. 
Moreover, through a new initiative, we include information from 
national societies following a survey on guideline implementation 
completed during the national society peer review of the guidelines 
document. It is hoped this information may help inform national so­
cieties about potential barriers to implementation.
2.1. What is new
These 2024 Guidelines contain a number of new and revised recom­
mendations, which are summarized in Tables 3 and 4, respectively.
Table 3 New recommendations
Recommendations
Classa
Levelb
5. Measuring blood pressure
It is recommended to measure BP using a validated and calibrated device, to enforce the correct measurement technique, and to apply a 
consistent approach to BP measurement for each patient.
I
B
Out-of-office BP measurement is recommended for diagnostic purposes, particularly because it can detect both white-coat hypertension 
and masked hypertension. Where out-of-office measurements are not logistically and/or economically feasible, then it is recommended that 
the diagnosis be confirmed with a repeat office BP measurement using the correct standardized measurement technique.
I
B
Most automated oscillometric monitors have not been validated for BP measurement in AF; BP measurement should be considered using a 
manual auscultatory method in these circumstances, where possible.
IIa
C
An assessment for orthostatic hypotension (≥20 systolic BP and/or ≥10 diastolic BP mmHg drop at 1 and/or 3 min after standing) should be 
considered at least at the initial diagnosis of elevated BP or hypertension and thereafter if suggestive symptoms arise. This should be 
performed after the patient is first lying or sitting for 5 min.
IIa
C
6. Definition and classification of elevated blood pressure and hypertension, and cardiovascular disease risk assessment
It is recommended to use a risk-based approach in the treatment of elevated BP, and individuals with moderate or severe CKD, established 
CVD, HMOD, diabetes mellitus, or familial hypercholesterolaemia are considered at increased risk for CVD events.
I
B
It is recommended that, irrespective of age, individuals with elevated BP and a SCORE2 or SCORE2-OP CVD risk of ≥10% be considered at 
increased risk for CVD for the purposes of risk-based management of their elevated BP.
I
B
SCORE2-Diabetes should be considered to estimate CVD risk among type 2 diabetes mellitus patients with elevated BP, particularly if they 
are <60 years of age.
IIa
B
History of pregnancy complications (gestational diabetes, gestational hypertension, pre-term delivery, pre-eclampsia, one or more 
stillbirths, and recurrent miscarriage) are sex-specific risk modifiers that should be considered to up-classify individuals with elevated BP and 
borderline increased 10-year CVD risk (5% to <10% risk).
IIa
B
High-risk ethnicity (e.g. South Asian), family history of premature onset atherosclerotic CVD, socio-economic deprivation, auto-immune 
inflammatory disorders, HIV, and severe mental illness are risk modifiers shared by both sexes that should be considered to up-classify 
individuals with elevated BP and borderline increased 10-year CVD risk (5% to <10% risk).
IIa
B
After assessing 10-year predicted CVD risk and non-traditional CVD risk modifiers, if a risk-based BP-lowering treatment decision remains 
uncertain for individuals with elevated BP, measuring CAC score, carotid or femoral plaque using ultrasound, high-sensitivity cardiac troponin 
or B-type natriuretic peptide biomarkers, or arterial stiffness using pulse wave velocity, may be considered to improve risk stratification 
among patients with borderline increased 10-year CVD risk (5% to <10% risk) after shared decision-making and considering costs.
IIb
B
Continued


<!-- PAGE 10 -->

### Page 10

### 7 Diagnosing hypertension and investigating underlying causes

Opportunistic screening for elevated BP and hypertension should be considered: 
• At least every 3 years for adults aged <40 years.
• At least annually for adults aged ≥40 years.
IIa
C
In individuals with elevated BP who do not currently meet risk thresholds for BP-lowering treatment, a repeat BP measurement and risk 
assessment within 1 year should be considered.
IIa
C
Other forms of screening for hypertension (i.e. systematic screening, self-screening, and non-physician screening) may be considered, 
depending on their feasibility in different countries and healthcare systems.
IIb
B
In individuals with increased CVD risk where their screening office BP is 120–139/70–89 mmHg, it is recommended to measure BP out of 
office, using ABPM and/or HBPM or, if not logistically feasible, make repeated office BP measurements on more than one visit.
I
B
Objective evaluation of adherence (either directly observed treatment or detecting prescribed drugs in blood or urine samples) should be 
considered in the clinical work-up of patients with apparent resistant hypertension, if resources allow.
IIa
B
If moderate-to-severe CKD is diagnosed, it is recommended to repeat measurements of serum creatinine, eGFR, and urine ACR at 
least annually.
I
C
Coronary artery calcium scoring may be considered in patients with elevated BP or hypertension when it is likely to change patient management.
IIb
B
Patients with resistant hypertension should be considered for referral to clinical centres with expertise in hypertension management for 
further testing.
IIa
B
It is recommended that patients with hypertension presenting with suggestive signs, symptoms, or medical history of secondary 
hypertension are appropriately screened for secondary hypertension.
I
B
Screening for primary aldosteronism by renin and aldosterone measurements should be considered in all adults with confirmed 
hypertension (BP ≥ 140/90 mmHg).
IIa
B
8. Preventing and treating elevated blood pressure
Opportunistic screening with office BP measurements to monitor development of BP during late childhood and adolescence, especially 
if one or both parents have hypertension, should be considered to better predict development of adult hypertension and associated 
CVD risk.
IIa
B
It is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy 
intake. It is also recommended to discourage consumption of sugar-sweetened beverages, such as soft drinks and fruit juices, starting 
at young age.
I
B
In patients with hypertension without moderate-to-advanced CKD and with high daily sodium intake, an increase of potassium intake by 
0.5–1.0 g/day—for example through sodium substitution with potassium-enriched salt (comprising 75% sodium chloride and 25% 
potassium chloride) or through diets rich in fruits and vegetables—should be considered.
IIa
A
In patients with CKD or taking potassium-sparing medication, such as some diuretics, ACE inhibitors, ARBs, or spironolactone, monitoring 
serum levels of potassium should be considered if dietary potassium is being increased.
IIa
C
It is recommended to take medications at the most convenient time of day for the patient, to establish a habitual pattern of medication 
taking to improve adherence.
I
B
In adults with elevated BP and low/medium CVD risk (<10% over 10 years), BP lowering with lifestyle measures is recommended and can 
reduce the risk of CVD.
I
B
In adults with elevated BP and sufficiently high CVD risk, after 3 months of lifestyle intervention, BP lowering with pharmacological 
treatment is recommended for those with confirmed BP ≥130/80 mmHg to reduce CVD risk.
I
A
It is recommended that in hypertensive patients with confirmed BP ≥140/90 mmHg, irrespective of CVD risk, lifestyle measures and 
pharmacological BP-lowering treatment is initiated promptly to reduce CVD risk.
I
A
It is recommended to maintain BP-lowering drug treatment lifelong, even beyond the age of 85 years, if well tolerated.
I
A
Because the benefit in reducing CVD outcomes is uncertain in these settings, and noting that close monitoring of treatment tolerance is 
advised, BP-lowering treatment should only be considered from ≥140/90 mmHg (office) among persons meeting the following criteria: 
• pre-treatment symptomatic orthostatic hypotension;
• age ≥85 years;
• clinically significant moderate-to-severe frailty;
• and/or limited predicted lifespan (<3 years).
IIa
B
In cases where BP-lowering treatment is poorly tolerated and achieving a target systolic of 120–129 mmHg is not possible, it is 
recommended to target a systolic BP level that is ‘as low as reasonably achievable’ (ALARA principle).
I
A
Once BP is controlled and stable under BP-lowering therapy, at least a yearly follow-up for BP and other CVD risk factors should 
be considered.
IIa
C
Continued
ESC Guidelines                                                                                                                                                                                          3921


<!-- PAGE 11 -->

### Page 11

### 9 Managing specific patient groups or circumstances

Young adults
Comprehensive screening for the main causes of secondary hypertension is recommended in adults diagnosed with hypertension before 
the age of 40 years, except for obese young adults where it is recommended to start with an obstructive sleep apnoea evaluation.
I
B
Since SCORE2 has not been validated for individuals <40 years, screening for HMOD may be considered in such young individuals with 
elevated BP without other increased CVD risk conditions to identify additional individuals for possible medical treatment.
IIb
B
Hypertension in pregnancy
In consultation with an obstetrician, low- to moderate-intensity exercise is recommended in all pregnant women without contraindications 
to reduce the risk of gestational hypertension and pre-eclampsia.
I
B
HBPM and ABPM should be considered to exclude white-coat and masked hypertension, which are more common in pregnancy.
IIa
C
Older and frail patients
It is recommended that treatment of elevated BP and hypertension among older patients aged <85 years who are not moderately to 
severely frail follows the same guidelines as for younger people, provided BP-lowering treatment is well tolerated.
I
A
When initiating BP-lowering treatment for patients aged ≥85 years, and/or with moderate-to-severe frailty (at any age), long-acting 
dihydropyridine CCBs or RAS inhibitors should be considered, followed, if necessary, by a low-dose diuretic if tolerated, but preferably not 
a beta-blocker (unless compelling indications exist) or an alpha-blocker.
IIa
B
As the safety and efficacy of BP treatment is less certain in individuals with moderate or severe frailty, clinicians should consider screening 
older adults for frailty using validated clinical tests; frail patients’ health priorities and a shared-decision approach should be considered when 
deciding on BP treatments and targets.
IIa
C
If BP drops with progressing frailty, deprescription of BP-lowering medications (and other drugs that can reduce BP, such as sedatives and 
prostate-specific alpha-blockers) may be considered.
IIb
C
Hypertension and orthostatic hypotension
Before starting or intensifying BP-lowering medication, it is recommended to test for orthostatic hypotension, by first having the patient sit 
or lie for 5 min and then measuring BP 1 and/or 3 min after standing.
I
B
It is recommended to pursue non-pharmacological approaches as the first-line treatment of orthostatic hypotension among persons with 
supine hypertension. For such patients, it is also recommended to switch BP-lowering medications that worsen orthostatic hypotension to 
an alternative BP-lowering therapy and not to simply de-intensify therapy.
I
A
Chronic kidney disease
In hypertensive patients with CKD and eGFR >20 mL/min/1.73 m2, SGLT2 inhibitors are recommended to improve outcomes in the 
context of their modest BP-lowering properties.
I
A
Other conditions
BP-lowering drug treatment is recommended for people with pre-diabetes or obesity when confirmed office BP is ≥140/90 mmHg or when 
office BP is 130–139/80–89 mmHg and the patient is at predicted 10-year risk of CVD ≥10% or with high-risk conditions, despite a 
maximum of 3 months of lifestyle therapy.
I
A
In patients with a history of aortic valve stenosis and/or regurgitation who require BP-lowering treatment, RAS blockers should be 
considered as part of that treatment.
IIa
C
In patients with a history of moderate-to-severe mitral valve regurgitation who require BP-lowering treatment, RAS blockers should be 
considered as part of that treatment.
IIa
C
Renovascular hypertension
Renal artery angioplasty without stenting should be considered for patients with hypertension and haemodynamically significant renal artery 
stenosis due to fibromuscular dysplasia.
IIa
C
Renal artery angioplasty and stenting may be considered in patients with haemodynamically significant, atherosclerotic, renal artery stenosis 
(stenosis of 70%–99%, or 50%–69% with post-stenotic dilatation and/or significant trans-stenotic pressure gradient) with: 
• Recurrent heart failure, unstable angina, or sudden-onset flash pulmonary oedema despite maximally tolerated medical therapy;
• Resistant hypertension;
• Hypertension with unexplained unilaterally small kidney or CKD;
• Bilateral renal artery stenosis or unilateral renal artery stenosis in a solitary viable kidney.
IIb
C
Renal artery angioplasty is not recommended in patients without confirmed haemodynamically significant renal artery stenosis.
III
A
10. Acute and short-term lowering of blood pressure
In patients with intracerebral haemorrhage presenting with systolic BP ≥220 mmHg, acute reduction in systolic BP >70 mmHg from initial 
levels within 1 h of commencing treatment is not recommended.
III
B
Continued


<!-- PAGE 12 -->

### Page 12

### 11 Patient-centred care in hypertension

An informed discussion about CVD risk and treatment benefits tailored to the needs of a patient is recommended as part of hypertension 
management.
I
C
Motivational interviewing should be considered for patients with hypertension at hospitals and community health centres to assist patients 
in controlling their BP and to enhance treatment adherence.
IIa
B
Physician–patient web communications are an effective tool that should be considered in primary care, including reporting on home BP 
readings.
IIa
C
Home BP measurement for managing hypertension by using self-monitored BP is recommended to achieve better BP control.
I
B
Self-measurement, when properly performed, is recommended due to positive effects on the acceptance of a diagnosis of hypertension, 
patient empowerment, and adherence to treatment.
I
C
Enhanced self-monitoring of BP using a device paired with a connected smartphone application may be considered, though evidence to date 
suggests that this may be no more effective than standard self-monitoring.
IIb
B
Multidisciplinary approaches in the management of patients with elevated BP and hypertension, including appropriate and safe task-shifting 
away from physicians are recommended to improve BP control.
I
A
© ESC 2024
ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ACR, albumin-to-creatinine ratio (urine); AF, atrial fibrillation; ALARA, as low as reasonably achievable; 
ARB, angiotensin receptor blocker; BP, blood pressure; CAC, coronary artery calcium; CCB, calcium channel blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, 
estimated glomerular filtration rate; HBPM, home blood pressure monitoring; HFpEF, heart failure with preserved ejection fraction; HIV, human immunodeficiency virus; HMOD, 
hypertension-mediated organ damage; MRA, mineralocorticoid receptor antagonist; RAS, renin–angiotensin system; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, 
Systematic COronary Risk Evaluation 2–Older Persons; SGLT2, sodium–glucose co-transporter 2. 
aClass of recommendation. 
bLevel of evidence.
Table 4 Revised recommendations
Recommendations in 2018 version
Classa
Levelb
Recommendations in 2024 version
Classa
Levelb
6. Definition and classification of elevated blood pressure and hypertension
It is recommended that BP be classified as optimal, 
normal, high–normal, or grades 1–3 hypertension, 
according to office BP.
I
C
It is recommended that BP be categorized as 
non-elevated BP, elevated BP, and hypertension to aid 
treatment decisions.
I
B
CV risk assessment with the SCORE system is 
recommended for hypertensive patients who are not 
already at high or very high risk due to established CVD, 
renal disease, or diabetes, a markedly elevated single 
risk factor (e.g. cholesterol), or hypertensive LVH.
I
B
SCORE2 is recommended for assessing 10-year risk of 
fatal and non-fatal CVD among individuals aged 40–69 
years with elevated BP who are not already considered 
at increased risk due to moderate or severe CKD, 
established CVD, HMOD, diabetes mellitus, or familial 
hypercholesterolaemia.
I
B
SCORE2-OP is recommended for assessing the 
10-year risk of fatal and non-fatal CVD among 
individuals aged ≥70 years with elevated BP who are 
not already considered at increased risk due to 
moderate or severe CKD, established CVD, HMOD, 
diabetes mellitus, or familial hypercholesterolaemia.
I
B
7. Diagnosing hypertension and investigating underlying causes
It is recommended that the diagnosis of hypertension 
should be based on: 
• Repeated office BP measurements on more than one 
visit, except when hypertension is severe (e.g. grade 3 
and especially in high-risk patients). At each visit, three 
BP measurements should be recorded, 1–2 min apart, 
and additional measurements should be performed if 
the first two readings differ by >10 mmHg. The 
patient’s BP is the average of the last two BP readings. 
Or
• Out-of-office BP measurement with ABPM and/or 
HBPM, provided that these measurements are 
logistically and economically feasible.
I
C
Where screening office BP is 140–159/90–99 mmHg, it is 
recommended that the diagnosis of hypertension should 
be based on out-of-office BP measurement with ABPM 
and/or HBPM. If these measurements are not logistically 
or economically feasible, then diagnosis can be made on 
repeated office BP measurements on more than one visit.
I
B
Where screening office BP is ≥160/100 mmHg: 
• It is recommended that BP 160–179/100–109 mmHg 
be confirmed as soon as possible (e.g. within 1 
month) preferably by either home or ambulatory BP 
measurements.
• It is recommended when BP ≥180/110 mmHg that 
hypertensive emergency be excluded.
I
C
Continued
ESC Guidelines                                                                                                                                                                                          3923


<!-- PAGE 13 -->

### Page 13

Echocardiography is recommended  in hypertensive 
patients when there are ECG abnormalities  or signs or 
symptoms of LV dysfunction.
I
B
Echocardiography is recommended in patients with 
hypertension and ECG abnormalities, or signs or 
symptoms of cardiac disease.
I
B
Echocardiography may be considered when the 
detection of LVH may influence treatment decisions.
IIb
B
Echocardiography may be considered in patients with 
elevated BP, particularly when it is likely to change 
patient management.
IIb
B
Ultrasound examination of the carotid arteries may be 
considered for the detection of asymptomatic 
atherosclerotic plaques or carotid stenosis in patients 
with documented vascular disease elsewhere.
IIb
B
Ultrasound examination of the carotid or femoral 
arteries for detecting plaque may be considered in 
patients with elevated BP or hypertension when it is 
likely to change patient management.
IIb
B
Measurement of PWV may be considered for 
measuring arterial stiffness.
IIb
B
Measurement of PWV may be considered in patients 
with elevated BP or hypertension when it is likely to 
change patient management.
IIb
B
8. Preventing and treating elevated blood pressure
Regular aerobic exercise (e.g. at least 30 min of 
moderate dynamic exercise on 5–7 days/week) is 
recommended.
I
A
Moderate intensity aerobic exercise of ≥150 min/week 
(≥30 min, 5–7 days/week) or alternatively 75 min of 
vigorous intensity aerobic exercise per week over 3 
days are recommended and should be complemented 
with low- or moderate-intensity dynamic or isometric 
resistance training (2–3 times/week) to reduce BP and 
CVD risk.
I
A
Body-weight control is indicated to avoid obesity (BMI 
>30 kg/m2 or waist circumference >102 cm in men and 
>88 cm in women), as is aiming at healthy BMI (about 
20–25 kg/m2) and waist circumference values (<94 cm in 
men and <80 cm in women) to reduce BP and CV risk.
I
A
It is recommended to aim for a stable and healthy BMI 
(20–25 kg/m2) and waist circumference values (<94 cm 
in men and <80 cm in women) to reduce BP and CVD 
risk.
I
A
Increased consumption of vegetables, fresh fruits, fish, 
nuts, and unsaturated fatty acids (olive oil); low 
consumption of red meat; and consumption of low-fat 
dairy products are recommended.
I
A
Adopting a healthy and balanced diet, such as the 
Mediterranean or DASH diets, is recommended to help 
reduce BP and CVD risk.
I
A
It is recommended to restrict alcohol consumption to: 
• Less than 14 units/week for men.
• Less than 8 units/week for women.
I
A
Men and women are recommended to drink less 
alcohol than the upper limit, which is about 100 g/week 
of pure alcohol. How this translates into number of 
drinks depends on portion size (the standards of which 
differ per country), but most drinks contain 8–14 g of 
alcohol per drink. Preferably, it is recommended to 
avoid alcohol to achieve the best health outcomes.
I
B
Among all anti-hypertensive drugs, ACE inhibitors, 
ARBs, beta-blockers, CCBs, and diuretics (thiazides and 
thiazide-like drugs, such as chlorthalidone and 
indapamide) have demonstrated effective reduction of 
BP and CV events in RCTs, and thus are indicated as the 
basis of anti-hypertensive treatment strategies.
I
A
Among all BP-lowering drugs, ACE inhibitors, ARBs, 
dihydropyridine CCBs, and diuretics (thiazides and 
thiazide-like drugs such as chlorthalidone and 
indapamide) have demonstrated the most effective 
reduction of BP and CVD events, and are therefore 
recommended as first-line treatments to lower BP.
I
A
It is recommended that if BP is not controlled with a 
three-drug combination, treatment should be 
increased by the addition of spironolactone or, if not 
tolerated, other diuretics such as amiloride or higher 
doses of other diuretics, a beta-blocker, or an 
alpha-blocker.
I
B
If BP is not controlled with a three-drug combination 
and in whom spironolactone is not effective or 
tolerated, treatment with eplerenone instead of 
spironolactone, or the addition of a beta-blocker if not 
already indicated and, next, a centrally acting 
BP-lowering medication, an alpha-blocker, hydralazine, 
or a potassium-sparing diuretic should be considered.
IIa
B
8. Preventing and treating elevated blood pressure (blood pressure targets)
It is recommended that the first objective of treatment 
should be to lower BP to <140/90 mmHg in all patients 
and, provided that the treatment is well tolerated, 
treated BP values should be targeted to 130/80 mmHg 
or lower in most patients.
I
A
To reduce CVD risk, it is recommended that treated 
systolic BP values in most adults be targeted to 120– 
129 mmHg, provided the treatment is well tolerated.
I
A
Continued


<!-- PAGE 14 -->

### Page 14

A diastolic BP target of <80 mmHg should be 
considered for all hypertensive patients, independent of 
the level of risk and comorbidities.
IIa
B
In cases where on-treatment systolic BP is at or below 
target (120–129 mmHg) but diastolic BP is not at target 
(≥80 mmHg), intensifying BP-lowering treatment to 
achieve an on-treatment diastolic BP of 70–79 mmHg 
may be considered to reduce CVD risk.
IIb
C
In older patients (aged ≥65 years) receiving 
BP-lowering drugs: 
• It is recommended that systolic BP should be 
targeted to a BP range of 130–139 mmHg.
I
A
Because the CVD benefit of an on-treatment systolic BP 
target of 120–129 mmHg may not generalize to the 
following specific settings, personalized and more lenient 
systolic BP targets (e.g. <140 mmHg): should be 
considered among patients meeting the following criteria: 
• pre-treatment, symptomatic, orthostatic 
hypotension;
• and/or age ≥85 years.
IIa
C
Because the CVD benefit of an on-treatment systolic BP 
target of 120–129 mmHg may not generalize to the 
following specific settings, personalized and more lenient 
BP targets (e.g. <140/90 mmHg) may be considered 
among patients meeting the following criteria: 
• clinically significant, moderate to severe frailty at any 
age;
• and/or limited predicted lifespan (<3 years).
IIb
C
8. Preventing and treating elevated blood pressure (renal denervation)
Use of device-based therapies is not recommended for 
the routine treatment of hypertension, unless in the 
context of clinical studies and RCTs, until further 
evidence regarding their safety and efficacy becomes 
available.
III
B
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation may 
be considered for resistant hypertension patients who 
have BP that is uncontrolled despite a three 
BP-lowering drug combination (including a thiazide or 
thiazide-like diuretic), and who express a preference to 
undergo renal denervation after a shared risk-benefit 
discussion and multidisciplinary assessment.
IIb
B
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation may 
be considered for patients with both increased CVD 
risk and uncontrolled hypertension on fewer than three 
drugs, if they express a preference to undergo renal 
denervation after a shared risk-benefit discussion and 
multidisciplinary assessment.
IIb
A
Due to a lack of adequately powered outcomes trials 
demonstrating its safety and CVD benefits, renal 
denervation is not recommended as a first-line 
BP-lowering intervention for hypertension.
III
C
Renal denervation is not recommended for treating 
hypertension in patients with moderately to severely 
impaired renal function (eGFR <40 mL/min/1.73 m2) or 
secondary causes of hypertension, until further 
evidence becomes available.
III
C
9.1. Managing specific patient groups or circumstances
Hypertension in pregnancy
In women with gestational hypertension, pre-existing 
hypertension superimposed by gestational 
hypertension, or with hypertension and subclinical 
organ damage or symptoms, initiation of drug 
treatment is recommended when systolic BP is  
≥140 mmHg or diastolic BP ≥90 mmHg.
I
C
In women with gestational hypertension, starting drug 
treatment is recommended for those with confirmed 
systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg.
I
B
Continued
ESC Guidelines                                                                                                                                                                                          3925


<!-- PAGE 15 -->

### Page 15

In all other cases, initiation of drug treatment is 
recommended when systolic BP is ≥150 mmHg or 
diastolic BP is ≥95 mmHg.
I
C
In pregnant women with chronic hypertension, starting 
drug treatment is recommended for those with 
confirmed office systolic BP ≥140 mmHg or diastolic 
BP ≥90 mmHg.
I
B
In women with chronic and gestational hypertension, it 
is recommended to lower BP below 140/90 mmHg but 
not below 80 mmHg for diastolic BP.
I
C
Systolic BP ≥170 mmHg or diastolic BP ≥110 mmHg in 
a pregnant woman is an emergency, and admission to 
hospital is recommended.
I
C
Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg in 
pregnancy can indicate an emergency, and immediate 
hospitalization should be considered.
IIa
C
Diabetes
Antihypertensive drug treatment is recommended for 
people with diabetes when office BP is ≥140/90 mmHg.
I
A
In most adults with elevated BP and diabetes, after a 
maximum of 3 months of lifestyle intervention, BP 
lowering with pharmacological treatment is 
recommended for those with confirmed office BP 
≥130/80 mmHg to reduce CVD risk.
I
A
In people with diabetes receiving BP-lowering 
drugs it is recommended: 
• To target SBP to 130 mmHg and <130 mmHg if 
tolerated, but not <120 mmHg.
• In older people (aged ≥65 years aged), to target to an 
SBP range of 130–139 mmHg.
I
A
In persons with diabetes who are receiving BP-lowering 
drugs, it is recommended to target systolic BP to 120– 
129 mmHg, if tolerated.
I
A
Chronic kidney disease
In patients with diabetic or non-diabetic CKD, it is 
recommended that an office BP ≥140/90 mmHg be 
treated with lifestyle advice and BP-lowering 
medication. 
I
A
In patients with diabetic or non-diabetic 
moderate-to-severe CKD and confirmed BP ≥130/80  
mmHg, lifestyle optimization and BP-lowering 
medication are recommended to reduce CVD risk, 
provided such treatment is well tolerated.
I
A
In patients with diabetic or non-diabetic CKD:
In adults with moderate-to-severe CKD who are 
receiving BP-lowering drugs and who have eGFR >30  
mL/min/1.73 m2, it is recommended to target systolic 
BP to 120–129 mmHg, if tolerated. Individualized BP 
targets are recommended for those with lower eGFR 
or renal transplantation.
I
A
• It is recommended to lower systolic BP to a range of 
130–139 mmHg.
I
A
• Individualized treatment should be considered 
according to its tolerability and impact on renal 
function and electrolytes.
IIa
C
RAS blockers are more effective at reducing 
albuminuria than other antihypertensive agents, and are 
recommended as part of the treatment strategy in 
hypertensive patients in the presence of 
microalbuminuria or proteinuria.
I
A
ACE inhibitors or ARBs are more effective at reducing 
albuminuria than other BP-lowering agents and should 
be considered as part of the treatment strategy for 
patients with hypertension and microalbuminuria or 
proteinuria.
IIa
B
Heart failure
In patients with HFrEF, it is recommended that 
BP-lowering treatment comprises an ACE inhibitor or 
ARB, a beta-blocker and diuretic and/or MRA if 
required.
I
A
In patients with symptomatic HFrEF/HFmrEF, the 
following treatments with BP-lowering effects are 
recommended to improve outcomes: ACE inhibitors 
(or ARBs if ACE inhibitors are not tolerated) or ARNi, 
beta-blocker, MRA, and SGLT2 inhibitors.
I
A
In patients with HFpEF, because no specific drug has 
proven its superiority, all major agents can be used.
I
C
In hypertensive patients with symptomatic HFpEF, 
SGLT2 inhibitors are recommended to improve 
outcomes in the context of their modest BP-lowering 
properties.
I
A
In patients with symptomatic HFpEF who have BP 
above target, ARBs and/or MRAs may be considered to 
reduce heart failure hospitalizations and reduce BP.
IIb
B
Continued


<!-- PAGE 16 -->

### Page 16

Stroke
In all hypertensive patients with ischaemic stroke or 
TIA, an SBP target range of 120–130 mmHg should be 
considered.
IIa
B
In patients with confirmed BP ≥130/80 mmHg with a 
history of TIA or stroke a systolic BP target of 120–129  
mmHg is recommended to reduce CVD outcomes, 
provided treatment is tolerated.
I
A
Different ethnic groups
In black patients, initial antihypertensive treatment 
should include a diuretic or a CCB, either in 
combination or with a RAS blocker.
I
B
In black patients from Sub-Saharan Africa who require 
BP-lowering treatment, combination therapy including 
a CCB combined with either a thiazide diuretic or a 
RAS blocker should be considered.
IIa
B
Resistant hypertension
Recommended treatment of resistant hypertension is: 
• Reinforcement of lifestyle measures, especially 
sodium restriction.
• Addition of low-dose spironolactone to existing 
treatment.
• Or the addition of further diuretic therapy if 
intolerant to spironolactone, with either eplerenone, 
amiloride, a higher dose thiazide/thiazide-like 
diuretic, or a loop diuretic.
• Or the addition of bisoprolol or doxazosin.
I
B
In patients with resistant hypertension and 
uncontrolled BP despite use of first-line BP-lowering 
therapies, the addition of spironolactone to existing 
treatment should be considered.
IIa
B
In patients with resistant hypertension in whom 
spironolactone is not effective or tolerated, treatment 
with eplerenone instead of spironolactone, or the 
addition of a beta-blocker if not already indicated, and, 
next, a centrally acting BP-lowering medication, an 
alpha-blocker, or hydralazine, or a potassium-sparing 
diuretic should be considered.
IIa
B
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation may 
be considered for resistant hypertension patients who 
have BP that is uncontrolled despite a three 
BP-lowering drug combination, and who express a 
preference to undergo renal denervation after a shared 
risk-benefit discussion and multidisciplinary assessment.
IIb
B
10. Acute and short-term management of blood pressure
In patients with acute intracerebral haemorrhage:
In patients with intracerebral haemorrhage, immediate 
BP lowering (within 6 h of symptom onset) should be 
considered to a systolic target 140–160 mmHg to 
prevent haematoma expansion and improve functional 
outcome.
IIa
A
• Immediate BP lowering is not recommended for 
patients with systolic BP <220 mmHg.
III
A
• In patients with systolic BP ≥220 mmHg, careful 
acute BP lowering with i.v. therapy to <180 mmHg 
should be considered.
IIa
B
In hypertensive patients with an acute cerebrovascular event, anti-hypertensive 
treatment is recommended:
For patients with ischaemic stroke or TIA and an 
indication for blood pressure lowering, it is 
recommended that BP lowering therapy be 
commenced before hospital discharge.
I
B
• Immediately for TIA.
I
A
• After several days in ischaemic stroke.
I
A
In severe hypertension, drug treatment with i.v. 
labetalol, oral methyldopa, or nifedipine is 
recommended.
I
C
In severe hypertension in pregnancy, drug treatment 
with i.v. labetalol, oral methyldopa, or oral nifedipine is 
recommended. Intravenous hydralazine is a second-line 
option.
I
C
© ESC 2024
ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ACR, albumin-to-creatinine ratio (urine); ARB, angiotensin receptor blocker; ARNi, angiotensin 
receptor–neprilysin inhibitor; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; 
DASH, Dietary Approaches to Stop Hypertension; eGFR, estimated glomerular filtration rate; HBPM, home blood pressure monitoring; HFpEF, heart failure with preserved ejection 
fraction; HF(m)rEF, heart failure with (mildly) reduced ejection fraction; HFrEF, heart failure with reduced ejection fraction; HMOD, hypertension-mediated organ damage; i.v., 
intravenous; LVH, left ventricular hypertrophy; MRA, mineralocorticoid receptor antagonist; RAS, renin–angiotensin system; RCT, randomized controlled trial; SBP, systolic blood 
pressure; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons; SGLT2, sodium–glucose co-transporter 2; TIA, 
transient ischaemic attack. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3927


<!-- PAGE 17 -->

### Page 17

### 3 Pathophysiology of elevated

blood pressure and hypertension
Persistently high BP in systemic arteries is the hallmark of hypertension, 
which is the most important modifiable risk factor for all-cause 
and CVD morbidity and mortality globally.2 Most patients with 
hypertension have essential or primary hypertension, where the exact 
cause remains unknown, while an estimated 10% have secondary 
hypertension, with an identifiable cause (notably some studies indicate 
that the prevalence of secondary hypertension may be substantially 
higher, with modern systematic screening).10
The pathophysiology of hypertension involves complex interactions 
between environmental and behavioural factors, genes, hormonal net­
works, and multiple organ systems (renal, cardiovascular, and central 
nervous system11) (Figure 1). In addition, vascular and immune 
mechanisms are involved.12 Dysregulation of these processes leads to 
hypertension, which if uncontrolled, can lead to hypertension-mediated 
organ damage (HMOD) and adverse CVD outcomes.
Details on the pathophysiological processes, molecular mechanisms, 
and environmental and psychosocial elements that underlie hypertension 
are provided in the Supplementary text (Supplementary data online).
4. Clinical consequences of 
elevated blood pressure  
and hypertension
Longstanding hypertension causes organ damage and ultimately leads 
to cardiovascular, cerebrovascular, and clinical renal disease, which 
are all major contributors to the global burden of chronic disease 
Physical activity
Sedentary behaviour
Sleep quality/quantity
Dietary patterns
Sodium and potassium intake
Obesity
Alcohol consumption
Drugs or substances that increase BP
Geopolitical status
Noise pollution
Air pollution
Climate
Salt sensitivity
Pressure- natriuresis
RAAS
Renal ischaemia
RAAS
Endothelin system
Sex hormones
Endothelial dysfunction
Small artery remodelling
Large artery stiﬀness         
Biological sex
BP-associated SNPs
Monogenic forms of hypertension
Epigenetic and foetal programming
Stress
Low socio-economic status
Social deprivation
Healthcare access
Gender identity, roles and norms
Gender-based violence
Discrimination
B
e h
a vi o
u ra l 
fa ct o
rs
G
e n
et ic
 f a
ct o
rs
S
o ci o
-e c
o n
o m
ic
 a n
d 
p sy c
h o
s o
ci al
 f a
ct o
rs
E
n vi r
o n
m e
n ta l 
fa ct o
rs
H
o r
m o
n a
l 
m e
c h
a n
i s
m s
R
e n
a l 
m e
c h
a n
i s
m s
N
e u
r a
l 
m e
c h
a n
i s
m s
V
a s
c u
l a
r
 
m e
c h
a n
i s
m s
Autonomic nervous system
(SNS/PNS)
Baroreceptor reﬂex
Figure 1 Pathophysiology of elevated blood pressure and hypertension. BP, blood pressure; PNS, parasympathetic nervous system; RAAS, 
renin-angiotensin-aldosterone system; SNP, single-nucleotide polymorphism; SNS, sympathetic nervous system. Complex interplay between genes, 
environmental, and behavioural factors, organs, physiological systems, and neurohumoral processes contribute to BP regulation. Dysfunction of these 
processes leads to hypertension. The contribution of these factors to elevated BP and hypertension may differ among males and females.


<!-- PAGE 18 -->

### Page 18

(Figure 2).2,13–22 Organs adversely affected by elevated BP and hyper­
tension include the heart, brain, kidneys, eyes, and vessels (macrocir­
culation and microcirculation in organs with low resistance, such as 
the brain or kidney23), which undergo structural and functional 
changes. Although factors besides BP can contribute to these changes 
(i.e. dyslipidaemia, hyperglycaemia), we use the term ‘hypertension- 
mediated organ damage’ to indicate the presence of subclinical 
complications of hypertension that indicate high risk for subsequent 
clinical events. HMOD may have different profiles in men and women; 
for instance, left ventricular hypertrophy (LVH) and left atrial dilatation 
are more frequent in women.24–28
Evidence of HMOD usually indicates long-standing elevated BP and/ 
or hypertension and confers incremental prognostic information re­
garding CVD risk in all BP categories.29–31 Unless treated, HMOD 
can progress from asymptomatic to symptomatic, ultimately resulting 
in overt CVD events.31
The pathophysiological mechanisms underlying HMOD in the heart, 
brain, kidneys, vessels, and eyes are detailed in the Supplementary text
(Supplementary data online). The clinical consequences of HMOD, es­
pecially cerebrovascular disease (stroke and cognitive decline), kidney 
disease (acute and chronic), and heart disease [heart failure, atrial fibril­
lation (AF), ischaemic heart disease, and valvular disease] are also dis­
cussed in the Supplementary text (Supplementary data online). In 
addition, the Supplement highlights the impact of different measures 
of BP on CVD risk, including systolic BP, diastolic BP, pulse pressure, 
and BP variability.22,32–36
5. Measuring blood pressure
5.1. Introduction and pertinent definitions
This section reviews practical aspects of BP measurement, including 
technique and clinical validation of devices. It also reviews the evi­
dence for the most appropriate BP measurement methods when 
screening populations for hypertension, diagnosing hypertension, 
and managing patients receiving BP-lowering interventions. The cur­
rent guidelines promote use of out-of-office measurement for 
diagnosis and ongoing management of hypertension, reflecting in­
creasing evidence for the stronger relationship of home and ambula­
tory monitoring with outcomes, the ability to detect white-coat 
and masked hypertension, new BP treatment targets as low as 
120–129 mmHg systolic (Table 5), and evidence supporting enabling 
patient involvement and shared decision-making.
Definitions:
Systolic BP: arterial BP during systole (maximum arterial 
pulsatile pressure). This is measured using an auscultatory device at 
the onset of the first Korotkoff sound. Oscillometric devices esti­
mate systole using an algorithm that imputes from mean arterial 
pressure.37
Diastolic BP: arterial BP during diastole (minimum arterial pulsatile 
pressure). This is measured using an auscultatory device at the time of 
complete disappearance of the Korotkoff sounds (fifth sound). If there 
is no disappearance of sounds (no fifth sound) then the fourth 
See footnote for information on sex-differences
White matter lesions
Silent microinfarcts
Microbleeds
Brain atrophy 
Cognitive impairment
Vascular dementia
Ischaemic stroke
Cerebral haemorrhage
Brain
Microvascular remodelling
Hypertensive retinopathy
Eye
Atherosclerosis
Vascular calcification
Arterial stiffness
Large and medium arteries
Endothelial dysfunction
   Vasoreactivity
Vascular remodelling
Fibrosis and inflammation
   Peripheral vascular resistance 
Microcirculation
LVH
LA and LV dilatation
AF
Obstructive and non-obstructive CAD 
Myocardial Infarction 
Diastolic and/or systolic 
heart failure
Heart
Kidney
Glomerular arteriolar hypertension
Glomerulosclerosis
Albuminuria/Proteinuria
  GFR
Figure 2 Persistently elevated blood pressure and hypertension lead to hypertension-mediated organ damage and cardiovascular disease. AF, atrial 
fibrillation; CAD, coronary artery disease; GFR, glomerular filtration rate; LA, left atrial; LV, left ventricular; LVH, left ventricular hypertrophy. See the 
supplementary data online for detailed information on sex differences.  
ESC Guidelines                                                                                                                                                                                          3929


<!-- PAGE 19 -->

### Page 19

Korotkoff sound (muffling) is used to estimate diastolic BP. 
Oscillometric devices estimate diastole using an algorithm that 
imputes from mean arterial pressure.37
Inter-arm difference: systolic BP difference of >10 mmHg when 
BP is measured sequentially in each arm.38
Postural/orthostatic hypotension: decrement of ≥20 mmHg 
in systolic BP and/or ≥10 mmHg in diastolic BP when BP is measured 
in the standing position at 1 and/or 3 min after standing following a 
5-min period in the sitting or lying position.
White-coat hypertension: BP that is above the threshold for 
diagnosing hypertension in the office but below the threshold in home/ 
ambulatory settings, e.g. ≥140/90 mmHg in office but <135/85 mmHg 
at home/ambulatory daytime (or 24-h BP < 130/80 mmHg).
Masked hypertension: BP that is below the hypertension 
diagnostic threshold in the office but above the hypertension diagnostic 
threshold in home/ambulatory settings, e.g. <140/90 mmHg in clinic 
but ≥135/85 mmHg at home/ambulatory daytime (or 24-h BP 
≥130/80 mmHg).
Office BP: also known as clinic BP. The two terms are interchange­
able. This guidelines document uses ‘office BP’ preferentially. Of note, 
office BP can be measured manually or using an automated device. In 
addition, automated office BP (AOBP) can be conducted in a setting at­
tended by a healthcare professional or in an unattended fashion. Finally, 
not all office BP measurements are equal, with some facilities using a 
standardized method (which is recommended and outlined below) 
and others unfortunately using suboptimal approaches to office BP 
measurement.
Home BP measurement (HBPM): an out-of-office approach 
to measuring BP when the patient measures their own BP at home 
using a validated monitor (usually an upper-arm oscillometric cuff 
device).
Ambulatory BP measurement (ABPM): an out-of-office BP 
measurement that uses a fully automated oscillometric device, usually 
for a 24-h period, and measures BP at set intervals.
5.2. Practical recommendations for 
measuring blood pressure
5.2.1. Clinical validation of equipment for measuring 
blood pressure
A prerequisite of BP measurement is that it must be undertaken 
using a device that has been clinically validated and confirmed to 
be accurate. Of the commercially available oscillometric BP meas­
urement devices, as few as 6% have been adequately tested.39–41
National and international organizations provide lists of validated monitors 
(e.g. www.stridebp.org, www.validatebp.org).
Since the 2018 ESC/ESH Guidelines on the management of arter­
ial hypertension, three arbiters of device accuracy (the Association 
for the Advancement of Medical Instrumentation, the ESH, and the 
International Organization for Standardization) have published a 
universal standard for validating devices for measuring BP.42 This 
standard will likely become widely adopted. Validation standards 
and methodology need to be developed and implemented for novel 
BP measurement devices that are non-occlusive and ‘cuffless’.43,44
5.2.2. Office blood pressure measurement
All BP measurements can be influenced by circumstances of measure­
ment, including position, ambient temperature, the technique of meas­
urement, accuracy of equipment, and physical condition of the 
patient.45 For BP measurements in the office, we recommend following 
a standardized method (Figure 3).
Patient preparation: BP should be measured with the patient 
seated comfortably after 5 min of rest. Patients should avoid exercising 
and stimulants (caffeine, tobacco) for at least 30 min before measure­
ment. The patient’s bladder should be emptied if needed.46 Patients 
should be seated with their legs unfolded and their back supported at 
the time of measurement. The arm should be supported (to avoid iso­
metric exercise-induced increases in BP). Clothing at the location of the 
cuff placement should be removed; rolling up of shirt sleeves should be 
avoided as this can result in a tourniquet effect.
BP measurement technique: auscultatory or oscillometric 
techniques can be used to measure BP non-invasively. The manual aus­
cultatory approach is the traditional method of measuring systolic and 
diastolic BP at the brachial artery site using a stethoscope. In contrast, 
oscillometric devices compute mean arterial BP using the oscillation 
amplitude with cuff deflation (or inflation) and then estimate systolic 
and diastolic BP. Oscillometric devices can be semi-automated (taking 
one reading per activation) or fully automated (obtaining multiple read­
ings before averaging them). Oscillometric devices are not typically va­
lidated for use in AF, and the manual auscultatory method is preferred 
in these circumstances when feasible.47–49
BP cuff selection and positioning: an appropriately sized cuff 
should be used, as an under-sized or over-sized cuff will artificially 
elevate or reduce BP, respectively.50 The bladder length should be 
75%–100% and the width 35%–50% of the arm circumference. The 
arm circumference can be measured at the mid-point of the olecranon 
and the acromion but many cuffs include sizing indicators. The cuff 
should be positioned on the patient’s upper arm at the level of the heart 
with the lower edge of the cuff a few centimetres above the antecubital 
fossa. The stethoscope should not be placed under the cuff. In those 
with significant obesity where a correctly fitting upper arm cuff is not 
available, measurement at the lower arm or wrist can be considered 
as an alternative.51
BP measurement by manual auscultation: three BP mea­
surements should be taken, each 1–2 min apart, and additional mea­
surements only if the readings differ by >10 mmHg (e.g. this may 
occur with arrhythmias or white-coat effects). The BP recorded should 
be the average of the last two BP readings.
BP measurement using AOBP measurement: as noted 
above, AOBP using oscillometric devices may be obtained with (at­
tended) or without (unattended) clinicians or staff present. Clear evi­
dence regarding superiority of unattended vs. attended AOBP in 
managing BP to reduce rates of CVD is lacking; however, because BP 
readings may differ for unattended vs. attended measurements,52 we 
advise that a consistent approach be used depending on local resource 
and preference. AOBP monitors typically make three or six readings at 
1-min intervals and provide an average. AOBP correlates more closely 
with mean ABPM than with the manual auscultatory technique and may 
reduce measurement error and white-coat effects.53
Inter-arm BP difference: at the initial visit, BP should be measured 
in both arms to detect an inter-arm difference. Though devices allowing 
simultaneous measurement in both arms exist, sequential arm measure­
ment is considered sufficiently reliable.54,55 Measurement in the contra­
lateral arm should be undertaken once the three measurements in the 
index arm have been taken, and if a difference is detected, further meas­
urement in the original arm is indicated to ensure the difference is con­
sistent. If systolic BP differs by >10 mmHg between arms, subsequent 
measurements are obtained using the arm with the higher BP value. 
Significant inter-arm BP differences may reflect arterial stenosis or


<!-- PAGE 20 -->

### Page 20

coarctation of the aorta, which may require investigation. Also, of note, in 
some patients one arm is preferred to the other for routine BP measure­
ment (e.g. to avoid measurement of BP in an arm with an arteriovenous 
fistula or an arm where axillary lymph node dissection has occurred).
Postural/orthostatic hypotension: patients should be as­
sessed for orthostatic hypotension at the initial visit and if concerning 
symptoms arise. After 5 min of rest in the sitting or lying position, BP 
should be measured at 1 min and/or 3 min after standing, with a thresh­
old for orthostatic hypotension of ≥20/10 mmHg (systolic BP/diastolic 
BP) drop. Measurement after lying may be more sensitive for detecting 
orthostatic hypotension and may better predict falls but may be less 
feasible than measurement after sitting in clinical practice.56
Pulse assessment: heart rate should be recorded at the initial visit 
and arrhythmia excluded.
5.2.3. Home blood pressure measurement
HBPM is an out-of-office approach to measuring BP when the patient 
measures their own BP at home using a validated monitor (usually an 
upper-arm oscillometric cuff device).57,58 A consistent approach to 
>10
mmHg
1
2
3
4
5
6
7
8
Office blood pressure measurement
Measure after 5 min seated comfortably in a 
quiet environment
Use a validated device 
with an appropriate cuff 
size based on arm circumference
Place the BP cuff at the level 
of the heart with the patient's 
back and arm supported
Assess for orthostatic 
hypotension at Ist visit and 
thereafter by symptoms
Measure BP three times 
(1–2 min apart) and 
average the last 2 readings
Record heart rate and exclude arrhythmia 
by pulse palpation
Measure BP in both 
arms at the Ist visit to 
detect between arm 
differences
Obtain further measurements if the 
readings differ by 
>10 mmHg
90
62
Figure 3 Summary of office blood pressure measurement. BP, blood pressure.  
ESC Guidelines                                                                                                                                                                                          3931


<!-- PAGE 21 -->

### Page 21

HBPM should be used (Figure 4). Patients should be counselled to fol­
low the same preparation steps as used in clinics, which are outlined 
in Section 5.2.2. Two measurements should be taken at each measure­
ment session, performed 1–2 min apart. Measurements should be 
made twice a day (morning and evening) at the same time for a min­
imum of 3 days and up to 7 days.59 At the end of the measurement per­
iod, all readings are averaged. If the average after 3 days is close to the 
treatment threshold, then measurement should continue for the full 7  
days. Patients should be informed to keep a record of their home BP 
values and to ask their healthcare provider that the device accuracy 
be intermittently checked. Devices older than 4 years may be inaccur­
ate and, if inaccurate, should be replaced.60
An average HBPM of ≥135/85 mmHg (equivalent to an office BP of 
≥140/90 mmHg) should be used to diagnose hypertension and an aver­
age systolic BP of 120–134 mmHg or diastolic BP of 70–84 mmHg 
should be used to diagnose elevated BP. Of note, we use the same low­
er BP threshold (120/70 mmHg) for both office and HBPM in defining 
elevated BP.61
3
Home-based blood pressure measurement
1
Use a validated BP 
device
2
Measure BP in a quiet room 
after 5 min of rest with arm 
and back supported
Obtain two readings on each occasion,
1–2 min apart
4
Obtain readings twice a day 
(morninga and evening) for 
at least 3 and ideally 7 days average HBPM
≥135/85 mmHg
Hypertension:
5
Record and average all 
readings and present 
results to clinician
Figure 4 Summary of home blood pressure measurement. BP, blood pressure; HBPM, home blood pressure measurement. aMorning HBPM readings 
should be obtained before breakfast and before intake of medication but not immediately after awakening.


<!-- PAGE 22 -->

### Page 22

5.2.4. Ambulatory blood pressure measurement
ABPM (summarized in Figure 5) is an out-of-office BP measurement 
that uses a fully automated device, usually for a 24-h period. The 
devices measure BP by the oscillometric method and are pro­
grammed to measure BP at set intervals. Readings are usually 
obtained at 15–30 min intervals during the day (typically 7 a.m. to 
11 p.m.) and 30–60 min intervals at night (typically 11 p.m. to 
7 a.m.). The software usually provides average BP measurements 
for daytime, night-time, and 24 h. A minimum of 70% useable BP 
recordings is required for a valid measurement session, typically 
numbering ≥27 measurements over 24 h. Preferably, seven noctur­
nal readings should also be obtained.62 However, emerging data in­
dicate that ≥8/≥4 wake/sleep readings may be adequate if more 
cannot be obtained.63 Prior to using mean ABPM values (either 
24 h, daytime, or night-time) the raw BP values at each measurement 
should be reviewed for possible outlier or erroneous values. A diary 
should record activities (e.g. meals and exercise) and sleep time to 
assist interpretation. The diagnostic thresholds for elevated BP and 
hypertension using ABPM, and comparison with office BP and 
HBPM, are provided in Table 5.61,64
1
2
3
4
Ambulatory blood pressure measurement
Use a validated BP 
device
Device usually records BP at 
15–30 min intervals during the 
day and 30–60 min at night
A minimum of 70%
usable BP recordings is required
A diary of the patient's activities, 
intake of medications and sleep 
time should be completed
ABPM ≥130/80 mmHg over 24 h or
≥135/85 mmHg for the daytime average or
≥120/70 mmHg for the night-time average
Hypertension:
Figure 5 Summary of ambulatory blood pressure measurement. ABPM, ambulatory blood pressure measurement; BP, blood pressure.  
Table 5 Comparison of office, home, and ambulatory blood pressure measurement thresholds for elevated blood 
pressure and hypertension
Office BP 
(mmHg)a
Home BP 
(mmHg)
Daytime ABPM 
(mmHg)
24 h ABPM 
(mmHg)
Night-time 
ABPM (mmHg)
Reference
Non-elevated BP
<120/70
<120/70
<120/70
<115/65
<110/60
Elevated BP
120/70–<140/90
120/70–<135/85
120/70–<135/85
115/65–<130/80
110/60–<120/70
Hypertension
≥140/90
≥135/85
≥135/85
≥130/80
≥120/70
© ESC 2024
ABPM, ambulatory blood pressure monitoring; BP, blood pressure. 
aThe BP thresholds provided assume that a standardized approach to office BP measurement is performed (Figure 3). However, evidence indicates that office BP measurement in routine 
clinical settings is often not done using a standardized approach and, in this case, the routine office BP value may be 5–10 mmHg higher than it would have been if measured using the 
recommended standardized approach.65,66
ESC Guidelines                                                                                                                                                                                          3933


<!-- PAGE 23 -->

### Page 23

5.2.5. Comparison of home and ambulatory blood 
pressure monitoring
There is overlap between home and ambulatory monitoring in terms of 
differentiating between hypertensive phenotypes. However, around 
15% of people will have diagnostic disagreement, of whom approximately 
50% will represent clinically significant differences of >5 mmHg.67 The ad­
vantages and disadvantages of home and ambulatory monitoring are out­
lined in Table 6.
5.3. What is the best method for 
measuring blood pressure to diagnose 
hypertension?
5.3.1. Blood pressure measurement for hypertension 
screening
Opportunistic screening is typically performed using office BP measure­
ment and is key in detecting possible hypertension. However, a single 
screening office BP alone does not typically have sufficient diagnostic 
test performance to establish a diagnosis, especially for BP values close 
to diagnostic thresholds. Therefore, a single screening office BP re­
quires some form of repeat BP assessment to confirm a diagnosis (pref­
erably out-of-office or repeat office if out-of-office is not available). 
Relatedly, the BP threshold for acting on a screening office BP by con­
ducting repeat BP assessments should also be lower than the office BP 
threshold used for diagnosing hypertension. This latter consideration is 
particularly relevant in the presence of increased CVD risk or markers 
of HMOD. Also of note, populations where masked hypertension is 
more prevalent include men, those who smoke, those with excessive 
alcohol intake, or those with diabetes or obesity.68,69 While a screening 
office BP of >160/100 mmHg is almost always consistent with a diagno­
sis of hypertension, a small proportion of patients will have extreme 
white-coat effects that motivate prompt repeat BP assessment.68
Hypertension screening approaches are discussed further in Section 7.1.
5.3.2. Blood pressure measurement for diagnosing 
hypertension
After detecting high BP in the office, subsequent BP measurement 
for diagnosing hypertension depends on the clinical circumstances. 
Office BP has lower specificity than ABPM for detecting hypertension, 
so diagnosis based on office BP alone is less desirable unless resources 
do not allow out-of-office measurements.70 For screening BP of 
160–179 mmHg systolic or 100–109 mmHg diastolic, prompt confirm­
ation (within 1 month) using either office or out-of-office methods is 
recommended, as delays in treatment are associated with increased 
CVD event rates.71 For BP of ≥180/110 mmHg, assessment for hyper­
tensive emergency is recommended. In the setting of hypertensive 
emergency, immediately commencing BP-lowering treatment is recom­
mended, otherwise, prompt confirmation (preferably within a week) 
can be considered prior to commencing treatment (Sections 7 and 10).
For screening BP of 140–159/90–99 mmHg, out-of-office BP should be 
measured to confirm the diagnosis.72 When treatment of elevated BP is 
being considered (e.g. 120–139/70–89 mmHg) for individuals with high 
risk CVD conditions or sufficiently high 10-year predicted CVD risk, 
out-of-office BP measurement is recommended, both to confirm BP 
and to assess for masked hypertension. Out-of-office measurements 
may also be helpful for individuals with office BP of 130–139/85–89  
mmHg to diagnose masked hypertension. Further details on the diag­
nostic evaluation of hypertension are provided in Section 7.2.
5.4. What is the best method for 
measuring blood pressure for long-term 
management of hypertension?
While repeat office measurement of BP remains the commonest ap­
proach to long-term management of hypertension, several lines of in­
vestigation support augmenting office BP measurements with 
out-of-office assessment.
5.4.1. Home monitoring
There are over 50 trials of different self-monitoring-based interventions.73
Self-monitoring is associated with lower mean systolic BP at 12 months 
[−3.2 mmHg; 95% confidence interval (CI) −4.9 to −1.6 mmHg].74
Furthermore, there are known benefits of telemonitoring, digital interven­
tions, and mobile health in managing BP.75–78 Self-monitoring is also likely 
to be cost-effective.79 Unfortunately, in clinical practice, some patients 
may not provide reliable information on their home BP, and both their de­
vice and measurement technique need to be checked.
5.4.2. Ambulatory monitoring
ABPM provides a reference BP measurement but repeat ABPM testing 
is sometimes not practical due to resource constraints and, uncom­
monly, low patient acceptability.80 There is a paucity of data on treat­
ment guided by ABPM vs. that of office or HBPM measurements. A 
trial of treatment guided by HBPM vs. clinic and ambulatory monitoring 
found equivalence in BP control and HMOD.81 Other studies reported 
a non-significant trend to worse BP control with ambulatory vs. office 
BP monitoring, though the ambulatory group also received fewer 
Table 6 Comparison of ambulatory and home blood 
pressure monitoring
Ambulatory monitoring 
Advantages 
• Can identify white-coat and masked hypertension
• Measurement in real-life settings and during usual activities
• Stronger prognostic evidence
• Night-time readings
• Abundant information from a single investigation, including short-term 
diurnal BP variability
• Additional BP phenotyping (e.g. nocturnal dipping status)
Disadvantages 
• Relatively expensive and sometimes limited availability
• Can be uncomfortable and affect sleep
Home monitoring 
Advantages 
• Identify white-coat and masked hypertension
• Cheap and widely available
• Measurement at home, which may be more relaxed than at doctor’s office
• Patient engagement in BP measurement and telemedicine potential
• Easily repeated and used over longer periods to assess day-to-day BP 
variability
Disadvantages 
• Only static BP at rest is typically available
• Potential for measurement error due to improper measurement 
technique or unvalidated or poorly calibrated device
• Nocturnal readings not usually possible
© ESC 2024
BP, blood pressure.


<!-- PAGE 24 -->

### Page 24

medications.82 Potential advantages of ABPM over HBPM include diag­
nosing nocturnal hypertension or symptomatic transient hypotension 
or hypertension with exertion. As such, ABPM and HBPM should be 
considered complementary and additive, rather than competing ap­
proaches to long-term BP management.83
5.5. Measuring blood pressure in selected 
groups
5.5.1. Pregnancy
Monitoring BP during pregnancy is typically done at antenatal visits, 
which vary dependent on trimester (with increasing frequency to­
wards term). BP tends to reach a nadir at 20–30 weeks of pregnancy 
before increasing towards term at 40 weeks.84 Only a small number 
of automated oscillometric BP monitors have been adequately vali­
dated in pregnancy and several have failed, usually due to providing 
BP values that are erroneously high.85 Auscultatory measurement 
with sphygmomanometry is consequently the clinical standard in 
pregnancy.85 Self-monitoring at home is not yet proven to be effect­
ive in gestational hypertension.86,87 While norms for BP during 
pregnancy remain unclear, the 2022 Chronic Hypertension and 
Pregnancy (CHAP) trial indicated benefit of targeting clinic BP below 
140/90 mmHg.88 Consideration of secondary causes of hyperten­
sion is important in young women with gestational hypertension. 
Further details are provided in Section 9.2 and the 2018 ESC 
Guideline for the management of cardiovascular disease during 
pregnancy.89
5.5.2. Atrial fibrillation
Hypertension is a risk factor for AF.90,91 Oscillometric BP monitors 
are not always accurate in the presence of AF, due to the greater 
variability of BP beat to beat, so multiple auscultatory measurements 
are recommended.48,92,93 Some oscillometric BP monitors include 
an algorithm for detecting AF, but an electrocardiogram (ECG) is still 
required to confirm the diagnosis.49,94
5.5.3. Orthostatic hypotension
Postural or orthostatic hypotension is common,95,96 present in ap­
proximately 10% of all hypertensive adults and up to 50% of older 
institutionalized adults.97,98 Orthostatic hypotension is defined as 
a BP drop of ≥20/10 mmHg 1 and/or 3 min after standing following 
a 5-min period in the seated or lying position.99–101 Diagnosis is 
made in the office. Routine ABPM is not currently suitable for for­
mally assessing orthostatic hypotension,102 though it may help in 
some cases, particularly when accompanied by a patient symptom 
diary.103
5.6. Novel methods of measuring blood 
pressure
New methods to measure BP are under development. Continuous of­
fice and out-of-office BP recordings and ABPM and HBPM have been 
developed that derive beat-to-beat, reading-to-reading, and day-to-day 
BP variability. However, there is no agreement on the optimum ap­
proach to measuring variability, and there is no trial evidence that redu­
cing BP variability specifically can reduce CVD events.104 Other 
emerging technologies include wearable, wrist-based BP measurement 
devices, devices evaluating central BP, and cuffless devices implementing 
plethysmographic or other technologies.105,106 However, there is at 
present insufficient scientific consensus on the accuracy standards 
and validation procedures that these cuffless devices must comply 
with prior to commercialization.43,44,107–109
In view of these issues, none of these cuffless measurement modal­
ities are currently recommended for routine clinical use.
Recommendation Table 1 — Recommendations for 
measuring blood pressure (see Evidence Tables 1–8)
Recommendations
Classa
Levelb
It is recommended to measure BP using a validated 
and calibrated device, to enforce the correct 
measurement technique, and to apply a consistent 
approach to BP measurement for each patient.41,42
I
B
All adult patients (≥18 years) are recommended to 
have their office and/or out-of-office BP measured 
on an opportunistic basis and recorded in their 
medical file, and be told what their current BP is.
I
C
Out-of-office BP measurement is recommended for 
diagnostic purposes, particularly because it can 
detect both white-coat hypertension and masked 
hypertension. Where out-of-office measurements 
are not logistically and/or economically feasible, then 
it is recommended that the diagnosis be confirmed 
with a repeat office BP measurement using the 
correct standardized measurement technique.70
I
B
It is recommended that office BP should be measured 
in both arms at least at the first visit, because a 
between-arm systolic BP difference of >10 mmHg is 
associated with an increased CVD risk and may 
indicate arterial stenosis.55,110
I
B
If a between-arm difference of >10 mmHg in systolic 
BP is recorded, then it is recommended that all 
subsequent BP readings use the arm with the higher 
BP reading.110
I
B
Out-of-office BP measurement is recommended for 
ongoing management to quantify the effects of 
treatment and guide BP-lowering medication 
titration, and/or identify possible causes of side 
effects (e.g. symptomatic hypotension). Where 
out-of-office measurements are not logistically and/ 
or economically feasible, then ongoing management 
is recommended to be based on repeated office BP 
measurements using the correct standardized 
measurement technique.74,111,112
I
B
It is recommended that all patients undergoing 
BP measurement also undergo pulse palpation 
at rest to determine heart rate and arrhythmias 
such as AF.113
I
C
Most automated oscillometric monitors have 
not been validated for BP measurement in AF; 
BP measurement should be considered using 
a manual auscultatory method in these 
circumstances where possible.47–49
IIa
C
Continued
ESC Guidelines                                                                                                                                                                                          3935


<!-- PAGE 25 -->

### Page 25

### 6 Definition and classification of

elevated blood pressure and 
hypertension, and cardiovascular 
disease risk assessment
6.1. Definition and classification of 
elevated blood pressure and hypertension
Epidemiological studies demonstrate a continuous and log-linear asso­
ciation between BP and adverse CVD outcomes.22,32,33,114,115 Starting 
at levels as low as 90 mmHg systolic, the higher the BP the higher the 
relative risk of CVD including atherosclerosis.32,114 These observational 
data are complemented by randomized clinical trials (RCTs),116 which 
have provided experimental evidence regarding the BP range for which 
BP lowering with treatment is proven to reduce CVD events. Of note, 
some studies suggest a stronger relative risk for CVD for a given BP 
among females compared with males.117,118
A healthy lifestyle should be encouraged for all adults to prevent an 
increase in BP and development of hypertension.119,120 To aid pharma­
cological treatment decisions, the 2024 ESC Guidelines recommend a 
simplified categorization of adults according to their BP (Figure 6). In 
compiling this categorization, priority was given to evidence from ran­
domized trials over observational data. However, it is important to re­
iterate that the risk of CVD attributable to BP is continuous and that 
interpreting randomized trial data is an iterative process involving an 
element of subjectivity. As such, no categorization of BP can be consid­
ered immutable or flawless.
The 2024 Guidelines define hypertension as a confirmed office sys­
tolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg. For this diagnosis 
to be made, confirmation is recommended with out-of-office measure­
ments (HBPM or ABPM) or at least one repeat office measurement at a 
subsequent visit, as detailed in Section 5 and Section 7.2. This definition is 
based on several factors. First, meta-analyses of randomized trials pro­
vide evidence among all adults and across various settings for the bene­
fit of BP-lowering therapy among patients with BP above this 
threshold.116,121,122 Second, most adults with BP above this threshold 
are at increased CVD risk, typically with 10-year risk estimates of 
≥10% for fatal and non-fatal CVD events.123–125 The higher the pa­
tient’s baseline absolute risk for CVD, the greater the net benefit 
from BP-lowering treatment and, at the population level, the lower 
the estimated number needed to treat (NNT).126–128 Third, this 
more traditional BP threshold for hypertension is already widely used 
by policymakers to define a disease state, and maintaining this BP 
threshold to define hypertension (vs. lowering it) does not require 
most adults to be labelled with what is widely considered a disease.129
Here, we introduce a new BP category called ‘elevated BP’, which 
is defined as an office systolic BP of 120–139 mmHg or diastolic BP 
of 70–89 mmHg. Within this BP range, the efficacy of BP-lowering ther­
apy has been established in meta-analyses of RCTs,116 but average CVD 
risk in the elevated BP group is not sufficiently high to merit drug treat­
ment in all patients.123,124,130 Pharmacological treatment initiation is, 
however, suggested for a subgroup of patients within this BP range 
who are at increased global risk of CVD as identified by the risk strati­
fication approach outlined in Sections 6.3, 6.4, and 8.
Non-elevated BP is defined as a systolic BP of <120 mmHg and a dia­
stolic BP of <70 mmHg. Fewer individuals within this BP range are at 
increased risk of CVD,124 and evidence for CVD benefit with 
BP-lowering pharmacological treatment is lacking due to an absence 
of trials. We use the term ‘non-elevated BP’ to define this BP category 
in recognition that these are treatment categories and not prognostic 
categories. Because the relative risk for CVD starts to increase at BP 
below this threshold (even as low as 90 mmHg systolic BP), particularly 
among women,117,118 we avoid terms like ‘normal BP’, ‘optimal BP’, or 
‘normotension’ in defining this category.
6.2. Principles of a risk-based approach for 
managing blood pressure and preventing 
cardiovascular disease
In the context of BP-lowering interventions, randomized trials demon­
strate a consistent relative risk reduction in adverse CVD outcomes 
per unit reduction in BP.131,139 However, many medical interventions in­
cur costs and have side effects. Therefore, guidance is needed on select­
ing patients most likely to benefit from BP-lowering treatment. This is 
especially true among adults with elevated BP (office systolic BP of 
120–139 mmHg and/or diastolic BP of 70–89 mmHg). Practical aspects 
for implementing a risk-based approach are further discussed in Section 8.
6.2.1. Role of cardiovascular disease risk assessment
The risk of adverse CVD outcomes increases log-linearly with constant 
increments in systolic BP and diastolic BP.22,32,33,114,140 Concurrently, at 
higher BP, there is clustering of additional CVD risk factors.141,142
Consequently, many patients with hypertension will have an estimated 
10-year risk for CVD events of ≥10%,116,121,122 which, for the purposes 
of these guidelines, is considered sufficiently high risk to merit consid­
eration of BP-lowering treatment in the setting of elevated BP.143
Using BP thresholds for hypertension alone for allocating treatment 
would lead to under-treatment of many high-risk patients.144,145,115
A substantial proportion of excess CVD events attributable to BP oc­
cur in patients with BP levels below the traditional threshold for 
An assessment for orthostatic hypotension (≥20 
systolic BP and/or ≥10 diastolic BP mmHg drop at 1 
and/or 3 min after standing) should be considered at 
least at the initial diagnosis of elevated BP or 
hypertension and thereafter if suggestive symptoms 
arise. This should be performed after the patient is 
first lying or sitting for 5 min.
IIa
C
Other BP measures and indices (pulse pressure, BP 
variability, exercise BP) may be considered to 
provide additional clinical information on CVD risk in 
some circumstances.
IIb
C
© ESC 2024
AF, atrial fibrillation; BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 2 — Recommendations for 
categorizing blood pressure (see Evidence Table 9)
Recommendation
Classa
Levelb
It is recommended that BP be categorized as 
non-elevated BP, elevated BP, and hypertension to 
aid treatment decisions.116,121,122,131–138
I
B
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 26 -->

### Page 26

hypertension diagnosis. As the efficacy of BP lowering on preventing 
CVD events extends down to a systolic BP of 120 mmHg and a diastolic 
BP of 70 mmHg,116,135,136,146 patients with elevated BP and increased 
CVD risk can also derive benefit from BP-lowering treatment.124,145
The heterogeneity in CVD risk among adults with elevated BP is lar­
ger than in those with hypertension, as such patients tend to be young­
er, and their absolute CVD risk depends more on the prevalence of 
concomitant CVD risk factors.123,147 Consequently, formally estimating 
the patient’s CVD risk, encapsulating demographics and other CVD risk 
factors, is recommended to guide BP-lowering treatment decisions 
among patients with elevated BP.148–151
6.3. Predicting cardiovascular disease risk
Certain conditions on their own are associated with sufficient CVD risk 
such that patients with elevated BP alongside these conditions can be 
considered for BP-lowering therapy (Figure 7). These include moderate 
or severe chronic kidney disease (CKD),152 established clinical CVD (cor­
onary heart disease, cerebrovascular disease, peripheral arterial disease, 
or heart failure)153–158 concomitant HMOD (see Figure 7; Section 7; 
Supplementary data online, Table S1),31,159 diabetes mellitus, and familial 
hypercholesterolaemia (probable or definite).160–163 Regarding diabetes, 
some adults aged <60 years with type 2 diabetes and elevated BP have 
10-year CVD risk of <10%. Accordingly, the diabetes-specific 
Non-elevated blood pressure
Office BP
SBP <120 mmHg and
DBP <70 mmHg
HBPM
SBP <120 mmHg and
DBP <70 mmHg
ABPM
Daytime SBP <120 mmHg and
Daytime DBP <70 mmHg
Elevated blood pressure
Office BP
SBP 120–139 mmHg or
DBP 70–89 mmHg
HBPM
SBP 120–134 mmHg or
DBP 70–84 mmHg
ABPM
Daytime SBP 120–134 mmHg or
Daytime DBP 70–84 mmHg
Hypertension
Office BP
SBP ≥140 mmHg or
DBP ≥90 mmHg
HBPM
SBP ≥135 mmHg or
DBP ≥85 mmHg
ABPM
Daytime SBP ≥135 mmHg or 
Daytime DBP ≥85 mmHg
Insufficient evidence confirming the efficacy and safety of BP
pharmacological treatment
Risk stratify to identify individuals with high cardiovascular risk for BP
pharmacological treatment
Cardiovascular risk is sufficiently high to merit
BP pharmacological treatment initiation
Blood pressure classification
The diagnosis of hypertension and elevated BP requires confirmation using out-of-office measurements  (HBPM or ABPM) or at least one additional subsequent office measurement
Figure 6 Blood pressure categories. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; DBP, diastolic blood pressure; HBPM, home 
blood pressure monitoring; SBP, systolic blood pressure. We note that the respective non-daytime ABPM thresholds for elevated BP and hypertension 
diagnosis are listed in Section 5 (Table 5).  
ESC Guidelines                                                                                                                                                                                          3937


<!-- PAGE 27 -->

### Page 27

Systematic COronary Risk Evaluation 2 (SCORE2)-Diabetes risk- 
prediction model should be considered to confirm CVD risk is sufficient­
ly high (≥10%) among individuals with type 2 diabetes mellitus who are 
aged <60 years.164
In the absence of these sufficiently high-risk conditions, risk-prediction 
models (SCORE2 and SCORE-OP) have been developed in the general 
population to predict 10-year risk of CVD.165,166 In adults with elevated 
BP without the above sufficiently high-risk conditions, risk-prediction 
models are recommended to inform BP-lowering treatment decisions. 
Risk-prediction models are more accurate than clinical judgment or tally­
ing of individual risk factors.167–169
6.3.1. 10-year cardiovascular disease risk-prediction 
models
Prediction models differ in their input variables, predicted endpoints 
(outputs), and populations in which they were derived and validated. 
We endorse the use of SCORE2 for individuals aged 40–69 years 
and SCORE2–Older Persons (SCORE2-OP) for individuals aged 
≥70 years for predicting 10-year global risk of fatal and non-fatal 
CVD events (stroke or myocardial infarction).165,166 The management 
of adults aged <40 years is discussed in Section 9.1. The SCORE2 and 
SCORE2-OP models are preferred over other 10-year risk-prediction 
models, as they predict both fatal and non-fatal CVD events, have 
been validated and recalibrated to European populations, and because 
SCORE2-OP is adjusted for the competing risk of non-cardiovascular 
mortality. Calculating SCORE2 or SCORE2-OP is recommended for 
individuals with elevated BP who are not already at sufficiently high 
CVD risk due to established CVD, moderate or severe CKD, prob­
able or definite familial hypercholesterolaemia, diabetes mellitus, or 
HMOD.165,166,170
For the purpose of BP-lowering treatment decisions, individuals with 
elevated BP and a predicted 10-year CVD risk of ≥10% by SCORE2 or 
SCORE2-OP are considered in these guidelines to be sufficiently high 
risk, with details on the choice of lifestyle or drugs to facilitate 
BP-lowering treatment in this setting provided in Section 8.171,172 A 
number of considerations influenced our choice to recommend a single 
risk threshold of ≥10%, vs. the alternative option of using age-specific 
risk thresholds, such as those provided in the 2021 ESC Guidelines 
on cardiovascular disease prevention in clinical practice.170 For ex­
ample, contemporary data indicate the heightened importance of BP 
control in older adults due to their higher absolute CVD risk (resulting 
in a lower NNT) and concomitantly to reduce age-dependent adverse 
outcomes attributable to increased BP, such as dementia. Recent 
treat-to-target trials (testing systolic BP targets of approximately 
120 mmHg) used a single CVD risk inclusion threshold and were also 
Moderate or severe
CKD
eGFR <60 mL/min/1.73 m2 or albuminuria ≥30 mg/g (≥3 mg/mmol)
Familial hypercholesterolaemia
Probable or definite familial hypercholesterolaemia
Diabetes mellitus
Type 1 and type 2 diabetes mellitusc
Established clinical cardiovascular disease
Atherosclerotic cardiovascular diseasea
Heart failure
Other forms of hypertensionmediated organ damage
Cardiacb
Vascularb
Figure 7 Sufficiently high cardiovascular risk conditions that warrant blood pressure-lowering treatment among adults with elevated blood pressure. 
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate. aCoronary heart disease, cerebrovascular disease, peripheral arterial disease. 
bSee Section 7. cSCORE2-Diabetes should be considered to identify lower-risk individuals (<10% 10-year CVD risk), who may not require BP-lowering 
medication, particularly in individuals <60 years.


<!-- PAGE 28 -->

### Page 28

enriched with older adults.135,136,146 In addition, the average CVD event 
rate in the control arm of a landmark meta-analysis showing the bene­
fits of more intensive BP-lowering treatment was approximately 
equivalent to a 10% 10-year risk.116 Finally, the task force, which in­
cluded patient members, felt that age-specific risk thresholds could re­
sult in BP treatment decisions being made solely based on age, which is 
difficult to support scientifically or otherwise. To try to avoid any con­
fusion with the 2021 ESC Guidelines on cardiovascular disease preven­
tion in clinical practice, we use the terms ‘sufficiently high risk’ or 
‘increased risk’ to describe a person with 10-year CVD risk of ≥10% 
(rather than the terms ‘high risk’ or ‘very high risk’).
6.4. Refining cardiovascular disease risk 
estimation beyond risk models
The SCORE2 and SCORE2-OP risk-prediction models incorporate 
traditional risk factors such as age, sex, systolic BP, cholesterol values, 
and smoking status to predict 10-year risk of CVD.165,166 However, 
they do not include ‘non-traditional’ CVD risk factors (detailed below 
and hereafter termed ’risk modifiers’). Non-traditional CVD risk 
modifiers can improve the predictive performance (i.e. discrimin­
ation) of other CVD risk-prediction models, and may also apply to 
SCORE2 or SCORE2-OP.173 For example, among individuals with 
elevated BP and borderline increased 10-year predicted CVD risk 
by SCORE2 or SCORE2-OP (estimates of 5% to <10%), these non- 
traditional CVD risk modifiers may help up-classify the patient’s risk 
and thereby prompt BP-lowering treatment (Figure 8).
6.4.1. Sex-specific non-traditional cardiovascular 
disease risk modifiers
Sex differences in the distribution of traditional and non-traditional 
CVD risk factors have been documented among patients with 
hypertension.174 Although sex itself is included as an input variable 
in the SCORE2 and SCORE2-OP, and though these models were 
derived separately in men and women, some sex-specific, non- 
traditional risk modifiers were not included, and their associated 
impact on CVD risk may not be fully captured by SCORE2, 
SCORE2-OP, or SCORE2-Diabetes.
The relationship between BP and overall CVD risk is similar in 
both sexes, though some studies even suggest a stronger relative 
risk for CVD for a given BP level among females compared with 
males.117 Female-specific, non-traditional CVD risk modifiers often 
arise at specific times throughout the life course, especially during 
pregnancy and the peri-partum period. Women with a history of 
hypertensive disorders of pregnancy, including gestational hyperten­
sion and pre-eclampsia, have a two-fold higher long-term risk of 
CVD vs. women without these pregnancy conditions.175–177 The 
relative long-term CVD risk associated with hypertensive disorders 
of pregnancy may also be higher in younger vs. older pregnant wo­
men.178,179 Most, but not all, of the excess CVD risk associated 
with hypertensive disorders of pregnancy is captured by convention­
al CVD risk factors.176,178 Gestational diabetes is independently as­
sociated with an approximately two-fold increase in the long-term 
relative risk of CVD events.180 Other complications such as pre- 
term delivery, recurrent miscarriage, and one or more stillbirths 
are associated with a 40% relative increase in long-term CVD 
risk.181–185 Accordingly, a history of specific pregnancy complica­
tions, including gestational hypertension, pre-eclampsia, gestational 
diabetes, pre-term delivery, one or more stillbirths, and recurrent 
miscarriage, can be considered as non-traditional CVD risk modi­
fiers to up-classify women with elevated BP and borderline increased 
10-year predicted CVD risk (5% to <10%) to sufficiently high risk, 
thereby influencing the risk-based management of their elevated BP.
Evidence whether other female-specific conditions (infertility, poly­
cystic ovary syndrome, and premature menopause) and male-specific 
conditions (androgenic alopecia and erectile dysfunction) improve pre­
diction of CVD sufficiently to inform risk-based BP-lowering treatment 
decisions is inconclusive at present.
Recommendation Table 3 — Recommendations for 
assessing cardiovascular disease risk among individuals 
with elevated blood pressure (office systolic blood 
pressure 120–139 mmHg or diastolic blood pressure 
70–89 mmHg) (see Evidence Tables 10 and 11)
Recommendations
Classa
Levelb
It is recommended to use a risk-based approach in 
the treatment of elevated BP, and individuals with 
moderate or severe CKD, established CVD, HMOD, 
diabetes mellitus, or familial hypercholesterolaemia 
are considered at increased risk for CVD 
events.31,153–159,161–163,172
I
B
SCORE2 is recommended for assessing 10-year risk 
of fatal and non-fatal CVD among individuals aged 
40–69 years with elevated BP who are not already 
considered at increased risk due to moderate or 
severe CKD, established CVD, HMOD, diabetes 
mellitus, or familial hypercholesterolaemia.143,165,172
I
B
SCORE2-OP is recommended for assessing the 
10-year risk of fatal and non-fatal CVD among 
individuals aged ≥70 years with elevated BP who are 
not already considered at increased risk due to 
moderate or severe CKD, established CVD, HMOD, 
diabetes mellitus, or familial 
hypercholesterolaemia.143,166,172
I
B
It is recommended that, irrespective of age, 
individuals with elevated BP and a SCORE2 or 
SCORE2-OP CVD risk of ≥10% be considered at 
increased risk for CVD for the purposes of 
risk-based management of their elevated 
BP.143,165,166,172
I
B
SCORE2-Diabetes should be considered to estimate 
CVD risk among type 2 diabetes mellitus patients 
with elevated BP, particularly if they are <60 years of 
age.164
IIa
B
© ESC 2024
BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; HMOD, 
hypertension-mediated organ damage; SCORE2, Systematic COronary Risk Evaluation 2; 
SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons. 
Established CVD: coronary artery disease, cerebrovascular disease, peripheral arterial 
disease, or heart failure. For details on HMOD see Section 7. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3939


<!-- PAGE 29 -->

### Page 29

6.4.2. Non-traditional cardiovascular disease risk 
modifiers shared by men and women
In addition to sex-specific risk modifiers, several other non-traditional 
risk factors are associated with an increased risk of CVD, but few 
have been shown to improve risk prediction or discrimination beyond 
traditional CVD risk factors.
We advise considering high-CVD-risk race/ethnicity (e.g. South 
Asian),186–188 family history of premature onset atherosclerotic 
CVD (CVD event in males aged <55 years and/or females <65  
years),189,190 socio-economic deprivation,191 inflammatory condi­
tions (e.g. systemic lupus erythematosus, rheumatoid arthritis, 
and psoriasis affecting 10% or more of body surface area or requir­
ing systemic therapy),192–202 HIV,203–205 and severe mental illness 
(major depressive disorder, bipolar disorder, and schizophre­
nia)206–208 as shared non-traditional risk modifiers to up-classify 
the risk of individuals with a borderline increased 10-year pre­
dicted risk using SCORE2/SCORE2-OP (5% to <10%) to sufficient­
ly high CVD risk.
Sex-specific modifiers
 (Class IIa) 
Shared modifiers
(Class IIa) 
High-risk ethnicity
Gestational hypertension
Gestational diabetes
Pre-eclampsia
Pre-term delivery
One or more stillbirth
Recurrent miscarriage
Family history of 
premature onset ASCVD
Socio-economic deprivation
Auto-immune inflammatory diseases
Severe mental illness
Risk modifiers
HIV
Figure 8 Cardiovascular disease risk modifiers to consider for up-classification of risk. ASCVD, atherosclerotic cardiovascular disease; HIV, human 
immunodeficiency virus.


<!-- PAGE 30 -->

### Page 30

6.4.3. Additional risk decision tests
Coronary artery calcium (CAC) scoring improves CVD risk prediction 
and reclassifies risk when added to conventional CVD risk factor-based 
estimation models.209,210 A CAC score of >100 Agatston units or 
≥75th percentile for age, sex, and ethnicity favours up-classification 
of CVD risk.127 Internal or external carotid plaque may also improve 
CVD risk prediction.211 Similarly, femoral artery plaque detection 
may improve CVD risk prediction.212–214 Arterial stiffness, as assessed 
by pulse wave velocity (PWV), is associated with increased risk of CVD 
events and improves CVD risk stratification.215–218 Common arterial 
stiffness thresholds for increased risk include carotid–femoral PWV 
of >10 m/s and brachial–ankle PWV of >14 m/s. After assessing 
10-year predicted CVD risk and non-traditional risk factors, if a risk- 
based treatment decision remains uncertain for patients with elevated 
BP, it is reasonable to measure a CAC score or, alternatively, carotid or 
femoral plaque, or arterial stiffness; most especially after shared 
decision-making with the patient and after considering cost (see 
Section 7 for more details on these tests). There is also evidence that 
elevated cardiac biomarker levels (specifically high-sensitivity cardiac 
troponin and B-type natriuretic peptide/N-terminus B-type natriuretic 
peptide) are significant and effective risk modifiers,219,220 with further 
supportive data from hypertensive participants.159,221,222 Of note, 
these cardiac biomarkers can be considered markers of HMOD 
(Section 7); however, we focus on them in this risk modifier section be­
cause they may be elevated due to other reasons besides high BP (such 
as atherosclerosis or heart rhythm disease).
6.5. Summary of the cardiovascular disease 
risk stratification approach for allocating 
blood pressure treatment
Measured BP combined with 10-year CVD risk-prediction models and 
non-traditional risk modifiers should be used for stratifying risk when allo­
cating BP-lowering treatment for persons with elevated BP (Figure 9). It is 
important to stress here that patients with confirmed hypertension are re­
commended to receive BP-lowering treatment and no further risk strati­
fication is needed.
For patients with elevated BP, the presence of diabetes, familial 
hypercholesterolaemia, established CVD (defined as prior acute or 
chronic coronary syndrome, cerebrovascular disease, symptomatic 
peripheral arterial disease, or heart failure), moderate or severe 
CKD, or HMOD confers increased CVD risk. One caveat is that, spe­
cifically for individuals with elevated BP and type 2 diabetes mellitus only 
aged <60 years, SCORE2-Diabetes should be considered to identify 
lower CVD risk individuals (<10% over 10 years).
Otherwise, for patients without these high-risk conditions, 10-year risk 
of CVD should be calculated using SCORE2 (if aged 40–69 years) and 
SCORE2-OP (if aged ≥70 years). Patients with elevated BP and a 
10-year predicted risk of CVD events ≥10% are considered sufficiently 
high risk to warrant BP-lowering treatment (either by lifestyle or drug 
treatment, see Section 8). For patients with elevated BP and borderline in­
creased predicted CVD risk by SCORE2/SCORE2-OP (5% to <10% over 
10 years), up-classification of risk may be considered in the presence of 
sex-specific or shared non-traditional risk modifiers. After considering 
sex-specific and shared non-traditional risk modifiers, if a risk-based 
BP-lowering treatment decision remains uncertain, it may be reasonable 
to measure CAC score, carotid or femoral plaque, high-sensitivity cardiac 
troponin or B-type natriuretic peptide biomarkers, or arterial stiffness.
Risk stratification for patients with non-elevated BP (systolic BP of 
<120 mmHg and diastolic BP of <70 mmHg) is not required for the 
purpose of allocating BP-lowering treatment, as the safety and efficacy 
of commencing BP-lowering treatment below this threshold is uncer­
tain. Risk assessment may nonetheless be needed in this setting when 
considering other prevention therapies (e.g. lipid lowering).
Recommendation Table 4 — Recommendations for 
refining cardiovascular disease risk (see Evidence 
Tables 12–14)
Recommendation
Classa
Levelb
History of pregnancy complications (gestational 
diabetes, gestational hypertension, pre-term 
delivery, pre-eclampsia, one or more stillbirths, 
and recurrent miscarriage) are sex-specific risk 
modifiers that should be considered to up-classify 
individuals with elevated BP and borderline 
increased 10-year CVD risk (5% to <10% risk). 
183,184,223,224
IIa
B
High-risk ethnicity (e.g. South Asian), family history of 
premature onset atherosclerotic CVD, 
socio-economic deprivation, auto-immune 
inflammatory disorders, HIV, and severe mental 
illness are risk modifiers shared by both sexes that 
should be considered to up-classify individuals with 
elevated BP and borderline increased 10-year CVD 
risk (5% to <10% risk). 186–191,193,198,202,204,208
IIa
B
Continued
After assessing 10-year predicted CVD risk and 
non-traditional CVD risk modifiers, if a risk-based 
BP-lowering treatment decision remains uncertain for 
individuals with elevated BP, measuring CAC score, 
carotid or femoral plaque using ultrasound, 
high-sensitivity cardiac troponin or B-type natriuretic 
peptide biomarkers, or arterial stiffness using pulse wave 
velocity, may be considered to improve risk stratification 
among patients with borderline increased 10-year CVD 
risk (5% to <10% risk) after shared decision-making and 
considering costs.209–211,215,218,225,226
IIb
B
© ESC 2024
BP, blood pressure; CAC, coronary artery calcium; CVD, cardiovascular disease; HIV, 
human immunodeficiency virus. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3941


<!-- PAGE 31 -->

### Page 31

Patient with elevated BPa office SBP 120–139 mmHg or
DBP 70–89 mmHg
Y
Established CVD,
moderate/severe CKD,
HMOD, DM, or FH
(Class I)
N
Calculate 
SCORE2 or SCORE2-OP
(Class I)
Patient with
T2DM (only)
and
<60 years old
10-year predicted CVD risk
Any of the following:
Gestational diabetes
Gestational hypertension
Pre-eclampsia
Pre-term delivery
One or more still births
Recurrent miscarriage
N
Consider shared risk modifiers
(Class IIa)
Any of the following:
High-risk ethnicity
Family history of premature onset ASCVD
Socio-economic deprivation
Auto-immune diseases
Severe mental illness
HIV
N
If still uncertain, shared decision-making informed by risk tools
(Class IIb)
Any of the following meeting abnormal criteria:
CAC score
Carotid or femoral plaque
High-sensitivity cardiac troponin
NT-proBNP
Pulse wave velocity
Lifestyle measures to reduce BP
(Class I)
Reassess risk/BP
one year later
(Class IIa)
N
Lifestyle measures to reduce BP
(Class I)
After 3 months of lifestyle measures, pharmacological treatment for patients with
≥130/80 mmHg 
(Class I)
Y
N
Y
Y
Calculate
SCORE2- Diabetes
(Class IIa)
Y
 <5%
5% – <10%
≥10% 
Consider sex-specific risk modifiers
(Class IIa)
aExercise caution when considering treating persons with elevated
BP and;
Moderate-to-severe frailty
Symptomatic orthostatic hypotension
Age ≥85 years
Figure 9 Summary of cardiovascular disease risk-stratification approach for blood pressure treatment in adults with elevated blood pressure. ASCVD, 
atherosclerotic cardiovascular disease; BP, blood pressure; CAC, coronary artery calcium; CKD, chronic kidney disease; CVD, cardiovascular disease; 
DBP, diastolic blood pressure; DM, diabetes mellitus; FH, familial hypercholesterolaemia; HMOD, hypertension-mediated organ damage; NT-proBNP, 
N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic 
COronary Risk Evaluation 2–Older Persons.


<!-- PAGE 32 -->

### Page 32

### 7 Diagnosing hypertension and

investigating underlying causes
7.1. Screening for hypertension
Hypertension is predominantly an asymptomatic condition that is typ­
ically detected by systematic or opportunistic screening in a healthcare 
setting. Systematic screening refers to any process where individuals 
are identified and invited to a healthcare setting solely to measure their 
BP and CVD risk profile. Opportunistic screening refers to BP being 
measured when the patient presents to a healthcare setting for any rea­
son, such as a routine check-up or the treatment of an acute or chronic 
condition. Self-screening and non-physician screening are also increas­
ingly used.227–230
Few data are available on the effectiveness of different hypertension 
screening strategies to reduce the morbidity and mortality associated 
with hypertension.231–233 More evidence is needed before systematic 
screening programmes with BP measurement can be recommended 
in all adults to reduce CVD events.231
Opportunistic BP screening in a primary care setting appears effect­
ive, with an estimated 90% of all adults aged >40 years in the UK having 
a BP check within a 5-year time period,234 though these findings may 
not extrapolate to other countries. When patients provide HBPM re­
cordings, these can also be used as part of an opportunistic screening 
programme (see Section 5.2).235
Despite ongoing uncertainty about the effect of hypertension 
screening programmes on CVD outcomes, many studies have de­
monstrated that screening (mostly opportunistic screening) in­
creases hypertension detection, and that the benefits of screening 
likely outweigh harms.70 Global initiatives to raise BP awareness, 
such as the May Measurement Month,228 or targeted initiatives, 
such as the barbershop health outreach programmes,229 are success­
ful examples of BP screening campaigns.
Screening for hypertension, like for global CVD risk assessment, 
should be intermittently repeated, e.g. every 3 years. Considering 
the rate of progression to hypertension in European population 
samples,236 it is reasonable to measure BP at least every 3 years 
in the case of non-elevated BP and low–moderate CVD risk (i.e. in­
dividuals aged <40 years). More frequent BP checks (i.e. yearly) 
should be considered in individuals 40 years or older and individuals 
with elevated BP not currently meeting indications for treatment170
(Figure 10).
7.2. Confirming the diagnosis of 
hypertension
As noted in Section 5, assessment at a single visit by office BP has lower 
specificity compared with ABPM for diagnosing hypertension.70,238–241
Accordingly, a protocol for confirming the diagnosis of hypertension is 
proposed (Figure 10), with out-of-office BP measurement as the 
preferred method for confirming cases of elevated BP or hypertension. 
For initial screening systolic BP of >160 mmHg and/or diastolic 
BP of >100 mmHg, a prompt re-evaluation (within days to weeks but 
not >1 month) preferably with ABPM or HBPM is advisable.71
BP of >180/110 mmHg at screening requires exclusion of 
hypertensive emergencies, which should be managed as appropriate 
(see 242 and Section 10) with prompt treatment. For individuals with 
BP of >180/110 mmHg at screening but without hypertensive emer­
gency, prompt confirmation (preferably within a week) can be consid­
ered prior to commencing treatment.
Recommendation Table 5 — Recommendations for 
blood pressure screening (see Evidence Table 15)
Recommendation
Classa
Levelb
Opportunistic screening for elevated BP and 
hypertension should be considered at least every 3 
years for adults aged <40 years.236,237
IIa
C
Opportunistic screening for elevated BP and 
hypertension should be considered at least annually 
for adults aged ≥40 years.231,237
IIa
C
In individuals with elevated BP who do not currently 
meet risk thresholds for BP-lowering treatment, a 
repeat BP measurement and risk assessment within 1 
year should be considered.
IIa
C
Continued
Other forms of screening for hypertension (i.e. 
systematic screening, self-screening, and 
non-physician screening) may be considered, 
depending on their feasibility in different countries 
and healthcare systems.231–233
IIb
B
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 6 — Recommendations for 
confirming hypertension diagnosis
Recommendations
Classa
Levelb
In individuals with increased CVD risk where their 
screening office BP is 120–139/70–89 mmHg, it is 
recommended to measure BP out of office, using 
ABPM and/or HBPM or, if not logistically feasible, by 
making repeated office BP measurements on more 
than one visit.70,238–241
I
B
Where screening office BP is 140–159/90–99 mmHg, 
it is recommended that the diagnosis of 
hypertension should be based on out-of-office BP 
measurement with ABPM and/or HBPM. If these 
measurements are not logistically or economically 
feasible, then diagnosis can be made on repeated 
office BP measurements on more than one 
visit.70,238–241
I
B
Where screening office BP is ≥160/100 mmHg: 
• It is recommended that BP 160–179/100–109  
mmHg be confirmed as soon as possible (e.g. 
within 1 month) preferably by either home or 
ambulatory BP measurements;
• It is recommended when BP ≥180/110 mmHg that 
hypertensive emergency be excluded.
I
C
© ESC 2024
ABPM, ambulatory blood pressure measurement; BP, blood pressure; CVD, cardiovascular 
disease; HBPM, home blood pressure measurement. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3943


<!-- PAGE 33 -->

### Page 33

7.3. Communicating the diagnosis
Behavioural responses to health-related threats are strongly influ­
enced by five core themes (termed ‘illness representations’), which 
are identity, timeline, cause, consequences, and control/cure.243,244
These illness representations form the basis of how patients under­
stand a diagnosis, and can influence their responses after being diag­
nosed with hypertension.243 This conceptual framework can help 
guide the clinical communication of a diagnosis of hypertension. 
For example, patients’ understanding of the chronic nature of hyper­
tension (i.e. timeline theme) is key for ensuring long-term engage­
ment with medical treatment.245 Prior to commencing treatment, 
it is helpful to understand the extent to which patients believe that 
medications are necessary and ascertain if they have concerns.246
The core illness representations and beliefs about medicines for clin­
icians to consider are included in Table 7.
The 2021 ESC Guidelines on cardiovascular disease prevention in 
clinical practice recommend “an informed discussion about CVD risk 
and treatment benefits—tailored to the needs of a patient” as part 
of a diagnosis communication in hypertension.170 This can be facilitated 
using an interdisciplinary healthcare-provided approach (see Section 11) 
and by visual information or other more accessible material that might 
optimally communicate hypertension-related risk.128 Visualizing risk by 
medical imaging to motivate risk-reducing behaviour changes may also 
be beneficial.247
7.4. Baseline assessment and diagnostic 
approach
7.4.1. Medical history, medication history, and 
physical examination
The purpose of clinical evaluation is to diagnose hypertension, delineate 
factors potentially contributing to hypertension, identify other CVD 
risk factors, define relevant comorbidities, screen for potential second­
ary causes of hypertension (where indicated), and establish whether 
N
Y
N
Y
Screening for hypertension by office BP
High CVD risk conditions or
SCORE2/SCORE2-OP ≥10%
or
SCORE2/SCORE2-OP 5% – <10% 
+ risk modifiers
 ≥40 years? 
Non-elevated BP
<120/70
mmHg
Elevated BP
120–139/70–89
mmHg
Hypertension
140–159/90–99
mmHg
Hypertension
160–179/100–109
mmHg
Hypertension
≥180/110
mmHg
Opportunistic
BP screening at least every
3 years
(Class IIa)
Opportunistic
BP screening at least every year
(Class IIa)
Evaluate for hypertensive emergency
(Class I)
Confirm BP
preferably with either home or ambulatory
BP measurements
(Class I)
Confirm BP promptly preferably with either home or ambulatory
BP measurements
(Class I)
Figure 10 Protocol for confirming hypertension diagnosis. BP, blood pressure; CVD, cardiovascular disease; SCORE2, Systematic COronary Risk 
Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons.


<!-- PAGE 34 -->

### Page 34

there is evidence of HMOD or existing cardiac, cerebrovascular, or re­
nal disease.
Details on medical history and physical examination steps are sum­
marized in the supplement (see Supplementary data online, Tables S2 
and S3), as well as drugs or substances that may increase BP (see 
Supplementary data online, Table S4).
7.4.2. Drug adherence and persistence with 
treatment
Adherence is defined as the extent to which a patient’s behaviour, e.g. 
with respect to taking medication, coincides with agreed recommenda­
tions from a healthcare provider. Persistence represents the amount of 
time from initiation to discontinuation of therapy.248 Adherence to med­
ical therapies is especially suboptimal in asymptomatic conditions such as 
hypertension.249–254 Non-adherence to BP-lowering therapy correlates 
with a higher risk of CVD events.255,256 Objective methods to assess ad­
herence, such as detecting prescribed drugs in blood or urine samples and 
directly observed treatment (witnessed pill intake during ABPM), have de­
monstrated their potential usefulness, particularly in the setting of appar­
ently resistant hypertension.257 However, all methods for testing drug 
adherence have limitations.
Non-adherence to BP-lowering therapy depends on many factors 
(Figure 11).253 Effective patient–physician communication is crucial to im­
prove adherence.258,259 Single-pill combinations improve persistence in 
BP-lowering treatment and are associated with lower all-cause mortality.260
7.4.3. Routine and optional tests
Routine tests include laboratory and clinical tests to detect increased CVD 
risk and relevant comorbidities (e.g. hyperlipidaemia and diabetes) (Table 8).
Optional tests should be considered in the initial assessment if they 
are likely to change patient management, with the main rationale being 
to improve CVD risk stratification.170 As highlighted in Section 6, for 
adults with elevated BP who also have a 10-year estimated CVD risk 
of 5% to <10%, optional tests including those for HMOD may be con­
sidered if up-classification of risk on the basis of an abnormal test result 
could prompt initiation of BP-lowering therapy.31,170 Evidence of sub­
clinical microvascular neurodegeneration and/or lacunar brain disease 
due to small-vessel pathology may also indicate HMOD.264
Table 7 Key illness representations and treatment beliefs: how these apply to communicating a hypertension diagnosis 
to the patient (note that gender influences these representations)
Illness 
representation
Example patient question
Application to a hypertension diagnosis conversation
Identity
What is the disease/illness label and the 
related symptoms?
The condition where your systolic BP is ≥140 and/or diastolic  
BP ≥90 mmHg is called hypertension. We classify systolic BP 120–139 or diastolic  
BP 70–89 mmHg as elevated BP. For most people, this has no noticeable signs or 
symptoms, therefore, we need to monitor your BP to assess how medications and 
behavioural changes are working.
Control
Is the illness controllable through medical 
intervention or behavioural change?
Hypertension can usually be controlled with medication and behavioural changes such as 
dietary changes and regular physical activity. For some people we need to try a few 
different options before we get BP under control.
Timeline
Is this an acute or chronic problem?
This is a serious long-term or chronic condition condition that will require long-term 
management. This means that it may need to be managed throughout life.
Consequences
What are the physical and psychosocial 
consequences?
If hypertension is not controlled, then there is a risk of a serious acute cardiovascular 
disease event such as a stroke or heart attack; however, if it is managed through the right 
medical intervention and behavioural changes, then this risk can be reduced and the 
condition will have less consequences for your life.
Causes
What caused the condition?
Multiple factors contribute to someone developing hypertension. These include both 
non-modifiable factors (e.g. genetics and age) and modifiable factors (e.g. diet, weight, 
and physical activity). We are best focusing on those things that we can control to 
reduce your BP.
Treatment beliefs
Example patient question
Application to a hypertension diagnosis communication
Necessity
To what extent is treatment necessary?
Taking BP-lowering medication every day is necessary to keep your BP under control and 
to help prevent a more serious health problem developing. Do you think that these 
medicines will help you?
Concerns
To what extent does treatment cause 
concern?
Some patients have concerns about taking daily medications throughout their life, e.g. 
about side effects. Do you have any concerns about taking your BP medications every day?
© ESC 2024
BP, blood pressure.
Recommendation Table 7 — Recommendations for 
assessing adherence and persistence with treatment 
(see Evidence Table 16)
Recommendation
Classa
Levelb
Objective evaluation of adherence (either directly 
observed treatment or detecting prescribed drugs in 
blood or urine samples) should be considered in the 
clinical work-up of patients with apparent resistant 
hypertension, if resources allow.261–263
IIa
B
© ESC 2024
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3945


<!-- PAGE 35 -->

### Page 35

While the role of optional tests for HMOD (Table 9) in the man­
agement of elevated BP is emphasized in these guidelines, we also 
note that these tests may help to optimize treatment in hyperten­
sive adults with BP of >140/90 mmHg who are prescribed 
BP-lowering therapy (e.g. by facilitating patient adherence and 
overcoming clinician inertia in achieving an intensive BP treatment 
target of as low as 120 mmHg systolic). The role of visualizing 
HMOD in helping motivate risk-reducing changes in patients and 
overcome physician inertia has been tested in interventional trials 
(Section 7.3).247,265–267
Non-adherence definition
Assessment
Intervention
Non-adherence definition
Assessments
Intervention
1
2
3
Patient does not initiate medication
Prescription fill data and self-report
Communicate benefits/safety of medication; alleviate fear of side effects/harm; discuss practicalities
Patient does not take medication as prescribed
Prescription refill data; self-report; electronic monitoring; 
chemical adherence testing (blood/urine)
Reminders; encourage habit formation; simplify drug regimen
Patient discontinues medication
Prescription refill data; self-report; electronic monitoring;
chemical adherence testing (blood/urine)
Motivational counseling on benefits/safety of medication; 
discuss side effects; medication reconciliation; review practical aspects (cost and ease of access to medication)
Non-adherence definition
Assessment
Intervention
Initiation
Implementation
Persistence
Figure 11 Definitions, assessments, and potential interventions for the three phases of adherence to BP-lowering medications.  
Table 8 Routine tests recommended in the initial work-up of a patient with elevated blood pressure or hypertension
Routine test
Clinical utility
Fasting blood glucose (and HbA1c if fasting blood glucose is 
elevated)
Assessing CVD risk and comorbidities
Serum lipids: total cholesterol, LDL cholesterol, HDL and 
non-HDL cholesterol, triglycerides
Assessing CVD risk
Blood sodium and potassium, haemoglobin and/or haematocrit, 
calcium, and TSH
Screening secondary hypertension (primary aldosteronism, Cushing’s disease, 
polycythaemia, hyperparathyroidism, and hyperthyroidism)
Blood creatinine and eGFR; urinalysis and urinary 
albumin-to-creatinine ratio
Assessing CVD risk and HMOD 
Guiding treatment choice 
Screening secondary hypertension (renoparenchymal and renovascular)
12-lead ECG
Assessing HMOD (left atrial enlargement, left ventricular hypertrophy) 
Assessing irregular pulse and other comorbidities (AF, previous acute myocardial infarction)
© ESC 2024
AF, atrial fibrillation; CVD, cardiovascular disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; HMOD, 
hypertension-mediated organ damage; LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.


<!-- PAGE 36 -->

### Page 36

HMOD assessment is also an important way to identify young adults 
<40 years old who have increased CVD risk, since 10-year estimated 
CVD risk by SCORE2 cannot be calculated in this age group (see 
Section 8.1). More details on diagnostic thresholds for HMOD by the 
various assessment options, including important sex differences, are 
provided in Supplementary data online, Tables S1 and S5 and Figure 12.
Finally, some individuals may be at heightened risk for CVD events 
when cardiac and vascular HMOD measurements like LVH and 
increased PWV do not regress over time with appropriate treatment 
and BP control.14,268–271
Investigations aimed at screening for secondary hypertension are 
additional optional tests and are detailed in Section 7.6. Of note, patients 
with an incidental adrenal nodule or nodules (typically detected on im­
aging of the abdomen done for other clinical reasons) warrant screen­
ing for elevated BP and hypertension. Those with adrenal 
incidentalomas and hypertension warrant a basic work-up for second­
ary hypertension to include screening for primary aldosteronism, 
Cushing’s syndrome and phaeochromocytoma.
7.4.3.1. The kidneys
CKD is defined as abnormalities of kidney structure or function, pre­
sent for at least 3 months with implications for health.272 Renal function 
is evaluated initially using serum creatinine and an estimated glomerular 
filtration rate (eGFR) equation (preferably race-free CKD-EPI) and typ­
ically for proteinuria.273 Our definition of moderate-to-severe CKD re­
quires an eGFR of <60 mL/min/1.73 m2 or albuminuria of ≥30 mg/g 
(≥3 mg/mmol). Intensive BP control in patients with CKD reduces rates 
of CVD events.274,275 CKD can influence the choice of BP-lowering 
treatment (Sections 8 and 9), as well as newer drugs for cardiovascular 
prevention, such as sodium–glucose co-transporter 2 (SGLT2) inhibi­
tors and finerenone.
We recommend repeat measurement of eGFR and urine albumin: 
creatinine ratio (ACR) at least annually if clinically significant CKD is di­
agnosed. Renal ultrasound and Doppler examination to evaluate causes 
of CKD and to exclude renoparenchymal and renovascular hyperten­
sion (RVH) should also be considered.276,277
7.4.3.2. The heart
A 12-lead ECG is a part of the initial routine work-up for all patients with 
hypertension and should be repeated whenever patients present with an 
irregular pulse or cardiac symptoms. The ECG should be analysed for 
LVH (Supplementary data online, Table S1) and AF.31,278–282
Echocardiography is recommended in patients with hypertension 
when the ECG is abnormal, murmurs are detected, or there are cardiac 
symptoms. A full, standardized, two-dimensional echocardiogram should 
be performed, preferably with tissue Doppler and strain assessment. 
Echocardiography can be considered for all patients with newly diag­
nosed hypertension, if local resources and reimbursement policies allow. 
Over 5 years of follow-up, subclinical left ventricular diastolic dysfunction 
predicts the incidence of CVD.283–285 In addition, LVH detected by echo­
cardiography predicts total and cardiovascular mortality and CVD events 
in the general population,286,287 including in young adults.26,268,288,289
Data on the associations with CVD of other metrics for detecting 
HMOD in the heart are also available.26,268,290 Since cardiac size and func­
tion differ by sex, sex-specific thresholds for detecting HMOD in the 
heart are used to avoid under-diagnosis in women.25,174,291
Table 9 Optional tests that may be used as clinically indi­
cated in the initial work-up of a patient with elevated blood 
pressure or hypertension to assess hypertension-mediated 
organ damage or established cardiovascular disease
Optional test
Clinical utility
Echocardiography
Assessing HMOD (hypertensive heart 
disease) 
Assessing established CVD (previous 
acute myocardial infarction, heart 
failure) 
Assessing thoracic aorta dilation
CAC by cardiac CT or carotid or 
femoral artery ultrasound imaging
Assessing HMOD (atherosclerotic 
plaque)
Large artery stiffness (carotid– 
femoral or brachial–ankle PWV)
Assessing HMOD (arterial stiffness)
High-sensitivity cardiac troponin 
and/or NT-proBNP
Assessing HMOD
Ankle–brachial index
Assessing established CVD 
(lower-extremity arterial disease)
Abdominal ultrasound
Assessing established CVD 
(abdominal aneurysm)
Fundoscopy
Assessing HMOD (hypertensive 
retinopathy) 
Diagnosing hypertensive emergency/ 
malignant hypertension 
(haemorrhages and exudates, 
papilloedema)
© ESC 2024
CAC, coronary artery calcium; CT, computed tomography; CVD, cardiovascular disease; 
HMOD, hypertension-mediated organ damage; NT-proBNP, N-terminal pro-brain 
natriuretic peptide; PWV, pulse wave velocity.
Recommendation Table 8 — Recommendations for 
assessing renal hypertension-mediated organ damage
Recommendation
Classa
Levelb
It is recommended to measure serum creatinine, 
eGFR, and urine ACR in all patients with 
hypertension.170,273
I
A
If moderate-to-severe CKD is diagnosed, it is 
recommended to repeat measurements of serum 
creatinine, eGFR, and urine ACR at least annually.276
I
C
Renal ultrasound and Doppler examination should 
be considered in hypertensive patients with CKD to 
assess kidney structure and determine causes of 
CKD and to exclude renoparenchymal and 
renovascular hypertension.276,277 CT or magnetic 
resonance renal angiography are alternative testing 
options.
IIa
C
© ESC 2024
ACR, albumin:creatinine ratio; CKD, chronic kidney disease; CT, computed tomography; 
eGFR, estimated glomerular filtration rate. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 9 — Recommendations for 
assessing cardiac hypertension-mediated organ damage
Recommendation
Classa
Levelb
A 12-lead ECG is recommended for all patients with 
hypertension.31,281
I
B
Continued
ESC Guidelines                                                                                                                                                                                          3947


<!-- PAGE 37 -->

### Page 37

7.4.3.3. The arteries
Cardiac computed tomography (CT) may be used to measure CAC 
and, if intravascular contrast is administered, fully visualize coronary 
artery disease to improve risk stratification.211,293 As noted in 
Section 6, CAC scoring can reclassify CVD risk upwards or down­
wards in addition to conventional risk factors.127,170,211,233,294
Carotid ultrasound detects presence or absence of carotid plaque 
(wall thickness ≥ 1.5 mm) and stenosis. Presence of plaque in the ca­
rotid or femoral arteries improves risk prediction for CVD events in 
asymptomatic patients on top of conventional risk-factor assess­
ment.211,247,265,267,295,296 Systematic use of intima media thickness 
does not appear to consistently improve prediction of future CVD 
events.297 Arterial stiffness is measured as carotid–femoral PWV or 
brachial–ankle PWV, and can contribute to predictive value and risk 
reclassification.28,31,215,216 PWV is currently used mostly for research 
purposes or in specialist referral centres. Checking for inter-arm BP 
difference may identify a subclavian stenosis as vascular HMOD.38
Other tests assessing the vasculature [such as abdominal ultrasound 
or ankle–brachial index (ABI)] should also be considered in patients 
with hypertension, when specific cardiovascular complications (ab­
dominal aneurysm, peripheral artery disease) are clinically suspected. 
Finally, microvascular HMOD can be assessed by fundoscopy. A sim­
plified classification has been proposed and validated.298 In hyperten­
sive individuals, the presence of mild or moderate hypertensive 
retinopathy is associated with an increased risk of CVD events.299
Fundoscopy is recommended also in hypertensive diabetic patients 
and in the work-up of malignant hypertension and hypertensive 
emergencies.
7.4.4. Genetic testing
Hypertension is considered a complex polygenic disorder, because 
many genes or gene combinations influence BP.300,301 However, some 
well-defined phenotypes relating to single-gene mutations (i.e. mono­
genic forms of hypertension) have been identified (see Supplementary 
data online, Table S6). These are rare, but knowledge of the genetic 
defect may allow targeted treatment of the proband and also proper 
management of the patient’s siblings.302,303 As such, genetic testing 
should be considered only for those with a high prior probability of hav­
ing a monogenic condition and such patients should be referred to spe­
cialized centres. In most patients with elevated BP or hypertension, 
routine genetic testing is not recommended. Family history and a pedi­
gree analysis can help to find a heritable pattern of hypertension or 
hypotension.304
7.5. Resistant hypertension: definition and 
diagnosis
Despite availability and use of multiple BP-lowering medications, 
many patients worldwide have uncontrolled hypertension.306–308
Considering this, societies have introduced the term ‘drug-resistant 
hypertension’, or ‘treatment-resistant hypertension’, or ‘resistant 
hypertension’,309 which has been reported in 10%–20% of patients 
with hypertension.310,311
Resistant hypertension is not a disease per se. Compared with 
treated patients who achieve BP control, patients with resistant 
hypertension (by any definition) have a worse prognosis: risk of 
myocardial infarction, stroke, end-stage renal disease, and death 
in these adults may be two- to six-fold higher.309 Secondary causes 
of hypertension are also more likely in the presence of resistant 
hypertension.312
All resistant hypertension definitions require a diuretic in the prescribed 
multiple-drug regimen, because excess salt intake and salt and water reten­
tion are key players in resistance to BP-lowering treatments (Table 10).309
Echocardiography is recommended in patients with 
hypertension and ECG abnormalities, or signs or 
symptoms of cardiac disease.14,31,292
I
B
Echocardiography may be considered in patients 
with elevated BP, particularly when it is likely to 
change patient management.31,291
IIb
B
© ESC 2024
BP, blood pressure; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 10 — Recommendations for 
assessing vascular hypertension-mediated organ dam­
age (see Evidence Table 17)
Recommendations
Classa
Levelb
Fundoscopy is recommended if BP >180/110 mmHg 
in the work-up of hypertensive emergency and 
malignant hypertension, as well as in hypertensive 
patients with diabetes.
I
C
Fundoscopy for detecting hypertensive retinopathy 
may be considered in patients with elevated BP or 
hypertension.299
IIb
B
Ultrasound examination of the carotid or femoral 
arteries for detecting plaque may be considered in 
patients with elevated BP or hypertension when it is 
likely to change patient management.211
IIb
B
Continued
Coronary artery calcium scoring may be considered 
in patients with elevated BP or hypertension when it 
is likely to change patient management.127,211
IIb
B
Measurement of PWV may be considered in patients 
with elevated BP or hypertension when it is likely to 
change patient management.28,31,215,216
IIb
B
© ESC 2024
BP, blood pressure; PWV, pulse wave velocity. 
aClass of recommendation. 
bLevel of recommendation.
Recommendation Table 11 — Recommendations for 
genetic testing in hypertension management
Recommendations
Classa
Levelb
Genetic testing should be considered in specialist 
centres for patients suspected to have rare 
monogenic causes of secondary hypertension or for 
those with phaeochromocytoma/ 
paraganglioma.302,305
IIa
B
Routine genetic testing for hypertension is not 
recommended.
III
C
© ESC 2024
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 38 -->

### Page 38

Coronary artery calcium score
>100 Agatston units
Carotid-femoral PWV >10 m/s
Brachial-ankle PWV >14 m/s
Plaque (focal wall thickening >1.5 mm)
Cornell voltage: SV3+RaVL>28 mm (men) 
SV3+RaVL>20 mm (women)
RaVL ≥11 mm
Sokolow–Lyon: SV1+RV5 >35 mm
Cardiac CT
Pulse wave velocity
Carotid or femoral ultrasound
Cardiac biomarkers
Echocardiography
ECG
eGFR
ACR
Moderate-to-severe kidney disease
LVH
LVH
Diastolic dysfunction
LV mass/height2.7(g/m2.7):
>50 (men)
>47 (women)
LV mass/BSA(g/m2): 
>115 (men)
>95 (women)
RWT ≥0.43
LV concentric geometry:
LA volume/height2 (mL/m2): >18.5 (men)
>16.5 (women)
LA volume index (mL/m2): 34
e’ <7cm; E/e’ >14
hs-cTnT or I >99th percentile upper reference limit
NT-proBNP >125 pg/mL if age <75 years or >450 pg/mL if ≥75 years eGFR <60 mL/min/1.73 m2 irrespective of albuminuria
Albuminuria ≥30 mg/g irrespective of eGFR
Assistance overcoming patient and physician inertia
Individuals <40
years old with elevated blood pressure
Uncertain situations
(i.e. BP or risk close to thresholds,
masked or white-coat hypertension,
non-traditional
CVD risk factors)
Individuals with elevated BP with
SCORE2/SCORE2-OP
risk of 5–<10%
Support decision to start or intensify BPlowering treatment for:
Why measure?
How to diagnose HMOD?
What to measure?
Which organ?
Kidney
Heart
Arteries
Figure 12 Tests and criteria for defining hypertension-mediated organ damage and considerations for their use in clinical practice. ACR, albumin: 
creatinine ratio; BP, blood pressure; BSA, body surface area; CT, computed tomography; CVD, cardiovascular disease; ECG, electrocardiogram; 
eGFR, estimated glomerular filtration rate; HMOD, hypertension-mediated organ damage; hs-cTnT, high-sensitivity cardiac troponin T; LA, left atrial; 
LV, left ventricular; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-brain natriuretic peptide; PWV, pulse wave velocity; RWT, relative 
wall thickness; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons. More details 
and references can be found in the Supplementary data online, Tables S1 and S5.  
ESC Guidelines                                                                                                                                                                                          3949


<!-- PAGE 39 -->

### Page 39

In addition, excluding pseudo-resistance is a prerequisite. Specifically, 
pseudo-resistance indicates poor adherence to BP-lowering treatment, 
which should be verified by careful questioning of the patient in the first 
instance (Section 7.4.3).257 In addition, white-coat hypertension must be 
excluded.263 Contributors to pseudo-resistance are listed in Table 11. 
Objective evaluation of adherence (either directly observed treatment 
or detecting prescribed drugs in blood or urine samples) should also 
be considered, if resources allow.
The work-up of patients presumed to have resistant hypertension is 
complex and often requires technologies that are not available to 
GPs.257,309 Accordingly, we recommend these patients are referred 
to specialized centres.
7.6. Secondary hypertension: when to 
screen/further investigations
7.6.1. General considerations
Secondary hypertension is more prevalent than previously thought 
(Figures 13–15).312–317 Depending on the definition used and the 
cohort studied, the prevalence of secondary hypertension is 10%–35% in 
all hypertensive patients318,319 and up to 50% of patients with resistant 
hypertension (though the latter prevalence estimate included persons 
with eGFR < 40 mL/min/1.73 m2).312 Primary aldosteronism is a 
common cause,315,320 with, e.g. a high prevalence of hyperaldosteron­
ism (up to 12%) observed in patients with BP of >180/110 mmHg.316
Despite these numbers, screening rates for primary aldosteronism, 
even in high-risk groups such as those with resistant hypertension321
and hypokalaemia,322 are low (around 2% and 4% of eligible patients, 
respectively). In most healthcare systems, GPs are typically the ‘gate­
keeper’ of access to specialized care and should be involved in screen­
ing patients for common causes of secondary hypertension, especially 
sleep apnoea and primary aldosteronism (Supplementary data online, 
Tables S2 and S3). Primary aldosteronism is associated with an increased 
risk of CVD events, which may be partly independent of BP.323,324
7.6.2. Primary aldosteronism
Though spontaneous or diuretic-induced hypokalaemia are strongly 
suggestive of primary aldosteronism, a history of hypokalaemia is 
not present in most patients diagnosed with this condition. The 
aldosterone-to-renin ratio (ARR) is thus recommended for primary 
aldosteronism screening (see Figure 13).325 This test can easily be done 
in treatment-naïve patients, though it is far more common for the 
ARR test to be considered when patients are already being treated for 
elevated BP or hypertension. This is relevant because ARR can be influ­
enced by the drugs being taken at the time of testing. Accordingly, there 
are 2 approaches to screen for aldosteronism among patients who are 
already undergoing treatment for elevated BP or hypertension: 
• The first is to conduct ARR testing in treated patients with an indication 
for aldosteronism screening as efficiently as possible and without chan­
ging or stopping their baseline BP-lowering medications, simply to facili­
tate such testing. The ARR result then needs to be interpreted in the 
context of the specific medication(s) the patient is taking. Advantages 
of this approach include reducing barriers to screening and no change 
in medication in these patients, many of whom do not have BP con­
trolled and in whom further deterioration in their BP control by stop­
ping or changing medication may increase risk of CVD. Disadvantages 
include the interpretation of the ARR result, which depends on the spe­
cific medications taken at the time of testing.326 Input from a hyperten­
sion specialist or endocrinologist may be necessary.
Recommendation Table 12 — Recommendations for 
resistant hypertension work-up (see Evidence Table 18)
Recommendation
Classa
Levelb
Patients with resistant hypertension should be 
considered for referral to clinical centres with expertise 
in hypertension management for further testing.309,312
IIa
B
© ESC 2024
aClass of recommendation. 
bLevel of evidence.
Table 10 Current definition of resistant hypertension
Definition of resistant hypertension
Hypertension is defined as resistant when a treatment strategy including 
appropriate lifestyle measures and treatment with maximum or maximally 
tolerated doses of a diuretic (thiazide or thiazide-like), a RAS blocker, and a 
calcium channel blocker fail to lower office systolic and diastolic BP values to 
<140 mmHg and/or <90 mmHg, respectively. These uncontrolled BP values 
must be confirmed by out-of-office BP measurements (HBPM or ABPM— 
Section 5.1 for relevant BP thresholds).
Key considerations
• Resistant hypertension is not a disease, but an indicator that should be 
used to identify patients at high risk for CVD, in which secondary 
hypertension is also frequent;
• Pseudo-resistant hypertension must be excluded, including that caused by 
non-adherence to treatment;
• In patients with decreased eGFR (i.e. <30 mL/min/1.73 m2) an adequately 
up-titrated loop diuretic is necessary to define resistant hypertension;
• Patients with suspected resistant hypertension should be referred to 
specialized centres;
• These ESC Guidelines do not include the terms ‘controlled resistant 
hypertension’ (BP at target but requiring ≥4 medications) or ‘refractory 
hypertension’ (BP not at target despite ≥5 medications).
© ESC 2024
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular 
disease; eGFR, estimated glomerular filtration rate; HBPM, home blood pressure 
monitoring; RAS, renin–angiotensin system.
Table 11 Conditions found to cause pseudo-resistance 
or resistance to blood pressure-lowering treatment
Causes of pseudo-resistant hypertension
Poor adherence to and persistence with treatment 
White-coat phenomenon 
Poor BP measurement method 
Marked brachial artery calcification (Osler phenomenon) 
Clinician inertia (inadequate doses, inappropriate combinations of 
BP-lowering drugs) 
Munchausen syndrome (rare)
Causes of resistant hypertension
Behavioural factors 
Overweight/obesity 
Physical inactivity 
Excess daily dietary sodium 
Excess habitual alcohol consumption
Use of drugs or substances that may increase BP 
See Supplementary data online, Table S4
Undetected secondary hypertension 
See Table 13
© ESC 2024
BP, blood pressure.


<!-- PAGE 40 -->

### Page 40

• To reliably estimate renin and aldosterone status (and therefore 
ARR), and to facilitate a ‘clean’ screen for aldosteronism, a second 
approach is to discontinue drugs that affect these variables when­
ever feasible before ARR testing (Table 12). Such interfering drugs 
include, beta-blockers, centrally acting drugs (e.g., clonidine and 
alpha-methyldopa) renin-angiotensin system (RAS) blockers and 
diuretics.326 Long-acting calcium channel blockers (CCBs), either di­
hydropyridine or non-dihydropyridine, and alpha-receptor antago­
nists do not interfere with the ARR and can be used instead of 
interfering medications before ARR testing. Should drugs that do 
not interfere with the ARR be contraindicated or insufficient to con­
trol BP, centrally acting sympatholytic drugs can also then be used, but 
at the risk of slightly more false positives (by renin suppression). 
Furthermore, when mineralocorticoid receptor antagonists (MRAs) 
cannot be stopped for safety reasons (i.e. severe hypokalaemia or se­
vere hypertension among patients with severe hyperaldosteronism), 
recent evidence suggests that the accuracy of ARR testing under 
this treatment is only marginally impacted, particularly in the presence 
of florid primary aldosteronism.327
Assessing sodium intake (preferably 24 h urinary sodium, or sodium- 
to-creatinine ratio in the morning urine sample) is also important for 
interpreting the ARR, as is time in menstrual cycle for females. ARR 
cut-offs vary depending on unit of measurement and by local labora­
tory. For detailed information, readers are referred to the latest pri­
mary aldosteronism guidelines.328,329
7.6.3. Renovascular hypertension
Renovascular hypertension (RVH) defines a condition where renal 
artery occlusion or stenosis decreases renal perfusion pressure to 
a level that activates the renin–angiotensin–aldosterone system 
(RAAS), thereby raising BP. Major causes are atherosclerosis and 
fibromuscular dysplasia (Figure 14 and Supplementary data online, 
Tables S1 and S2). Atherosclerosis is the most common form of 
RVH, especially in older adults.318 Fibromuscular dysplasia is a sys­
temic non-atherosclerotic vascular disease involving medium-sized 
muscular arteries. When renal arteries are involved, fibromuscular 
dysplasia may induce RVH (FMD-RVH), especially in children and 
younger women.330–332
Though not highly sensitive, very elevated renin levels raise the sus­
picion for RVH. The work-up of RVH (Table 13) is based on imaging 
tests, such as renal artery Doppler ultrasound, with bilateral assessment 
of renal arterial resistive index, or abdominal CT angiography, or mag­
netic resonance imaging (MRI), in line with current ESC Guidelines on 
the diagnosis and treatment of peripheral arterial diseases,277 which 
will be updated in 2024. Of note, bystander renal artery stenosis may 
be present in patients with essential hypertension, without causing sec­
ondary hypertension due to RVH. Since fibromuscular dysplasia is a sys­
temic disease, CT or MRI angiography from head to pelvis is 
recommended in patients with FMD-RVH.277,332
7.6.4. Obstructive sleep apnoea syndrome
Obstructive sleep apnoea syndrome (OSAS) is prevalent in hyperten­
sion and particularly in resistant hypertension, with studies indicating 
that up to 60% of patients with resistant hypertension have features 
of OSAS.314 OSAS should be suspected in patients with hypertension 
and suggestive symptoms (see Supplementary data online, Table S2), 
in all patients with resistant hypertension, and in patients with non- 
dipping or reverse-dipping pattern at 24 h BP monitoring, especially if 
obese (Figure 15). Using validated questionnaires may help identify pa­
tients at high risk of OSAS.333 Lack of suggestive symptoms does not 
rule out OSAS. A simplified polysomnogram confirms the diagnosis [ap­
noea–hypopnoea index (AHI) > 5] and can quantify the severity of 
OSAS (mild: AHI < 15; moderate: AHI of 15–30; severe: AHI > 30).334
Table 12 Drugs and conditions that affect aldosterone, renin, and aldosterone-to-renin ratio
Factor
Effect on plasma aldosterone levels
Effect on renin levels
Effect on ARR
Serum potassium status
Hypokalaemia
↓
→↑
↓ (FN)
Potassium loading
↑
→↓
↑
Sodium restriction
↑
↑↑
↓ (FN)
Sodium loading
↓
↓↓
↑ (FP)
Drugs
Beta-adrenergic blockers
↓
↓↓
↑ (FP)
Calcium channel blockers (DHPs)
→↓
→↑
→↓ (FN with short-acting DHPs)
ACE inhibitors
↓
↑↑
↓ (FN)
ARBs
↓
↑↑
↓ (FN)
Potassium-sparing diuretics
↑
↑↑
↓ (FN)
Potassium-wasting diuretics
→↑
↑↑
↓ (FN)
Alpha-2 agonists (clonidine, methyldopa)
↓
↓↓
↑ (FP)
NSAIDs
↓
↓↓
↑ (FP)
Steroids
↓
→↓
↑ (FP)
Contraceptive agents (drospirenone)
↑
↑
↑ (FP)
© ESC 2024
↑, raised; ↓, lowered; →, no effect; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARR, aldosterone-to-renin ratio; DHPs, dihydropyridines; FN, false negative; FP, 
false positive; NSAID, non-steroidal anti-inflammatory drug.
ESC Guidelines                                                                                                                                                                                          3951


<!-- PAGE 41 -->

### Page 41

Primary aldosteronism
Mostly asymptomatic
Spontaneous or diureticprovoked hypokalaemia
AF 
Disproportionate HMOD
Muscle weakness and tetany
Family history of primary aldosteronism, early onset hypertension and/or stroke
Adrenal incidentaloma
Signs and symptoms
Diagnosis
Pathophysiology
Treatment
Aldosterone-renin ratio (ARR)
Confirmatory tests (e.g. saline suppression test)
Adrenal vein sampling or functional imaging
Genetic testing
Aldosterone-producing adenoma
Familial forms due to germline mutations
Bilateral hyperplasia
Medical: mineralocorticoid receptor antagonists
Surgical: unilateral adrenalectomy
Figure 13 Summary of primary aldosteronism as a common form of secondary hypertension. AF, atrial fibrillation; HMOD, hypertension-mediated 
organ damage.  
Table 13 Optional tests that should be used to screen for secondary hypertension in the presence of suggestive signs, 
symptoms, or medical history
Cause of secondary 
hypertension
Screening test
Primary aldosteronism
Aldosterone-to-renin ratio 
Helpful information can also be provided by reviewing prior potassium levels (hypokalaemia increases the likelihood of 
coexistent primary hyperaldosteronism)
Renovascular hypertension
Renal doppler ultrasound 
Abdominal CT angiogram or MRI
Phaeochromocytoma/paraganglioma
24 h urinary and/or plasma metanephrine and normetanephrine
Obstructive sleep apnoea syndrome
Overnight ambulatory polysomnography
Renal parenchymal disease
Plasma creatinine, sodium, and potassium 
eGFR 
Urine dipstick for blood and protein 
Urinary albumin-to-creatinine ratio 
Renal ultrasound
Cushing’s syndrome
24 h urinary free cortisol 
Low-dose dexamethasone suppression test
Thyroid disease (hyper- or 
hypothyroidism)
TSH
Hyperparathyroidism
Parathyroid hormone 
Calcium and phosphate
Coarctation of the aorta
Echocardiogram 
Aortic CT angiogram
© ESC 2024
CT, computed tomography; eGFR, estimated glomerular filtration rate; MRI, magnetic resonance imaging; TSH, thyroid-stimulating hormone.


<!-- PAGE 42 -->

### Page 42

Restless/intermittent sleep,
recurrent awakenings daytime sleepiness, fatigue,
impaired concentration
Increased neck circumference
Apnoea, snoring
Obesity
Signs and symptoms
Atrial fibrillation
Non-dipping or reverse dipping pattern 24 h ABPM
Obstructive sleep apnoea
Pathophysiology
Intermittent upper airway obstruction during sleep
Overnight ambulatory polysomnography
Diagnosis
Treatment
Weight loss
CPAP
Mandibular advancement devices
Figure 15 Summary of obstructive sleep apnoea as a common form of secondary hypertension. AF, atrial fibrillation; ABPM, ambulatory blood pres­
sure monitor; CPAP, continuous positive airway pressure.  
Renovascular hypertension
Migraine, pulsatile tinnitus (FMD)
Pulmonary oedema (bilateral)
Multisite atherosclerosis
Unexplained small kidney or kidney asymmetry
Age <40 years (FMD)
Signs and symptoms
Pathophysiology
Diagnosis
Treatment
Significant renal artery stenosis:
Atherosclerosis
Fibromuscular dysplasia
Rare causes
Renal doppler ultrasound
Abdominal CT-Angio or MRI
Vascular bruits
Arterial dissections and/or aneurysms (FMD)
Medical: optimal CV
risk management
Interventional: renal angioplasty without (FMD) or with stenting (atherosclerosis)
Acute    eGFR after RAS blocker
GFR, albuminuria,    renin
Age >60 years with acute change in BP or flash pulmonary oedema
(atherosclerosis)
Figure 14 Summary of renovascular disease as a common form of secondary hypertension. CT-Angio, computed tomography angiography; 
CV, cardiovascular; FMD, fibromuscular dysplasia; GFR, glomerular filtration rate; MRI, magnetic resonance imaging; RAS, renin–angiotensin system.  
ESC Guidelines                                                                                                                                                                                          3953


<!-- PAGE 43 -->

### Page 43

7.6.5. Phaeochromocytoma/paraganglioma
Phaeochromocytomas/paragangliomas (PPGLs) are a rare form of sec­
ondary hypertension characterized by a highly heterogeneous clinical 
presentation.335,336 PPGLs are usually discovered incidentally.337
A PPGL should be suspected in the presence of signs and symptoms of 
catecholamine excess or in syndromic PPGL, in patients with a family his­
tory of PPGL, and in carriers of a germline mutation in one of the 
PPGL-causing genes.338 Since normetanephrine and metanephrine are se­
creted constitutively, as opposed to the highly variable nature of catechol­
amine secretion, they are preferred as screening tests for PPGL (Table 13).
8. Preventing and treating elevated 
blood pressure and hypertension
The ultimate goal of preventing and treating elevated BP and hyperten­
sion is to reduce CVD, to improve quality of life, and to prevent prema­
ture death. Crucially, besides BP, other CVD risk factors need to be 
comprehensively addressed (e.g. smoking, glucose, dyslipidaemia) as de­
tailed in the 2021 ESC Guidelines on cardiovascular disease prevention 
in clinical practice.170 Indeed, it is worth emphasizing that, when com­
bined, these CVD risk factors have multiplicative (not additive) effects 
on CVD risk.340
8.1. Prevention strategies in early life
Detailed information on this topic is provided in the Supplementary data 
online. High BP tracks from childhood to adulthood.341,342 Hypertension 
in childhood was redefined in a 2022 ESC Consensus Document.343
8.2. Non-pharmacological interventions
A major underlying contributor to elevated BP and hypertension in the 
general adult population is unhealthy lifestyle, with severe consequences 
for all-cause and CVD mortality. As such, we give lifestyle interventions to 
reduce BP a special status in our recommendations throughout these 
guidelines (Figures 16 and 17). This is reflected by a modified approach 
to the class of recommendations for lifestyle interventions compared 
with medical interventions (pharmacological or procedural). Given the 
salutary benefits of healthy lifestyle on a range of outcomes that extend 
well beyond BP-lowering effects,347 including broad mental and physical 
health benefits, we do not require lifestyle interventions to have RCT evi­
dence for efficacy in reducing CVD events through BP lowering to achieve 
a Class I recommendation. In deciding to give lifestyle interventions this 
status, the task force also recognizes that: (i) lifestyle interventions are 
less likely to be subjected to clinical outcomes trials (e.g. due to funding 
limitations and lack of interest from industry), and (ii) the risks of adverse 
effects and toxicity relating to healthy lifestyle interventions are low. In 
contrast, in these guidelines, to achieve a Class I recommendation (irre­
spective of level of evidence) there needs to be evidence that medical in­
terventions that reduce BP also decrease CVD events by BP lowering.
8.2.1. Dietary sodium and potassium intake
8.2.1.1. Sodium
Reducing dietary salt (sodium chloride) intake in individuals with high 
baseline intake lowers CVD event rates.348 Extensive observational stud­
ies have reported dose–response associations between high dietary so­
dium intake and CVD events.349–351 The potential impact of salt 
reduction on population health is significant, particularly in countries 
where the population’s average salt intake is high. Pooled data from long- 
term follow-up salt-reduction trials demonstrate that reducing salt by 
2.5 g/day is associated with an approximately 20% reduction in CVD 
events at the population level.349
The health benefits of salt reduction are likely mediated, largely, by 
BP-lowering effects.352–354 An almost linear relationship has been de­
scribed in a dose–response meta-analysis between sodium intake ran­
ging from 0.4 to 7.6 g/day and reduction of systolic and diastolic BP is 
independent of baseline BP.355,356 Women appear to be, on average, 
more sodium sensitive than men,357 and may have greater outcome 
benefits when receiving comparable sodium-restricted diets.358 Trial 
evidence for the BP-lowering benefits of salt reduction extend down 
to daily sodium intakes of <1.5 g/day.356,358–361
The task force acknowledges that the observational data linking so­
dium intake to CVD outcomes are mixed and that some studies have 
not found a link between salt intake and CVD.362,363 In addition, a po­
tential J-curve exists between sodium intake and CVD events (where­
by some analyses suggest that sodium reduction to very low levels 
could be harmful).363,364 While there are differences of opinion, the 
task force agreed that, on balance, (i) observational J-curve data are 
often due to reverse causality or confounding,114,348,365,366 (ii) the re­
lationship between dietary sodium and stroke is typically linear in 
shape, without any J-curve, (iii) if the J-curve were causal, the adverse 
effect of very low sodium on CVD would have to be mediated by some 
harmful mechanism that overcomes the expected benefit mediated by 
BP lowering (which is unlikely), and (iv) estimation of sodium intake 
using spot-urine sodium testing (which was commonly done in studies 
reporting a J-curve) may not be as valid as other methods.367 For ex­
ample, most (but not all)362 reports measuring 24 h urine sodium ex­
cretion (a surrogate measure of sodium intake) have not reported a 
J-curve association with CVD.350,364 Furthermore the causal evidence 
demonstrating reduced CVD with sodium restriction (using potassium- 
enriched salt substitutes) in the Salt Substitute and Stroke Study (SSaSS) 
Recommendation Table 13 — Recommendations for 
screening for secondary hypertension (see Evidence 
Tables 19 and 20)
Recommendations
Classa
Levelb
It is recommended that patients with hypertension 
presenting with suggestive signs, symptoms or medical 
history of secondary hypertension are appropriately 
screened for secondary hypertension.312,314,315,323,339
I
B
Screening for primary aldosteronism by renin 
and aldosterone measurements should be 
considered in all adults with confirmed 
hypertension (BP ≥140/90 mmHg).313,316,323,339
IIa
B
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 14 — Recommendations for 
screening for hypertension in children and adolescents 
(see Evidence Table 21)
Recommendation
Classa
Levelb
Opportunistic screening with office BP 
measurements to monitor development of BP during 
late childhood and adolescence, especially if one or 
both parents have hypertension, should be 
considered to better predict development of adult 
hypertension and associated CVD risk.344–346
IIa
B
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 44 -->

### Page 44

and Diet, ExerCIse and carDiovascular hEalth-Salt  (DECIDE-Salt) trials 
was compelling,348,368 even though sodium restriction in these trials 
was not below 2 g/day.
It is recommended to restrict total dietary sodium intake to ap­
proximately 2 g/day or less (equivalent to approximately 5 g or about 
a teaspoon of salt per day). This includes added salt and salt already 
contained in food. While the feasibility of this sodium target can be 
debated, the evidence for the benefits of this sodium target among 
patients with elevated BP or hypertension is sufficient, particularly 
in terms of lowering BP. The optimal sodium intake in the general 
population with non-elevated BP is less clear (noting also that 
the BP-lowering effect of salt reduction among patients with 
non-elevated BP appears lower).353,354 A more feasible compromise 
in the general population might be a target sodium intake range of 2– 
4 g/day.369,370 It needs to be emphasized that large parts of daily so­
dium intake occur by means of sodium consumption contained in 
processed foods.
8.2.1.2. Potassium
Optimal dietary potassium intake, e.g. by consuming diets rich in fruits and 
vegetables, has BP-lowering effects and may be associated with lower 
CVD risk.348,364,368,371–373The association between potassium intake, systol­
ic BP, and CVD events may be sex-specific, being stronger in women.374 The 
World Health Organization (WHO) recommends over 3.5 g/day (∼90  
mmol/day) of dietary potassium.375 Excessive potassium supplementation 
should, however, be avoided374and CKD guidelines recommend dietary po­
tassium restriction to <2.4 g/day in persons with advanced CKD (see 
Supplementary data online).376
A lower urinary sodium-to-potassium ratio (Na+/K+ ratio; a surro­
gate for reduced dietary sodium intake complemented by increased po­
tassium intake) has been associated with a greater reduction in systolic 
and diastolic BP than with a higher ratio.348,377
In patients with hypertension and high dietary sodium, increased dietary 
intake of potassium (in addition to lower dietary sodium) should be con­
sidered.348,350,378In patients with persistently high sodium intake (>5 g/day) 
Aerobic exercise training
At least 150 min/week moderateintensity or 75 min/week vigorous intensity: brisk walking, jogging,
cycling, swimming
(Class I)
Isometric resistance exercise training:
Low-to-moderate-intensity
(3 sets of 1–2 min contraction:
hand-grip, plank, wall sit)
Dynamic resistance exercise training:
Large muscle groups, low-tomoderate-intensity (2–3 sets with
10–15 reps.: squat, push-ups, sit-up)
Increase daily physical activity
(steps/day, take stairs, walk/cycle)
Avoid sedentary lifestyle
BP
Reduction
CV Risk
Reduction
Dynamic or isometric resistance training to complement aerobic exercise training 
2–3 times/week
(Class I)
Figure 16 Physical activity according to different types of exercise and reduction of blood pressure and overall cardiovascular disease risk. Priority is 
given to aerobic exercise training (green). BP, blood pressure; CVD, cardiovascular disease.  
ESC Guidelines                                                                                                                                                                                          3955


<!-- PAGE 45 -->

### Page 45

and without moderate-to-advanced CKD, particularly women, an increase 
in potassium intake by 0.5–1.0 g/day may be considered to achieve a fa­
vourable Na+/K+ ratio of 1.5–2.0 and to reduce CVD risk. Potassium sup­
plementation can be achieved by substituting sodium using potassium 
enriched salts (75% sodium chloride and 25% potassium chloride)368,379,380
or by increasing dietary potassium intake [e.g. a 125 g (medium) banana 
contains about 450 mg potassium, or unsalted boiled spinach (840 mg/ 
cup) or mashed avocado (710 mg/cup)]. In patients with CKD and/or 
those taking potassium-sparing medication, such as some diuretics, 
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs) or spironolactone, serum levels of potassium should be 
monitored (noting that phlebotomy recommendations to avoid spuriously 
high potassium results should be followed).
8.2.2. Physical activity and exercise
In a systematic review and meta-analyses, aerobic (endurance) exercise 
was suggested as the first-line exercise therapy for reducing BP in pa­
tients with elevated BP and hypertension vs. alternative forms of exercise, 
such as dynamic or isometric resistance training.381 In patients with 
hypertension, regular aerobic exercise substantially lowers systolic BP 
by up to 7–8 mmHg and diastolic BP by up to 4–5 mmHg.381,382 For non- 
white patients with hypertension, dynamic resistance training elicits BP 
reductions that appear comparable to aerobic exercise.383 Isometric re­
sistance training also achieves clinically relevant BP reductions in patients 
with hypertension, but results are inconsistent and more data from more 
high-quality intervention trials are required (see Supplementary data 
online).381,384,385 With respect to mode and intensity of aerobic exercise, 
Increase physical activity
Increase potassium intake
Optimize weight management and diet
No smoking
Reduce alcohol intake
Reduce table salt
(sodium chloride) intake
BP
Reduction
CV Risk
Reduction
Figure 17 Effects of main lifestyle factors on blood pressure and cardiovascular risk reduction. BP, blood pressure; CV, cardiovascular. Smoking ces­
sation reduces overall cardiovascular risk but not BP (long arrow). Salt reduction reduces BP and (for persons with high baseline intake) reduces car­
diovascular risk. Increased potassium intake and higher physical activity, as well as optimized weight management, reduce BP and are associated with 
lower overall cardiovascular risk (short arrows).


<!-- PAGE 46 -->

### Page 46

high-intensity interval training elicits comparable BP reductions to mod­
erate continuous exercise, with high-intensity interval training achieving 
greater improvement in physical fitness.386
In patients with known hypertension, engaging in physical activity is 
associated with reduced CVD mortality risk vs. sedentary patients 
with hypertension.387
An exaggerated BP response to exercise may yield diagnostic merits for 
predicting incident hypertension and CVD. In a meta-analysis, an exagger­
ated BP response to exercise was associated with an increased risk for 
masked hypertension.388 The risk of coronary heart disease also increases 
with higher systolic BP during exercise, independent of systolic BP at rest.389
Prior recommendations for at least 150 min/week of moderate inten­
sity aerobic exercise (≥30 min, 5–7 days/week) can be maintained.1,390
Alternatively, 75 min of vigorous-intensity exercise per week over 3 days 
may be performed, with additional benefits derived by achieving 300 min 
of moderate-intensity or 150 min of vigorous-intensity aerobic physical 
activity per week.390,391 As acute aerobic exercise induces intensity- 
dependent short-term reductions in ambulatory BP after exercise, patients 
with elevated BP and hypertension may benefit from daily exercise to im­
prove their 24 h BP profile and avoid BP peaks on sedentary days.392
Aerobic exercise should be complemented by low- or moderate-intensity 
resistance training (2–3 times per week), e.g. dynamic resistance, starting at 
2–3 sets of 10–15 repetitions at 40%–60% of one-repetition maximum393
or isometric resistance training with three sets of 1–2 min contractions, 
such as hand-grip, plank, or wall sit (Figure 16).381,394
In uncontrolled hypertension at rest, high-intensity exercise should 
be applied with caution, with resting systolic BP of >200 mmHg and dia­
stolic BP of >110 mmHg indicating relative contraindications.395 Age, 
sex, gender,396 ethnicity, and comorbidities, as well as individual prefer­
ences, should be considered for individual exercise prescription. 
Detailed information on exercise prescription in terms of frequency, in­
tensity, time (duration) and type and progression are available in the 
with cardiovascular disease,390 which include recommendations for 
pre-participation screening and cardiopulmonary exercise testing.390
8.2.3. Weight reduction and diet
Visceral obesity is common and associated with incident hyperten­
sion.397,398 An average weight loss of 5 kg has been associated with 
an average systolic and diastolic BP reduction of 4.4 and 3.6 mmHg, re­
spectively.399 Data show that, starting at an index body mass index 
(BMI) of 40 kg/m2, a median weight loss of 13% is associated with a 
22% lower risk for hypertension.400,401 Maintaining even moderate 
weight loss of 5%–10% of initial body weight can improve not only 
BP, but also glucose and lipid metabolism, and potentially reduce pre­
mature all-cause mortality.402–404 However, achieving long-term effects 
in patients with hypertension via weight loss is challenging and the mag­
nitude of these effects remains unclear.405,406 Weight stabilization dur­
ing middle-age appears to be an important and attainable goal to 
prevent obesity-related increase in BP later in life.407
Evidence-based diets, such as the Mediterranean diet and the Dietary 
Approaches to Stop Hypertension (DASH) diet, are established inter­
ventions in patients with hypertension to reduce their BP and CVD 
risk.408,409 Additional information on healthy dietary patterns is pro­
vided in the 2021 ESC Guidelines on cardiovascular disease prevention 
in clinical practice and Supplementary data online.170
In combination with weight-loss and exercise interventions410 and 
low sodium intake,411 the DASH diet has added effect on BP reduc­
tion.412 Pharmacological treatment of obesity with orlistat achieved a 
slight reduction of 2.6 mmHg in systolic BP.413 The greatest 
BP-lowering effects of weight-loss medications may be achieved with 
the glucagon-like peptide 1 (GLP-1) receptor agonists.414–416 For ex­
ample, in the Semaglutide Treatment Effect in People with Obesity 
(STEP-1) trial, the GLP-1 analogue semaglutide resulted in a mean 
weight reduction of 12.4% and a 5.1 mmHg reduction in systolic BP.415
8.2.4. Alcohol, coffee, and soft drinks
In a 2020 Cochrane review, the short-term effects of alcohol on BP were 
dose dependent; low-dose alcohol (<14 g) did not affect BP within 6 h, 
medium-dose (14–28 g) decreased both systolic and diastolic BP, and high- 
dose alcohol (>30 g) first decreased BP up to 12 h and then increased BP 
following >13 h of consumption by 3.7 mmHg systolic and 2.4 mmHg dia­
stolic.417 The trials in this Cochrane review included small numbers of wo­
men. In the longer term, no evidence has been found for a protective effect 
of chronic alcohol consumption on hypertension, for either sex. In con­
trast, even low-dose alcohol consumption (10 g/day) increases chronic 
risk of hypertension by 14% in men, but not in women.418 As per the 
tice, men and women are recommended to stay within the upper limit of 
drinking alcoholic beverages (100 g/week of pure alcohol). Defining num­
ber of drinks depends on portion size, the standards of which differ per 
country, but translates to 8–14 g/drink.170 Emerging data indicate it is likely 
healthiest to avoid all alcohol, where possible.419
Coffee intake is not associated with a higher risk of hypertension in 
the general population; in fact, higher coffee consumption may be asso­
ciated with a lower risk for incident hypertension.420 Data regarding the 
association between tea drinking and CVD are inconclusive, though 
mechanistic trials have suggested benefits on BP lowering.421 In con­
trast, energy drinks with high concentrations of ingredients such as 
taurine and caffeine increase BP and may lead to acute or chronic car­
diovascular complications in young adults.422–424
Consuming two or more servings per day of sugar-sweetened bev­
erages was associated with a 35% higher risk of coronary artery disease 
in women in the Nurses’ Health Study.425 In the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort, both sugar- and 
artificially sweetened soft drinks were associated with higher all-cause 
mortality.426 In children and adolescents, sugar-sweetened beverages 
increased systolic BP and the risk for incident hypertension.427 It is re­
commended to restrict free sugar consumption, in particular 
sugar-sweetened beverages, to a maximum of 10% of energy intake.
8.2.5. Smoking
To stop smoking is arguably the most effective measure in preventing 
major CVD events at the individual level, likely through improved vas­
cular health.428–431 Estimated health benefits will be even more sub­
stantial looking at all-cause morbidity and mortality, e.g. including 
smoking cessation for cancer prevention.
The effects of electronic cigarettes (e-cigarettes) on BP remain un­
clear and to date there are no robust outcomes data. However, grow­
ing evidence suggests that e-cigarettes can increase BP (see 
Supplementary data online).432,433
Among adults, smoking affects ambulatory BP by raising daily BP,434 but 
effects of chronic smoking on office BP appear to be small.435 Smoking ces­
sation advice helps, but more intensive interventions are superior.436,437 As 
recommended by previous ESC Guidelines, smoking cessation is recom­
mended to reduce CVD risk and improve non-CVD health.1,170
ESC Guidelines                                                                                                                                                                                          3957


<!-- PAGE 47 -->

### Page 47

8.3. Pharmacological interventions
8.3.1. Treatment strategy to reduce adverse 
cardiovascular disease outcomes
The main goal of reducing BP is to prevent adverse CVD outcomes. The 
relative risk reduction afforded by a fixed degree of BP reduction is largely 
independent of pre-treatment BP.116 There is a clear relationship be­
tween the intensity of BP lowering and the relative and absolute reduction 
in risk of CVD events for all adults, regardless of age (at least up to 
85 years), sex, prior CVD, diabetes, or AF.116,131,443–445 With this strong 
evidence for the ‘the lower the better, but within reason’ paradigm, deci­
sion rules are required for selecting patients most likely to benefit from 
treatment.172 In this section, a summary of evidence for BP-lowering 
drug treatment is provided, followed by strategies for their use for pre­
venting CVD.
8.3.2. Drug classes with evidence on clinical outcomes 
in the target population
The major drug classes with robust evidence for BP-mediated reduction 
in CVD events are ACE inhibitors, ARBs, dihydropyridine CCBs, diuretics 
(thiazides and thiazide-like diuretics such as hydrochlorothiazide, 
chlorthalidone, and indapamide), and beta-blockers (see Supplementary 
data online, Tables S7 and S8).122,446,447 The first four are recommended 
as first-line options for starting hypertension treatment in the general 
population. Beta-blockers can be added preferentially in circumstances 
such as in the presence of angina or heart failure, after myocardial infarc­
tion, or for controlling heart rate, where they are the cornerstone of ther­
apy.122,448,449 In such settings, second-generation (cardioselective) and, 
specifically, third-generation (vasodilating) beta-blockers are preferred.450
However, beta-blockers are less effective than ACE inhibitors, ARBs, 
CCBs, or diuretics at preventing stroke, and have a higher discontinuation 
rate due to side effects.451,452 Beta-blockers and diuretics, especially when 
combined, are associated with an increased risk of new-onset diabetes in 
predisposed patients.453,454 The effect of RAS blockers and CCBs on pre­
venting progression of HMOD also appears to be superior to beta- 
blockers.455–458 Beta-blockers should also be avoided in patients with iso­
lated systolic hypertension or more generally with arterial stiffness, as they 
increase stroke volume (given the lower heart rate).218
When therapy and adherence with the above-mentioned drug classes 
is optimized but insufficient to reach BP goals, other drug classes can be 
used for treating hypertension. Of these, spironolactone, an MRA, ap­
pears to be the most effective at further lowering BP in resistant hyper­
tension; however, more evidence of CVD risk-lowering effects with 
MRAs among all hypertensive populations, especially those without re­
sistant hypertension, is needed.459 Specifically, while use of MRAs in pa­
tients with heart failure has provided clinical evidence on the 
effectiveness of MRAs for preventing CVD events, dedicated outcome 
trials in patients with primary hypertension without heart failure are lack­
ing. Because the present guidelines require trial evidence for CVD out­
come benefit for a BP-lowering drug or procedure to achieve a Class I 
recommendation, and given no outcome trials of MRAs have been con­
ducted in general samples of patients with primary hypertension, we have 
given MRAs a Class IIa recommendation (see below). We acknowledge 
that spironolactone was provided a Class I recommendation in the 2018 
ESC/ESH Guidelines on the management of arterial hypertension. 
However, to be consistent with our requirement for trial evidence for 
CVD outcomes benefit in patients with hypertension, the task force 
agreed to provide a Class IIa recommendation for spironolactone in 
these 2024 Guidelines. Importantly, it was also agreed that a Class IIa rec­
ommendation (i.e. should be considered) is an endorsement of MRAs for 
Recommendation Table 15 — Recommendations for 
non-pharmacological treatment of blood pressure and 
cardiovascular risk reduction (see Evidence Tables 22–26)
Recommendations
Classa
Levelb
Restriction of sodium to approximately 2 g per day is 
recommended where possible in all adults with 
elevated BP and hypertension [this is equivalent to 
about 5 g of salt (sodium chloride) per day or about a 
teaspoon or less].353,354
I
A
Moderate intensity aerobic exercise of ≥150 min/ 
week (≥30 min, 5–7 days/week) or alternatively 
75 min of vigorous intensity aerobic exercise per 
week over 3 days are recommended and should be 
complemented with low- or moderate-intensity 
dynamic or isometric resistance training (2–3 times/ 
week) to reduce BP and CVD risk. 1,381,390–393
I
A
It is recommended to aim for a stable and healthy 
BMI (e.g. 20–25 kg/m2) and waist circumference 
values (e.g. <94 cm in men and <80 cm in women) to 
reduce BP and CVD risk.399–401
I
A
Adopting a healthy and balanced diet, such as the 
Mediterranean or DASH diets, is recommended to 
help reduce BP and CVD risk.412,438,439
I
A
Men and women are recommended to drink less 
alcohol than the upper limit, which is about 
100 g/week of pure alcohol. How this translates into 
number of drinks depends on portion size (the 
standards of which differ per country), but most 
drinks contain 8–14 g of alcohol per drink. Preferably, 
it is recommended to avoid alcohol to achieve the 
best health outcomes.170,419,440,441
I
B
It is recommended to restrict free sugar 
consumption, in particular sugar-sweetened 
beverages, to a maximum of 10% of energy intake. It 
is also recommended to discourage consumption of 
sugar-sweetened beverages, such as soft drinks and 
fruit juices, starting at a young age.425–427
I
B
It is recommended to stop tobacco smoking, initiate 
supportive care and refer to smoking cessation 
programmes, as tobacco use strongly and 
independently causes CVD, CVD events, and 
all-cause mortality.428,429,431,437
I
A
In patients with hypertension without moderate to 
advanced CKD and with high daily sodium intake, an 
increase of potassium intake by 0.5–1.0 g/day—for 
example through sodium substitution with potassium- 
enriched salt (comprising 75% sodium chloride and 
25% potassium chloride) or through diets rich in fruits 
and vegetables—should be considered.348,368,373,374,442
IIa
A
In patients with CKD or taking potassium-sparing 
medication, such as some diuretics, ACE inhibitors, 
ARBs, or spironolactone, monitoring serum levels of 
potassium should be considered if dietary potassium 
is being increased.
IIa
C
© ESC 2024
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass 
index; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; 
DASH, Dietary Approaches to Stop Hypertension. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 48 -->

### Page 48

treating resistant hypertension but one that acknowledges some uncer­
tainty of outcomes benefit. Future outcome trials of MRAs, perhaps in­
cluding finerenone,460–462 are encouraged in patients with hypertension.
Clinical outcome evidence from trials for other BP-lowering drug 
classes, such as alpha-blockers, hydralazine, minoxidil, other potassium- 
sparing diuretics, and centrally acting agents, is less compelling and caution 
regarding adverse effects is warranted. However, they may be a final add­
ition if all other therapeutic efforts are insufficient to decrease BP. Of note, 
in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart 
Attack (ALLHAT) trial, the alpha-blocker arm was stopped early due to 
futility of benefit for the CVD outcome.463
8.3.3. New therapies with blood pressure-lowering 
properties that await supportive evidence from 
cardiovascular outcomes trials prior to guideline 
endorsement and routine use in hypertension
A few other drug classes with indication in heart failure have emerged 
that also have BP-lowering properties. For example, the angiotensin 
receptor–neprilysin inhibitor (ARNi) sacubitril/valsartan, which was ini­
tially developed for hypertension,464 reduces CVD mortality and 
morbidity in patients with heart failure, an effect that may have been 
mediated, in part, by superior BP lowering compared with enalapril 
alone.465,466 In a post hoc subgroup analysis, sacubitril/valsartan lowered 
BP in adults with both heart failure with preserved ejection fraction 
(HFpEF) and resistant hypertension.467 In the context of research stud­
ies, sacubitril/valsartan has been used in higher doses (200 mg or 
400 mg once daily) for treating hypertension.464,466,468,469
SGLT2 inhibitors have shown favourable effects on CVD events and 
renal haemodynamics in patients with and without type 2 diabetes, and 
in heart failure trials.470 In these trials, SGLT2 inhibitors did lower BP, 
though only modestly.471 Small trials among adults with hypertension 
have confirmed the potential for BP lowering with this drug class.472,473
Other new drugs with preliminary data include GLP-1 agonists and 
the new non-steroidal MRAs, e.g. finerenone, in managing hyperten­
sion.415,460,461 In addition, novel aldosterone synthase inhibitors (bax­
drostat and lorundrostat) have significantly lowered BP in patients 
with uncontrolled hypertension in phase 2 trials.474,475
The dual endothelin-A and -B receptor antagonist aprocitentan also 
reduced office and 24 h BP compared with placebo at 4 weeks in pa­
tients with resistant hypertension in a phase 3 trial.476 Zilebesiran, an 
investigational RNA interference agent administered subcutaneously, 
inhibits hepatic angiotensinogen synthesis and a single dose reduced 
24 h BP over approximately 6 months.477
8.3.4. Drug combinations and up-titrating strategies
To treat hypertension, many patients will require more than one 
BP-lowering medication. Combining drugs from different drug classes 
can have additive or synergistic effects and lead to greater BP reduction 
than increasing the dose of one drug.478–483 The superior BP-lowering 
efficacy of combination therapy is mediated, at least in part, by the po­
tential of combination therapy to target multiple pathophysiological 
pathways contributing to perturbed BP in each patient.484 A further 
benefit of combination therapy is the potential to use lower doses of 
each individual BP-lowering agent, which may reduce side effects and 
improve adherence and persistence,485 though the evidence for this hy­
pothesis has been questioned.486
Upfront low-dose combination therapy is therefore recommended 
in persons with hypertension, with the potential advantages of fewer 
side effects and swifter BP control being important for long-term ad­
herence.487–489 If combination BP-lowering therapy is pursued, single- 
pill combinations are preferred. For those with elevated BP who have 
an indication for BP-lowering treatment, monotherapy is recom­
mended in the first instance.
One caveat to combination therapy in hypertension is that patient-level 
response to individual BP-lowering drug classes can be heterogeneous (sug­
gesting some patients may benefit from more personalized treatment com­
pared with routine combinations).490 This is relevant also with respect to 
race/ethnicity (see Section 9). Another caveat is that the evidence for re­
duced CVD outcomes with BP-lowering drugs in combination therapy is 
based on observational studies.491–493 There are no outcomes data from 
prospective trials that prove superiority of upfront combination therapy (ei­
ther as single-pill combinations or as separate pills) over upfront monother­
apy in the isolated treatment of hypertension.486Therefore, we considered 
giving upfront combination therapy (either as separate pills or as single-pill 
combinations) a Class IIa recommendation in these guidelines. However, gi­
ven the totality of evidence for outcomes benefit in observational studies, 
randomized trial data for better BP control and adherence, and importantly, 
also given CVD outcomes benefit for polypills (a form of single-pill combin­
ation) in randomized trials,494–496we chose to provide a Class I recommen­
dation for upfront combination therapy in adults with confirmed 
hypertension, in agreement with 2018 ESC recommendations.
The major four drug classes (ACE inhibitors, ARBs, dihydropyridine 
CCBs, and thiazide or thiazide-like diuretics) are recommended as first- 
line BP-lowering medications, either alone or in combination.122,447,484,497
An exception is the combination of two RAS blockers, which is not re­
commended.498–500 For most hypertensive patients, a single-pill com­
bination, initially containing two of these major drug classes, and 
initially at low dose, is recommended.489,501,502 Doses of BP-lowering 
drugs are presented in the Supplementary data online, Tables S7 and S8.
When BP is still uncontrolled under maximally tolerated triple- 
combination (RAS blocker, CCB, and diuretic) therapy, and after adher­
ence is assessed, the patient should be considered resistant and 
referred to an expert centre for appropriate work-up (see Section 
7.5). At the same time, the addition of spironolactone should be consid­
ered.459 If spironolactone is not tolerated, eplerenone or other MRA, 
or beta-blockers (if not already indicated), should be considered. 
Eplerenone may need to be dosed higher (50–200 mg) for effective BP 
lowering. In a meta-analysis, eplerenone 25 mg did not lower BP.503 Due 
to the shorter time of action than spironolactone, eplerenone may need 
to be administered twice daily for treating hypertension. An alternative 
to MRA as fourth-line treatment for BP lowering is the use of beta-blockers 
for persons who do not already have a compelling indication. A vasodilating 
beta-blocker (e.g. labetalol, carvedilol, or nebivolol) is preferred when a 
beta-blocker is chosen.504 However, we note that the BP-lowering effects 
of beta-blockade appears to be less potent than spironolactone in the set­
ting of resistant hypertension.459
Only thereafter should hydralazine, other potassium-sparing diuretics 
(amiloride and triamterene), centrally acting BP-lowering medications, 
or alpha-blockers be considered. Given multiple side-effects, minoxidil 
should only be considered if all other pharmacological agents prove inef­
fective in resistant hypertension.505
As noted above, polypills combining fixed doses of BP-lowering 
treatment, lipid-lowering therapy and, if indicated, aspirin are effective 
in more general CVD prevention.496,506–509 However, the polypill is not 
available for routine clinical use in many European countries.
8.3.5. A practical algorithm for intensive, effective, 
and tolerable blood pressure lowering with drug 
therapy, including considerations around single-pill 
combinations
The aim of the algorithm in Figure 18 is to introduce a low-dose double- 
and then triple-combination strategy while monitoring tolerance 
ESC Guidelines                                                                                                                                                                                          3959


<!-- PAGE 49 -->

### Page 49

Low-dose double combinationa therapy
ACEi or ARBs / CCBs / Diuretics
(Class I)
BP controlled after 1–3 months
(assessment at 1 month preferred if possible)
Y
FU at least every year
Low-dose triple combination therapy 
ACEi or ARBs / CCBs / Diuretics
(Class I)
BP controlled after 1–3 months
(assessment at 1 month preferred if possible)
Y
FU at least every year
BP controlled after 1–3 months
(assessment at 1 month preferred if possible)
Y
FU at least every year
Refer to hypertension clinic
(Class IIa)
At any step:
add beta-blockers if compelling indications
(angina, post-myocardial infarction, systolic heart failure,
or heart rate control)
(Class I)
Maximally tolerated triple combination therapy 
ACEi or ARBs / CCBs / Diuretics
(Class I)
Test for adherence
(Class IIa)
Add spironolactone
(Class IIa)
Apparent resistant hypertension
N
N
N
 aInitial monotherapy preferred
Elevated BP category (120/70–139/89 mmHg)
Moderate-to-severe frailty
Symptomatic orthostatic hypotension
Age ≥85 years
See section on management of resistant hypertension for further steps as needed
Figure 18 Practical algorithm for pharmacological blood pressure lowering. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin recep­
tor blocker; BP, blood pressure; CCB, calcium channel blocker; FU, follow-up.


<!-- PAGE 50 -->

### Page 50

N
Patient centred care
Normal
Abnormal
≥10%
<5%
5% – <10%
Age <40 years, resistant hypertension,
suggestive signs and/or symptoms
Targeted secondary hypertension treatment
Screen for secondary hypertension
(Class I)
Calculate SCORE2/
SCORE2-OP
(Class I)
Assess risk modifiers
(Class IIa)
Consider risk tools
(Class IIb)
Age ≥85 years, moderate-to-severe frailty, 
symptomatic OH, short life expectancy
Established CVD, moderate-to-severe CKD,
hypertension-mediated organ damage, 
diabetes mellitusa, familial hypercholesterolaemia
Y
N
N
N
Y
Y
Y
Non-elevated BP
Office SBP <120 mmHg and
DBP <70 mmHg
Elevated BP
Office SBP 120–139 mmHg and/or DBP 70–89 mmHg
Hypertension
Office SBP ≥140 mmHg and/or
DBP ≥90 mmHg
ABPM / HBPM
preferred over office BP
Target SBP 120–129 mmHg
(Class I)
Target DBP 70–79 mmHg
(Class IIb)
Screen BP
opportunistically
Lifestyle measures
Drug treatment for confirmed
BP ≥130/80 mmHg
Monitor BP and medication toleranceb
Screening for hypertension
Opportunistic: every 3 years <40 years;
every year ≥40 years
HBPM/ABPM or repeated standardized office BP
Confirming hypertension
Lifestyle measures
Figure 19 Central Illustration. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular disease; CKD, chronic kidney 
disease; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; OH, orthostatic hypotension; SBP, systolic blood pressure; SCORE2, 
Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons. Summary algorithm for BP classification 
and management. See Section 5 for recommendations on out-of-office confirmation of the three BP categories. aAdults with type 2 diabetes mellitus 
only and younger than 60 years should be considered for SCORE2-Diabetes assessment. bThough scientific data demonstrate that, under research 
conditions, the optimal target BP is ≤120/70 mmHg, the target BP recommended by  these guidelines in routine practice is 120–129/70–79 mmHg. 
If achieving this target is not possible, or if treatment is not well tolerated, then BP should be treated to as low as reasonably achievable. For persons 
with elevated BP, treatment with lifestyle measures for 3 months is first recommended, prior to considering medications.  
ESC Guidelines                                                                                                                                                                                          3961


<!-- PAGE 51 -->

### Page 51

among patients with hypertension, and only afterwards to start up- 
titrating doses to maximum amounts.
Initiation with monotherapy, slower up-titration, and lower dosing 
should be considered in the setting of elevated BP and increased CVD 
risk, or in moderate-to-severe frailty, limited life expectancy, symptom­
atic orthostatic hypotension, or older people (aged ≥85 years). Ideally, 
BP should be treated to target within 3 months to retain the confidence 
of the patient, to ensure long-term adherence, and to reduce CVD risk.71
An overview of the recommended approach to BP management in all 
adult patients is provided in Figure 19 (Central Illustration). Also, of 
note, teleconsultation, multidisciplinary or nurse-led care, or patient 
self-monitoring can help with achieving BP control in certain healthcare 
systems.75,510,511
8.3.6. Timing of blood pressure-lowering drug 
treatment
Current evidence does not show benefit of diurnal timing of 
BP-lowering drug administration on major CVD outcomes.512 It is im­
portant that medication is taken at the most convenient time of day to 
improve adherence. Patients should also be encouraged to take medi­
cations at the same time each day and in a consistent setting, to help 
ensure adherence.246,513
8.4. Selecting patients for pharmacological 
blood pressure-lowering treatment
Commencement of BP-lowering treatment is often decided based on 
office BP measurements but, where possible, the present guidelines 
strongly recommend using out-of-office BP measurement for confirm­
ing elevated BP and hypertension (see Section 5). As detailed in Section 6, 
an office BP of <120/70 mmHg is categorized in these guidelines as 
non-elevated BP.
When a patient is diagnosed with confirmed hypertension (sustained 
BP ≥ 140/90 mmHg), starting BP-lowering treatment is recommended 
irrespective of CVD risk, which should consist of a simultaneous combin­
ation of lifestyle interventions and pharmacological therapy. Lifestyle in­
terventions are crucial as an initial treatment step, and must be strongly 
emphasized with the patient, but concurrent pharmacological therapy is 
recommended. This concurrent initiation of lifestyle and pharmacological 
therapy should not give patients the impression that lifestyle changes are 
of lesser importance, and the patient should be counselled that these life­
style changes may allow subsequent discontinuation or down-titration of 
medication, which can be used as motivation to persist with lifestyle 
changes. After treatment initiation, the patient should be seen frequently 
(e.g. every 1–3 months with a GP or specialist) until BP is controlled. BP 
should be controlled, preferably within 3 months (see also Section 6 and 
algorithm Figure 18). If lifestyle changes are effective in BP lowering, 
pharmacological treatments may subsequently be down-titrated or 
stopped as appropriate.
When office BP is 120–139/70–89 mmHg, the patient is considered 
as having elevated BP, and further CVD risk stratification is recom­
mended to guide therapy (Table 14). 
• In patients with elevated BP who are not at increased risk for CVD 
(10-year CVD risk <10%) and do not have other high-risk conditions 
or risk modifiers, BP-lowering lifestyle measures are recommended. 
Recommendation Table 16 — Recommendations for 
pharmacological 
treatment 
of 
hypertension 
(see 
Evidence Tables 27, 28, and 29)
Recommendations
Classa
Levelb
Among all BP-lowering drugs, ACE inhibitors, ARBs, 
dihydropyridine CCBs, and diuretics (thiazides and 
thiazide-like drugs such as chlorthalidone and 
indapamide) have demonstrated the most effective 
reduction of BP and CVD events, and are therefore 
recommended as first-line treatments to lower 
BP.122,446
I
A
It is recommended that beta-blockers are combined 
with any of the other major BP-lowering drug classes 
when there are other compelling indications for their 
use, e.g. angina, post-myocardial infarction, heart 
failure with reduced ejection fraction, or for heart 
rate control.122,448–450
I
A
It is recommended to take medications at the most 
convenient time of day for the patient to establish a 
habitual pattern of medication taking to improve 
adherence.246,513
I
B
Given trial evidence for more effective BP control vs. 
monotherapy, combination BP-lowering treatment is 
recommended for most patients with confirmed 
hypertension (BP ≥140/90 mmHg) as initial therapy. 
Preferred combinations are a RAS blocker (either an 
ACE inhibitor or an ARB) with a dihydropyridine 
CCB or diuretic. Exceptions to consider include 
patients aged ≥85 years, those with symptomatic 
orthostatic hypotension, moderate-to-severe frailty, 
or elevated BP (systolic BP 120–139 mmHg or 
diastolic BP 70–89 mmHg) with a concomitant 
indication for treatment.131,480,483,484,489
I
B
Continued
In patients receiving combination BP-lowering 
treatment, fixed-dose single-pill combination 
treatment is recommended.484,489,501,502,514
I
B
If BP is not controlled with a two-drug combination, 
increasing to a three-drug combination is 
recommended, usually a RAS blocker with a 
dihydropyridine CCB and a thiazide/thiazide-like 
diuretic, and preferably in a single-pill combination.489
I
B
If BP is not controlled with a three-drug combination, 
adding spironolactone should be considered.459
IIa
B
If BP is not controlled with a three-drug combination 
and in whom spironolactone is not effective or 
tolerated, treatment with eplerenone instead of 
spironolactone,503 or the addition of a beta-blocker if 
not already indicated459 and, next, a centrally acting 
BP-lowering medication,515 an alpha-blocker,515
hydralazine, or a potassium-sparing diuretic should 
be considered.516
IIa
B
Combining two RAS blockers (ACE inhibitor and an 
ARB) is not recommended.498–500,517
III
A
© ESC 2024
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood 
pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; RAS, renin– 
angiotensin system. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 52 -->

### Page 52

While there are not enough outcomes data for a drug recommenda­
tion in lower CVD risk adults with elevated BP, there is some evi­
dence to suggest that relative treatment effects of BP lowering are 
similar across a wide range of predicted risk categories, including 
among those with a <10% risk.518 Therefore, while we do not pro­
vide a formal recommendation for this, if initial lifestyle measures are 
not successful after 6–12 months, drug treatment might be discussed 
on an individual basis among lower CVD-risk adults when BP is be­
tween 130/80 and <140/90 mmHg.518
• In patients with elevated BP (office BP of 120–139/70–89 mmHg) 
who are at sufficiently high risk for CVD (e.g. 10-year CVD risk 
≥ 10%) or in the presence of high-risk conditions or borderline 
10-year CVD risk (5% - <10%) combined with risk modifiers or 
abnormal risk tool tests, BP-lowering lifestyle measures should be 
initiated for 3 months. Following this, pharmacological therapy is re­
commended for persons with confirmed BP of ≥130/80 mmHg, 
when these lifestyle changes have not worked or are not being imple­
mented (Section 8.2) Prompt addition of pharmacological therapy, if 
needed by 3 months, should be emphasized, to avoid therapeutic 
inertia.519 For those with BP of 120–129/70–79 mmHg, ongoing 
and intensified lifestyle intervention is preferred.
The above recommendations apply to all individuals with elevated BP, 
irrespective of age. However, recognizing the lack of conclusive evi­
dence and added risk of side effects among certain subgroups, the 
task force also recommends that, among patients with elevated BP, 
BP-lowering treatment should always be started based on individual 
clinical judgment and shared decision-making.
In addition, consideration of BP-lowering drug treatment should be 
deferred until BP is >140/90 mmHg in the following settings: pre- 
treatment symptomatic orthostatic hypotension, age ≥85 years, clinic­
ally significant moderate-to-severe frailty, and/or limited predicted life­
span (<3 years) due to high competing risk (including eGFR < 30 mL/ 
min/1.73 m2). Patients with elevated BP in these settings are less likely 
to obtain sufficient net benefit from BP-lowering drug therapy or to tol­
erate intensive drug therapy. Section 9 contains more information on 
the treatment of specific subgroups, including older and frail adults.
Table 14 Initiation of blood pressure-lowering treatment based on confirmed blood pressure category and cardiovas­
cular disease risk
Blood 
pressure 
(mmHg)
Non-elevated BP 
(<120/70)
Elevated BP (120/70 to 139/89)
Hypertension (≥140/90)
Risk
(a)
All adults with SBP 120– 
129 mmHg
(b)
SBP 130–139 AND 10-year 
estimated CVD risk <10% 
AND no high-risk 
conditions or risk modifiers 
or abnormal risk tool tests
(a)
SBP 130–139 AND high-risk conditions 
(e.g. established CVD, diabetes mellitus, 
CKD, FH or HMOD)
(b)
SBP 130–139 AND 10-year estimated 
CVD risk ≥10%
(c)
SBP 130–139 AND 10-year estimated 
CVD risk 5% - <10% AND risk 
modifiers or abnormal risk tool tests
Assumed all at sufficiently high risk to 
benefit from pharmacological 
treatment
Treatment
Lifestyle measures for 
prevention 
Screen BP and CVD risk 
opportunistically
Lifestyle measures for treatment 
Monitor BP and CVD risk yearly
Lifestyle measures and pharmacological 
treatment (after 3-month delay). 
Monitor BP yearly once treatment control is 
established
Lifestyle measures and 
pharmacological treatment 
(immediate) 
Monitor BP yearly once treatment 
control is established
Target (mmHg)
Maintain BP <120/70
Aim BP 120–129/70–79 mmHga
© ESC 2024
BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; FH, familial hypercholesterolaemia; HMOD, hypertension-mediated organ 
damage; SBP, systolic blood pressure. 
aCaution in adults with orthostatic hypotension, moderate-to-severe frailty, limited life expectancy, and older patients (aged ≥85 years).
Recommendation Table 17 — Recommendations for 
initiating blood pressure-lowering treatment (see 
Evidence Tables 30–32)
Recommendations
Classa
Levelb
In adults with elevated BP and low/medium CVD 
risk (<10% over 10 years), BP lowering with 
lifestyle measures is recommended and can reduce 
the risk of CVD.119,120,348,408,411,520,521
I
B
In adults with elevated BP and sufficiently high CVD 
riskc, after 3 months of lifestyle intervention, BP 
lowering with pharmacological treatment is 
recommended for those with confirmed BP ≥130/ 
80 mmHg to reduce CVD risk.116,522
I
A
It is recommended that in hypertensive patients 
with confirmed BP ≥140/90 mmHg, irrespective of 
CVD risk, lifestyle measures and pharmacological 
BP-lowering treatment are initiated promptly to 
reduce CVD risk.116,121,122
I
A
It is recommended to maintain BP-lowering drug 
treatment lifelong, even beyond the age of 85 years, 
if well tolerated.523–525
I
A
Because the benefit in reducing CVD outcomes is 
uncertain in these settings, and noting that close 
monitoring of treatment tolerance is advised, 
BP-lowering treatment should only be considered 
from ≥140/90 mmHg among persons meeting the 
following criteria: pre-treatment symptomatic 
orthostatic hypotension, age ≥85 years, clinically 
significant moderate-to-severe frailty, and/or 
limited predicted lifespan (<3 years).131,524,526,527
IIa
B
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence. 
c10-year estimated CVD risk of ≥10%; or 10-year estimated CVD risk of 5% - ≤10% plus risk 
modifiers or abnormal risk tool tests; or high-risk conditions (e.g. established CVD, diabetes, 
moderate or severe CKD, familial hypercholesterolaemia, or hypertension-mediated organ damage).
ESC Guidelines                                                                                                                                                                                          3963


<!-- PAGE 53 -->

### Page 53

8.5. Intensity of blood pressure-lowering 
therapy and ideal treatment targets
8.5.1. Expected degree of blood pressure reduction 
with approved drugs
The magnitude of BP reduction achieved with the main classes of 
BP-lowering medications (ACE inhibitors, ARBs, dihydropyridine CCBs, 
diuretics, and beta-blockers) as monotherapy is similar overall.528,529 BP 
reduction with standard doses of any of these five classes can be expected 
to be approximately 9/5 mmHg with office BP and 5/3 mmHg with 
ABPM.478 These BP-lowering effects may attenuate over time.530
Combination therapy (e.g. with three drugs at half standard dose) over 
the short term can lower office BP by up to 20/11 mmHg.478,531 The rea­
son why beta-blockers are not considered first-line BP-lowering medica­
tions (outside of compelling indications) is not because of inferior 
BP-lowering properties (particularly for vasodilating beta-blockers),532
but because of inferior efficacy in reducing CVD events (particularly 
stroke) among patients with hypertension, and tolerance issues.533–536
The BP-lowering effect of each BP medication class generally increases 
with the dose administered, though this relationship is not linear.537
Effects of each medication can also vary at the individual level, sometimes 
requiring personalization by matching the patient with the best medica­
tion for them.490 The magnitude of BP reduction for any BP-lowering 
medication may increase as a function of the pre-treatment BP, which 
is also known as Wilders principle.538,539
The BP-lowering effect of pharmacological therapy is typically evi­
dent after 1–2 weeks of treatment,540 but the maximum effect might 
take longer to manifest. Therefore, the advised follow-up after 1–3  
months (1 month preferred with a GP or specialist) allows for assess­
ment of tolerance/safety, but also allows enough time to gauge the 
full BP-lowering effect of each drug titration (see Section 8.3.4).
8.5.2. The ideal target of blood pressure-lowering 
treatment
As discussed in Section 6, optimal control of BP translates into CVD 
risk reduction, thereby reducing morbidity and mortality in the 
population.116,478,541
BP threshold is defined as the BP at which BP-lowering treatment is 
initiated, while BP target is the BP goal with treatment.
The BP threshold to initiate BP-lowering therapy is not necessarily the 
same as the recommended BP target once therapy is commenced (in 
other words, treatment threshold and treatment target may not be the 
same for a given patient). Specifically, for hypertensive patients in whom 
BP-lowering treatment is recommended above a baseline BP of ≥140/ 
90 mmHg, the recommended target of BP-lowering therapy is 120–129/ 
70–79 mmHg, provided treatment is well tolerated (see Supplementary 
data online). Persons with elevated BP who receive treatment are also re­
commended to achieve a target of 120–129/70–79 mmHg.
Therefore, the treatment target in the 2024 Guidelines is always 
120–129/70–79 mmHg (but only if treatment is tolerated and with cer­
tain exceptions where more lenient targets are advised). In contrast, the 
treatment threshold may differ based on CVD risk, specifically in the ele­
vated BP category. For example, in addition to hypertensive adults with 
BP ≥140/90 mmHg, there are individuals with an office systolic BP of 
130–139 mmHg and/or diastolic BP of 80–89 mmHg who have suffi­
ciently high CVD risk to recommend BP-lowering drug treatment.
The BP target range of 120–129/70–79 mmHg recommended 
in these guidelines reflects the most current evidence from contempor­
aneous RCTs135,136,146,542–545 and from meta-analyses of RCTs.131 Of 
note, this treatment target reduces CVD events in older adults136,523
with evidence for efficacy of more intensive BP-lowering treatment 
targets established up to age 85 years.131 Furthermore, research 
data indicate that, to optimally reduce CVD risk, achieving an on- 
treatment BP of 120/70 mmHg is the best point on the BP target range 
provided in our guideline recommendations (Figure 20). However, while 
we strongly considered recommending a treatment target of exactly 
120/70 mmHg with out-of-office BP confirmation, we instead chose a 
target range of 120–129/70–79 mmHg (preferably with out-of-office 
BP confirmation but also allowing for office BP) for the following rea­
sons: providing flexibility to patients and clinicians; feedback from exter­
nal peer review; feedback from patients that lifestyle is preferred to 
medication unless BP is in the hypertensive range; the knowledge that 
contemporary treat-to-target intensive BP trials included only persons 
with baseline systolic BP of ≥130 mmHg; and a recognition that the 
BP values recorded under research conditions using systematic ap­
proaches to measurement (while strongly recommended by these 
guidelines) are not always the same as BP values recorded under rou­
tine clinical care, which can be 5–10 mmHg higher.65,66
In addition, the trial data confirming efficacy for our recommended 
treatment target of 120–129/70–79 mmHg do not necessarily apply 
to moderately-to-severely frail adults who were generally excluded 
from trials. Furthermore, the data supporting this BP target among 
adults aged >85 years are inconclusive.131 Frailty can occur at different 
ages and is, together with tolerability of BP-lowering treatment, an im­
portant characteristic when considering the BP target for a given pa­
tient. Accordingly, personalized BP-lowering treatment should be 
instituted in people aged ≥85 years and/or those with significant frailty. 
Recommended indicators of frailty in guiding BP-lowering treatment 
are given in Section 9.
Several important nuances are highlighted and warrant consideration 
prior to implementing the new BP target of 120–129/70–79 mmHg 
among patients receiving BP-lowering therapy: 
• Evidence for a systolic BP-lowering treatment target of 120–129 mmHg 
is strong (Class I, level of evidence A).
• Evidence for a specific diastolic BP-lowering treatment target 
is less strong in those who are treated to a systolic target of 
120–129 mmHg. While most adults treated to a systolic BP target 
of 120–129 mmHg will also achieve a diastolic BP of 70–79 mmHg, 
not all will.543,546 Furthermore, adults who achieve systolic BP con­
trol are generally at low relative risk for CVD, even when diastolic 
BP is 70–90 mmHg.547,548 Nonetheless, due in part to the known 
higher risk of isolated diastolic hypertension among younger 
adults,549 the task force agreed that it is reasonable to target an 
on-treatment diastolic BP of 70–79 mmHg among patients with 
diastolic BP of ≥80 mmHg who are already at the systolic BP tar­
get of 120–129 mmHg (Class IIb, level of evidence C).
• The task force acknowledges the 2021 ESC Guidelines on cardio­
vascular disease prevention in clinical practice,170 which take a step­
wise approach to their recommendations for BP-lowering treatment. 
The 2021 Guidelines recommended an on-treatment systolic BP tar­
get of 130–139 mmHg as the first step and then—based on patient 
preferences, risk, and frailty—to aim for a target on-treatment 
systolic BP of <130 mmHg as the second step. While we recognize 
the potential value of this two-step approach, which many clinicians 
may choose to follow, the current guidelines emphasize one on- 
treatment BP target (120–129/70–79 mmHg, provided treatment is 
tolerated). This one-step approach is based on the evidence, and mo­
tivated to discourage therapeutic inertia around BP lowering. As an 
illustrative example of the latter concern for therapeutic inertia, an


<!-- PAGE 54 -->

### Page 54

on-treatment systolic BP of 135 mmHg (office) may be considered 
reasonable when reviewing the 2021 ESC Guidelines on cardiovascu­
lar disease prevention in clinical practice but, we hope, will not be 
considered reasonable to those who follow the updated 2024 ESC 
Guidelines presented here. Specifically, it is well established that an 
on-treatment systolic BP of 135 mmHg is not optimal relative to 
more intensive control.116,131,135,136,445,542,543,545
• We acknowledge that the results from RCTs cannot always be extra­
polated to routine clinical care. In addition, we recognize the increased 
risk of side effects among patients receiving more intensive BP-lowering 
treatments, compared with traditional BP targets.545,550Accordingly, an 
important caveat to our treatment target of 120–129/70–79 mmHg is 
the recommendation to pursue this target only when treatment is well 
tolerated. In cases where BP-lowering treatment is not well tolerated 
and a target of 120–129/70–79 mmHg is not possible, it is recom­
mended to follow the ‘as low as reasonably achievable’ (ALARA) prin­
ciple, by targeting treatment to a BP that is as low as reasonably 
achievable.
• In addition to adults with significant frailty and/or who are ≥85  
years of age, the evidence for a BP-lowering treatment target of 
120–129/70–79 mmHg may also not generalize to patients with: 
(i) pre-treatment symptomatic orthostatic hypotension, (ii) limited 
predicted lifespan (e.g. <3 years),527 and/or (iii) high levels of 
competing risk for non-CVD death including CKD with eGFR 
< 30 mL/min/1.73 m2) (see Section 9).
Finally, as outlined in Section 5, these guidelines endorse a ‘trust but 
verify’ approach to office BP measurements, and, where possible, con­
firming BP with accurate out-of-office BP measurements (ABPM, 
HBPM) is recommended prior to starting treatment, to monitor the 
treatment effect of BP-lowering medication.
8.5.3. Personalizing treatment strategies
Though promising, there is little to no evidence to date from 
CVD outcome trials to use novel biomarkers for individualizing 
BP-lowering treatment.551,552 Nonetheless, different patient groups 
SBP 120 mmHg 
is the optimal point in this range if tolerated
SBP target range
120–129 mmHg 
(Class I)
Target SBP as low as reasonably achievable
(preferably <140)
if 120–129 mmHg target not tolerated or in these settings: 
Pre-treatment symptomatic orthostatic hypotension and/or age ≥85 years  
(Class IIa)
Clinically significant moderate-to-severe frailty at any age 
and/or limited predicted lifespan
(<3 years)
(Class IIb)
Exclude hypertensive emergency
Assess for symptoms or signs of hypotension
Non-elevated SBP
(<120 mmHg)
Elevated SBP
(120–139 mmHg)
20
40
60
80
120 130 140
160
180
200
220
240
100
110
260
280
mmHg
Systolic hypertension
(≥140 mmHg)
Figure 20 Systolic blood pressure categories and treatment target range. BP, blood pressure; SBP, systolic blood pressure.  
ESC Guidelines                                                                                                                                                                                          3965


<!-- PAGE 55 -->

### Page 55

can be identified, and medication initiation can be tailored to pre- 
existing conditions, such as diabetes mellitus, CKD, AF, post- 
myocardial infarction, heart failure, metabolic syndrome, and pro­
teinuria/albuminuria (Section 9). History of previous side effects 
and possible and compelling indications also need to be considered 
when selecting treatment (see Supplementary data online, Tables S9 
and S10). Cardioselective beta-blockers may be used in low dose in 
chronic asthma,553,554 in line with their use in patients with heart 
failure with chronic asthma.
For considerations of BP-lowering treatment among specific pa­
tient populations of interest, including different racial/ethnic popula­
tions, see Section 9.
8.5.4. Duration and monitoring of drug therapy
BP-lowering treatment is usually chronic, often lifelong. This raises 
the question of long-term efficiency, long-term side effects, adher­
ence, and persistence with therapy. While BP-lowering therapies 
typically provide an overall durable effect, some attenuation of 
effect may be seen over time.66,530 First-line BP-lowering medica­
tion classes appear to be safe for long-term use.555–557 Once BP is 
controlled, at least a yearly follow-up is advised. Because of the 
known temporal variability in BP558,559 and medication efficacy in 
the long term,530 medication changes may be necessary over 
time (see Supplementary data online).
8.6. Device-based blood pressure lowering
Several device-based therapies designed to lower BP have been inves­
tigated.560,561 To date, the best evidence exists for catheter-based renal 
denervation.
8.6.1. Catheter-based renal denervation
Sympathetic nervous system overactivity contributes to the develop­
ment and progression of hypertension.562 Renal denervation aims to 
interrupt afferent and efferent sympathetic nerves in the adventitia 
and perivascular tissue of the renal arteries.563 The 2018 ESC/ESH 
Guidelines on the management of arterial hypertension did not recom­
mend the use of device-based therapies for routine treatment of hyper­
tension, unless in the context of clinical studies and RCTs.1 This was 
based on negative data using first-generation radiofrequency catheters 
(see Supplementary data online).
More recent data from sham-controlled trials investigating second- 
generation radiofrequency and ultrasound catheters demonstrated a 
BP-lowering efficacy in a broad range of patients, with and without con­
comitant BP-lowering medications, including those with resistant 
hypertension.564–568 Long-term, non-randomized, follow-up data 
from the Global Symplicity Registry,569 Symplicity HTN-3 trial,570
Spyral HTN-ON MED pilot trial,571 and A Study of the Recor 
Medical Paradise System in Clinical Hypertension (RADIANCE-HTN) 
SOLO trial572 indicate a sustained BP-lowering effect for up to 3 years. 
A single-centre open-label study suggested sustained BP reductions up 
to 10 years.573 These data also highlight a potentially important advan­
tage of renal denervation, namely that the BP-lowering effect of this 
intervention might be ‘always on’, making this approach attractive for 
patients with suboptimal medication adherence.254 Some patients 
may prefer a one-off procedure rather than taking daily medications 
chronically and may request renal denervation.
Of significance, there are no reported procedure-related serious 
safety signals in the first- and second-generation trials beyond the usual 
risk of femoral arterial access procedures (noting that most trials to 
date were not powered for safety outcomes and that the task force 
could find no published meta-analysis data on exact rates of major 
bleeding and major femoral artery vascular access complications after 
renal denervation procedures). However, the rate of major bleeding 
Recommendation Table 18 — Recommendations for 
blood pressure targets with treatment (see Evidence 
Table 34)
Recommendations
Classa
Levelb
To reduce CVD risk, it is recommended that treated 
systolic BP values in most adults be targeted to 120– 
129 mmHg, provided the treatment is well 
tolerated.22,122,131,523,541
I
A
In cases where BP-lowering treatment is poorly 
tolerated and achieving a systolic of 120–129 mmHg 
is not possible, it is recommended to target a systolic 
BP level that is ‘as low as reasonably achievable’ 
(ALARA principle).22,122,131,523,541
I
A
Because the CVD benefit of an on-treatment systolic 
BP target of 120–129 mmHg may not generalize to 
the following specific settings, personalized and more 
lenient BP targets (e.g. <140 mmHg) should be 
considered among patients meeting the following 
criteria: pre-treatment symptomatic orthostatic 
hypotension, and/or age ≥85 years.131
IIa
C
Because the CVD benefit of an on-treatment systolic 
BP target of 120–129 mmHg may not generalize to 
the following specific settings, personalized and more 
lenient BP targets (e.g. <140/90 mmHg) may be 
considered among patients meeting the following 
criteria: clinically significant moderate-to-severe 
frailty at any age, and/or limited predicted lifespan 
(<3 years).
IIb
C
In cases where on-treatment systolic BP is at or below 
target (120–129 mmHg) but diastolic BP is not at 
target (≥80 mmHg), intensifying BP-lowering 
treatment to achieve an on-treatment diastolic BP of 
70–79 mmHg may be considered to reduce CVD risk.
IIb
C
© ESC 2024
ALARA, as low as reasonably achievable; BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 19 — Recommendations for 
follow-up in patients with treated hypertension (see 
Evidence Table 33)
Recommendation
Classa
Levelb
Once BP is controlled and stable under BP-lowering 
therapy, at least a yearly follow-up for BP and other 
CVD risk factors should be considered.
IIa
C
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 56 -->

### Page 56

and major femoral artery vascular access complications for coronary 
angiography using a femoral approach is typically reported as 
1%–4%574,575 but has been reported as 5%–10% in some studies.575
Trials investigating radial access for renal denervation are currently on­
going (ClinicalTrials.gov identifier: NCT05234788). After renal denerv­
ation, there is a 0.25%–0.5% rate of renal artery stenosis/dissection 
requiring stenting.576 Long-term follow-up data up to 3 years have 
not suggested worsening of renal function beyond the expected rates 
in patients with hypertension with mildly-to-moderately reduced renal 
function.569,577 Of note, sham-controlled trials to date excluded pa­
tients with severely reduced kidney function at baseline.564,566–568
Despite the clear promise of renal denervation in reducing BP, there 
are some concerns that warrant consideration, as we indicate in the re­
commendations. First, the effect of current renal denervation catheter 
technologies on BP lowering is relatively modest for an invasive proced­
ure (meta-analyses report placebo-corrected systolic BP lowering 
of approximately 6 mmHg on office BP assessment and 4 mmHg on 
24 h ABPM).578 As such, the average BP-lowering effect of renal de­
nervation appears no more than for one standard BP-lowering medica­
tion. Accordingly, many adults undergoing renal denervation will likely 
require ongoing, post-procedural, BP-lowering drugs.
Second, the cost-effectiveness of renal denervation has not been fully 
established. Since effects of current renal denervation technologies are 
similar to that of one standard BP-lowering medication, most of which 
are generic, it is difficult to see a scenario where renal denervation 
could be proven cost-effective for most patients. An exception might 
be patients who are at very high risk of CVD events and who have un­
controlled BP due to resistant hypertension (with or without 
non-adherence).579,580
Third, there are no adequately powered outcomes trials demon­
strating that renal denervation reduces CVD events and is safe in the 
long term. While observational reports have suggested associations be­
tween renal denervation and reduced risk for CVD events,581,582 these 
observational data have major inferential limitations including a signifi­
cant potential for confounding. While BP lowering is typically a good 
surrogate for CVD benefit, there is no guarantee that this is true 
with renal denervation and, furthermore, off-target effects independent 
of BP could influence CVD and other adverse-event rates after the pro­
cedure. Because of the lack of outcomes trials, renal denervation can­
not reach the Class I indication threshold set by this task force. 
Arguments that outcomes trials will not be funded are insufficient to 
influence guideline recommendations. However, it is hoped that the 
position of these guidelines will motivate industry to sponsor the neces­
sary renal denervation outcomes trials.
Fourth, related to the lack of outcomes data, the potentially ‘always 
on’ effect of renal denervation could backfire if late complications 
emerge. Medications causing complications or side effects can simply 
be stopped and replaced with alternative medications when such pro­
blems emerge; this is not true with renal denervation.
Fifth, the impact of scaling up renal denervation on usual cardiac de­
partment catheterization laboratory workflows is of some concern. 
Specifically, it is important that renal denervation procedures do not 
delay timely access to other elective procedures with proven efficacy 
in reducing CVD outcomes.583
Sixth, there is still no direct evidence to gauge whether renal denerv­
ation procedures are successful and that the kidneys are denervated 
and do not reinnervate over time.584 Relatedly, the concept of respon­
ders and non-responders to renal denervation (and the hypothesis that 
predictors of response might be found to help identify patients most 
suitable for the procedure) is questioned. Medical interventions, 
including drugs, are naturally subject to inter-individual variability in re­
sponse.567 Additionally, there are few examples in medicine of consist­
ent and clinically useful predictors of treatment response for medical 
conditions that have complex genetic and environmental underpinnings 
(i.e. conditions like hypertension).
A multidisciplinary hypertension team, including experts in hyperten­
sion and percutaneous cardiovascular interventions, is recommended to 
evaluate the indication and to perform the procedure.585 Based on the 
available evidence, renal denervation may be considered for patients 
who have uncontrolled, true resistant hypertension with a three-drug 
combination and who express a preference to undergo renal denerv­
ation.566,568,585 This recommendation is informed, in part, by the higher 
risk of CVD events in this subgroup, which represents a major unmet 
clinical need and which also means that cost-effectiveness considerations 
are likely to be optimal in this setting. In patients who are non-adherent 
or intolerant to multiple BP-lowering medications, particularly first-line 
agents, and who have high predicted CVD risk and a BP that is not at tar­
get, renal denervation may, for the same reasons, be considered if the pa­
tients express a preference to undergo renal denervation after a tailored 
shared decision-making process. The shared decision-making process re­
quires that the patients are fully informed about the benefits, limitations, 
and risks associated with renal denervation.
Recommendation Table 20 — Recommendations for 
device-based treatment of hypertension (see Evidence 
Table 35)
Recommendations
Classa
Levelb
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation 
may be considered for resistant hypertension 
patients who have BP that is uncontrolled despite a 
three BP-lowering drug combination (including a 
thiazide or thiazide-like diuretic), and who express a 
preference to undergo renal denervation after a 
shared risk-benefit discussion and multidisciplinary 
assessment.564,566–568,586–590
IIb
B
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation 
may be considered for patients with both increased 
CVD risk and uncontrolled hypertension on fewer 
than three drugs, if they express a preference to 
undergo renal denervation after a shared risk-benefit 
discussion and multidisciplinary assessment.564,566– 
568,586–590
IIb
A
Due to a lack of adequately powered outcomes trials 
demonstrating its safety and CVD benefits, renal 
denervation is not recommended as a first-line 
BP-lowering intervention for hypertension.
III
C
Renal denervation is not recommended for treating 
hypertension in patients with moderate-to-severely 
impaired renal function (eGFR <40 mL/min/1.73 m2) 
or secondary causes of hypertension, until further 
evidence becomes available.
III
C
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration 
rate. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3967


<!-- PAGE 57 -->

### Page 57

8.6.2. Other devices
Most device-based therapies investigated for BP-lowering therapy in 
hypertension have been aimed at modulating the autonomic nervous 
system activity (baroreflex activation therapy, endovascular barore­
flex amplification therapy, and carotid body ablation).560 Cardiac 
neuromodulation therapy aims to lower left ventricular preload by 
variably altering the atrioventricular interval using a dual-chamber, 
rate-responsive, implantable pulse generator in patients indicated 
for implantation or replacement of a dual-chamber pacemaker.591,592
Some, though not all, of these devices have shown promising results in 
non-randomized, single-arm studies. A sham-controlled trial investi­
gating central iliac arteriovenous stent anastomosis was terminated 
early after longer-term follow-up data indicated an increase in heart 
failure in the stent group.561 Therefore, the use of these device-based 
therapies is not recommended for routinely treating hypertension un­
til further evidence regarding their safety and efficacy becomes avail­
able (see Supplementary data online).
8.7. Unintended and potentially harmful 
consequences of blood pressure lowering 
and implications for treatment targets
8.7.1. Adverse effects of blood pressure-lowering 
medications
8.7.1.1. Symptomatic adverse effects
BP-lowering medications have multiple side effects, which may be more 
common in females.536,593,594 Although generally well tolerated, common 
side effects include headaches, cough, dizziness or light-headedness, diar­
rhoea or constipation, fatigue, ankle swelling, and erectile problems, de­
pending on the drug class (see Supplementary data online, 
Table S9).536,550,593–597
In randomized trials of adults aged >60 years, the overall rate of 
symptomatic BP-lowering drug withdrawal was higher than the rate 
of placebo withdrawal (approximately 15% vs. 5%).593 A systematic re­
view, which included 280 638 participants in 58 RCTs, reported no evi­
dence for an increased relative risk of falls in those taking BP-lowering 
drugs.550 There was, however, an increased relative risk of mild hyper­
kalaemia, acute kidney injury, hypotension, and syncope. Furthermore, 
very frail adults were excluded from BP-lowering trials, which is rele­
vant because such patients are more prone to adverse effects and poly­
pharmacy (see Supplementary data online).596
8.7.1.2. Renal effects
A systematic review reported an increased risk of acute kidney injury and 
hyperkalaemia associated with BP-lowering treatment.550 Analyses 
of outcomes by specific drug class showed that drugs affecting the 
RAAS were more likely to be associated with acute kidney injury 
and hyperkalaemia.550
Patients with significant CKD tend to be excluded from 
RCTs.137,545,598 It is important to remember these exclusion criteria, 
and that patients with CKD are more likely to suffer from resistant 
hypertension, when extrapolating the results of more intensive BP low­
ering to patients with moderate-to-severe CKD (see Section 9).599
8.7.1.3. Erectile dysfunction
Older classes of BP-lowering drugs (including diuretics, beta-blockers, 
and centrally acting medications) are associated with erectile 
dysfunction.600 However, newer classes have neutral effects.601
Angiotensin receptor antagonists may have beneficial effect on erectile 
function.602
8.7.2. Pill burden and non-adherence
More intensive treatment of elevated BP and hypertension may be as­
sociated with an increased risk of polypharmacy and pill burden, which 
are themselves associated with non-adherence.603,604 Single-pill, fixed- 
dose drug combinations can help to reduce pill burden and are recom­
mended to improve adherence (refer to Section 8.3.4).
Increased intensity of BP lowering (while ultimately cost reducing in 
terms of CVD reduction)605 can also result in higher upfront direct and 
indirect healthcare costs, with more people requiring medication and 
higher demand for technology-based adherence strategies, which can 
be challenging to implement, especially in resource-poor settings.604
8.7.3. Potentially harmful consequences of blood 
pressure lowering for frail older people
Unintended consequences of BP lowering (hypotension, syncope, falls) can 
be hazardous for frail older people in particular.606 Retrospective studies 
have shown that adults aged >75 years from the general population, 
who would have met the criteria for inclusion in the Systolic Blood 
Pressure Intervention Trial (SPRINT), had a rate of injurious falls and syn­
cope that was nearly five times that of the standard care group in the trial. 
This suggests that healthy participant bias may have contributed to the 
findings of SPRINT and other similar BP-lowering trials, and that the results 
may not fully generalize to older adults in more routine clinical care.607
Patients’ functional ability should be considered in addition to age to 
help negate any unintended consequences of BP lowering in a frailer co­
hort. Despite their chronological age, older patients with hypertension 
who are fit and can independently carry out activities of daily living will 
benefit from guideline-directed treatment similar to younger cohorts.131
However, tailoring treatment targets and treatment plans for frail older 
patients is necessary to avoid unintended consequences. This should in­
clude assessing frailty, including cognitive status, risk of falls, propensity 
for symptomatic orthostatic hypotension, polypharmacy, and other co­
morbid conditions.608,609 Of note, and as detailed in Section 9, some 
data indicate a benefit of more intensive BP-lowering on cognitive func­
tion.523,610,611 For those with loss of function but preserved activities of 
daily living, a more detailed geriatric assessment is required to explore 
the risks and benefits of treatment, as well as considerations for tailoring 
therapeutic strategies where appropriate. For patients who are both func­
tionally impaired and unable to carry out activities of daily living, the thera­
peutic goals of hypertension treatment should be personalized, and 
medications discontinued where appropriate (see Section 9.3).596
8.7.4. Clinical inertia in blood pressure lowering
The fear of serious adverse events with BP-lowering medications is of­
ten cited as a reason for clinical inertia, although the evidence to date 
from meta-analyses of RCTs suggests these side-effect concerns may 
be exaggerated.550,612 However, RCTs often select populations with 
less frailty and multimorbidity who are more likely to tolerate treat­
ment.613 Consequently, fewer adverse effects might be reported 
than would be expected in the general population. It remains up to in­
dividual clinicians to initiate shared decision-making with each patient, 
especially patients in vulnerable groups and those who have experi­
enced previous adverse events, weighing up potential benefits against 
risks of treatment.614,615


<!-- PAGE 58 -->

### Page 58

### 9 Managing specific patient groups

or circumstances
9.1. Young adulthood (18–40 years)
9.1.1. Definition and epidemiology
In the present guidelines ‘young adulthood’ is defined as age 18–40 years. 
The prevalence of hypertension in young adults is increasing in men and 
women.616–618 Unhealthy lifestyle, gender, obesity, and socio-economic 
factors contribute.617,619–621 Hypertension-attributable CVD burden in 
young adults, evaluated as mortality or years of living with disability, 
has increased in the last decades, especially in low- and middle-income 
countries and in men.622 Hypertension awareness, treatment, and con­
trol in young adults is lower than in other age categories, a result driven 
by worse control in young men.623
Systolic and diastolic hypertension and isolated diastolic hyperten­
sion are associated with increased CVD risk in the young (see 
Supplementary data online).624 Isolated systolic hypertension in the 
young is discussed in Section 9.4.
9.1.2. Secondary hypertension in young adulthood
Secondary hypertension is more frequent in younger than in later- 
onset hypertension, with a prevalence of 15%–30% in hypertensive 
young adults reported from some referral centres.625,626 Major causes 
of secondary hypertension include drug-induced hypertension (e.g. 
oestrogen-progesterone oral contraceptives; cold medication) and pri­
mary aldosteronism. The use of recreational drugs/substances, as well 
as supplements and energy drinks should be investigated (see Section 7).
Combined oestrogen-progesterone contraceptives are among the most 
common causes of drug-induced hypertension in young women,627,628 and 
should not be used in hypertensive women unless there is no other method 
available or acceptable to the patient.629Conversely, progestin-only contra­
ceptives are generally considered safe in women with hyperten­
sion.89,630,631 Fibromuscular dysplasia should be considered as a cause of 
secondary hypertension in young women,626,632 whereas primary aldoster­
onism, the most common form of secondary hypertension, is equally com­
mon in different age classes.316 Screening for secondary hypertension is 
thus recommended in young adults with hypertension. However, in obese 
young adults, primary hypertension is more common, though OSAS should 
also be considered in this instance.633
9.1.3. Measurement and management of blood 
pressure in young adults
Out-of-office BP measurement is recommended in young adults for 
confirming diagnosis, since the white-coat phenomenon occurs in the 
young.634 Because of the lower absolute CVD risk in this age category 
compared with older adults, hard-endpoint randomized trials of BP 
lowering in young adults have not been performed. However, since 
relative risk reduction by BP-lowering treatment is homogeneous in 
any age group, including those <55 years old,131 young adults with suit­
able indications are also expected to benefit from BP-lowering therapy. 
The hypertension management algorithm based on CVD risk proposed 
in Section 6 is not fully applicable in young adults, since SCORE2 has not 
been validated for individuals <40 years old. Even risk stratification 
based on lifetime risk assessment does not apply to very young adults 
(e.g. 20–30 years of age).128 In the absence of established CVD, diabetes 
mellitus, familial hypercholesterolaemia, and moderate or severe CKD 
a BP-lowering treatment initiation threshold of office 140/90 mmHg is 
appropriate in most young adults. However, HMOD assessment may 
be considered in patients aged <40 years to stratify individuals with ele­
vated BP into a higher risk category. For example, arterial stiffness bet­
ter reclassifies CVD risk in individuals aged <50 years than in older 
individuals.28,215 Echocardiographic left ventricular mass also maintains 
its added reclassification and discrimination on top of risk scores in 
young adults (see Section 6 for discussion of risk modifiers).289
Irrespective of cardiovascular risk, all young adults with elevated BP 
are recommended to follow lifestyle guidance for BP lowering. A dis­
cussion about family planning should be taken with young women of 
childbearing potential at each visit.635,636
Adherence to treatment is low in young adults, <50% in some stud­
ies.251 Therefore, communicating the importance of adherence, educa­
tion, and follow-up clinics is important. (see Sections 7 and 11).
9.2. Pregnancy
9.2.1. Definition and epidemiology
Hypertension in pregnancy is typically defined as systolic BP of 
≥140 mmHg and/or diastolic BP of ≥90 mmHg, measured using repeated 
BP readings in the office or hospital on two separate occasions or 
≥15 min apart in severe hypertension (≥160/110 mmHg).1,637,638
Hypertension in pregnancy is the second leading cause of maternal 
death after maternal peri-partum haemorrhage.639 Approximately 
7% of pregnancies are complicated by hypertension, of which 3% 
are due to pre-eclampsia and around 1% are chronic or pre-existing 
hypertension.640 Women with a history of hypertensive disorders 
during pregnancy are at increased risk of subsequent hypertension 
and CVD.640–642
9.2.2. Classifying hypertension in pregnancy
Hypertension in pregnancy includes:
• Chronic hypertension: precedes pregnancy, develops before 20  
weeks of gestation, persists for >6 weeks post-partum, and may be 
associated with proteinuria.
• Gestational hypertension: develops after 20 weeks of gestation 
and usually resolves within 6 weeks post-partum.
Recommendation Table 21 — Recommendations for 
managing hypertension in young adults (see Evidence 
Tables 36 and 37)
Recommendations
Classa
Levelb
Comprehensive screening for the main causes of 
secondary hypertension is recommended in adults 
diagnosed with hypertension before the age of 40 
years, except for obese young adults where it is 
recommended to start with an obstructive sleep 
apnoea evaluation.316,626
I
B
Since SCORE2 has not been validated for individuals 
<40 years, screening for HMOD may be considered in 
such young individuals with elevated BP without other 
increased CVD risk conditions to identify additional 
individuals for possible medical treatment.28,215
IIb
B
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease; HMOD, hypertension-mediated organ 
damage; SCORE2, Systematic COronary Risk Evaluation 2. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3969


<!-- PAGE 59 -->

### Page 59

• Antenatally unclassifiable hypertension: BP is first recorded 
after 20 weeks of gestation, and hypertension is diagnosed but it is 
unclear if chronic or not; reassessment is necessary 6 weeks 
post-partum.
• Pre-eclampsia: gestational hypertension accompanied by new- 
onset: (i) proteinuria (>0.3 g/day or ≥30 mg/mmol ACR), (ii) other 
maternal organ dysfunction, including acute kidney injury (serum cre­
atinine ≥ 1 mg/dL), liver dysfunction (elevated transaminases > 40  
UI/L with or without right upper quadrant or epigastric abdominal 
pain), neurological complications (convulsions, altered mental status, 
blindness, stroke, severe headaches, and persistent visual scotomata), 
or haematological complications (platelet count < 150 000/µL, disse­
minated intravascular coagulation, haemolysis), or (iii) uteroplacental 
dysfunction (such as foetal growth restriction, abnormal umbilical ar­
tery Doppler waveform analysis, or stillbirth).643 The only cure for 
pre-eclampsia is delivery, which is recommended at 37 weeks’ gesta­
tion, or earlier in high-risk cases. Of note, proteinuria is not manda­
tory for diagnosing pre-eclampsia but is present in about 70% of 
cases.644 Also, as proteinuria may be a late manifestation of 
pre-eclampsia, it should be suspected when de novo hypertension is 
accompanied by headache, visual disturbances, abdominal pain, or 
abnormal laboratory tests, specifically low platelets and/or abnormal 
liver function.
Other potential causes for high BP, including pain and anxiety, must be 
excluded when treating hypertension during pregnancy.
9.2.3. Measuring blood pressure in pregnancy
See Section 5.5.1 for information on BP measurement approaches in 
pregnancy.645 It is important to restate here that oscillometric devices 
tend to under-estimate the true BP and are unreliable in severe pre- 
eclampsia; only a few have been validated in pregnancy. Importantly, 
only the relatively few devices validated for measuring BP in pregnancy 
and pre-eclampsia should be used (https://stridebp.org).
9.2.4. Investigating hypertension in pregnancy
Basic laboratory investigations include urinalysis, blood count, haemato­
crit, liver enzymes, serum creatinine, and serum uric acid. Serum uric 
acid is increased in pre-eclampsia and identifies women at increased 
risk of adverse maternal and foetal outcomes in hypertensive 
pregnancies.646
All pregnant women should be assessed for proteinuria in early preg­
nancy (e.g. 11–14 weeks’ gestation).647 A dipstick test of ≥1+ should 
prompt further investigations, including ACR, which can be quickly de­
termined in a single spot-urine sample.648 An ACR of <30 mg/mmol 
(<0.3 mg/mg) can rule out proteinuria.649 Higher values should prompt 
24 h urine collection.
In one study, 10% of pregnant women with chronic hypertension had 
secondary hypertension (estimated to affect 0.24% of all pregnan­
cies).650 Secondary hypertension during pregnancy is associated with 
an increased risk of adverse outcomes.650 The most common cause 
of secondary hypertension during pregnancy is CKD. The onset of 
hypertension during the first trimester, at the peak of human chorionic 
gonadotropin (HCG) secretion, should prompt consideration of pri­
mary aldosteronism.651 Phaeochromocytoma in pregnant women is 
rare (0.002% of all pregnancies) but highly morbid.652,653
9.2.5. Preventing hypertension and pre-eclampsia
Low-to-moderate-intensity exercise, especially if supervised and in­
itiated during the first trimester of pregnancy, decreases the incidence 
of developing gestational hypertension.654 As such, after consultation 
with their obstetrician, all pregnant women should participate in phys­
ical activity, unless contraindicated.655 Factors indicating risk of pre- 
eclampsia are discussed in the Supplementary data online.
Women at high or moderate risk of pre-eclampsia should be advised 
to take 100–150 mg of aspirin daily at bedtime from gestational weeks 
12–36.647,656,657
Oral calcium supplementation of 0.5–2 g daily is recommended for 
preventing pre-eclampsia in women with low dietary intake of calcium 
(<600 mg daily).658,659
9.2.6. Treatment initiation and blood pressure 
targets
Acute management of BP in pre-eclampsia and eclampsia is detailed in 
Section 10.4.
Meta-analyses have found no evidence for an increased risk for deli­
vering small-for-gestational-age babies in pregnant women with mild 
hypertension receiving BP-lowering medications.660 Despite a historical 
paucity of trial data, previous European guidelines1,89 recommended 
initiating BP-lowering drug treatment (i) in all women with persistently 
elevated office BP of ≥150/90 mmHg, and (ii) in women with gestation­
al hypertension (with or without proteinuria), pre-existing hyperten­
sion with superimposed gestational hypertension, or hypertension 
with subclinical HMOD, when office BP is >140/90 mmHg.
In the CHAP trial, treating pregnant women with chronic hyperten­
sion and BP of ≥140/90 mmHg reduced the occurrence of pre- 
eclampsia with severe features, and reduced medically indicated 
pre-term birth <35 weeks, compared with only treating severe hyper­
tension (BP ≥ 160/105 mmHg).88 Tight BP control (target diastolic 
BP < 85 mmHg) compared with less-tight BP control (target diastolic 
BP < 100 mmHg) reduces the incidence of subsequent severe maternal 
hypertension (BP ≥ 160/110 mmHg), but not foetal or other maternal 
outcomes in women with mild hypertension at baseline (diastolic BP of 
85–105 mmHg).661
Treatment with BP-lowering drugs in all pregnant women with con­
firmed BP of ≥140/90 mmHg is recommended to reduce the progres­
sion to severe hypertension and the related risks for adverse pregnancy 
outcomes.660,661 In women with pre-existing and gestational hyperten­
sion with and without pre-eclampsia, we recommend lowering BP be­
low 140 mmHg for systolic and to 80–90 mmHg for diastolic BP.661
Evidence to support a BP target as low as 120–129/70–79 mmHg is 
lacking in pregnancy, though such evidence exists for non-pregnant pa­
tients receiving BP-lowering medication.
9.2.7. Managing mild hypertension in pregnancy 
(office blood pressure 140–159/90–109 mmHg)
RAS inhibitors are not recommended in pregnancy due to adverse foe­
tal and neonatal outcomes. The BP-lowering drugs of choice are: beta- 
blockers (most data are available for labetalol, a non-selective beta- 
blocker that also acts as an alpha-blocker in higher doses; metoprolol 
and bisoprolol are also considered safe), dihydropyridine CCBs (most 
data are available for nifedipine, which is generally considered first 
choice, also felodipine, nitrendipine, amlodipine, and isradipine can be 
used), and methyldopa.662,663 A meta-analysis suggests that beta- 
blockers and CCBs are more effective than methyldopa in preventing 
severe hypertension.660 Of note, however, atenolol should be avoided, 
as it is associated with foetal growth restriction.664,665 Methyldopa has 
been associated with an increased risk of post-partum depression and 
caution is therefore advised both intra-partum and post-partum.637


<!-- PAGE 60 -->

### Page 60

Hydralazine can be particularly effective for severe hypertension in 
pregnancy and can be administered intravenously in hypertensive ad­
missions (Section 10).666–668 While thiazide diuretics in pregnancy 
have limited safety data and should be used with caution, other diuretics 
such as furosemide are not contraindicated and may be necessary in 
some situations (see Supplementary data online).669
9.2.8. Managing severe hypertension in pregnancy 
(>160/110 mmHg)
Acute onset of severe hypertension persisting for more than 15 min is 
considered a hypertensive emergency in pregnancy and is covered in 
Section 10.4.2.
9.2.9. Managing blood pressure post-partum
For women with hypertension during pregnancy, BP should be mea­
sured within 6 h of delivery and, if possible, daily for at least a week after 
discharge from the hospital.637 Post-partum hypertension is common 
in the first week and associated with prolonged hospitalization.670
Women with hypertension in pregnancy are at increased risk of 
chronic hypertension,671 CKD,672 and CVD.177,223,640 The relative 
risk of chronic hypertension is highest in the first 6 months following 
delivery, motivating regular screening in these women.673 Women 
with gestational hypertension, especially those with pre-eclampsia, 
have higher risk of masked hypertension.674 BP measurements, ideally 
including out-of-office measurements, urine analyses, and CVD risk as­
sessment, should at least be performed 6–12 weeks, 6 months, and 
12 months post-partum and, after that, annually. Recent data indicate 
the potential utility of self-monitoring of BP during the busy early post- 
partum period.675
All BP-lowering drugs are excreted into breast milk.637 Except for 
propranolol, atenolol, acebutolol, and nifedipine, most drugs are ex­
creted in very low concentrations in breast milk (see Supplementary 
data online, Table S11).637
9.2.10. Risk of recurrence of hypertensive disorders 
in a subsequent pregnancy
About 20%–30% of women with hypertensive disorders in a previous 
pregnancy will experience recurrence in a subsequent pregnancy.676,677
The earlier the onset of hypertension in the first pregnancy, the higher 
the risk of recurrence in a subsequent pregnancy.677
Further details on managing hypertension and other cardiovascular 
disorders in pregnancy are available elsewhere.89,637
9.3. Very old age (≥85 years), frailty, 
multimorbidity, and polypharmacy
9.3.1. Definition of frailty
The most common definition of frailty is an age-associated, biological 
syndrome characterized by decreased biological reserves, due to dysre­
gulation of several physiological systems.682 This puts an individual at 
risk when facing physiological stressors, and is associated with poor 
outcomes, such as disability, hospitalization, and death.683 The esti­
mated prevalence of frailty in people aged >65 years is 7%–16% and 
is greater in women than in men.684,685 Although the main determinant 
of frailty is age, chronological age must be differentiated from biological 
age.686 An older patient can be fit and robust while a multimorbid 
young patient can be frail. Using multiple drugs may have more unpre­
dictable effects on BP in older patients, because of increased competi­
tion for underlying mechanisms responsible for their degradation and 
elimination, and because the ability of the baro-687 and chemo-reflex688
systems in maintaining a steady treated BP level can decline with ageing.
With respect to BP, two issues compound interpretation of the 
frailty literature. First, frailty on its own is a strong predictor of mortality 
and cardiovascular complications689 and is accompanied by a decrease 
in systolic BP.690 This raises the issue of the so-called BP J-curve (see 
Section 9.8) and reverse causality, with frailty rather than excessive 
BP lowering being the root cause of adverse health outcomes. Only 
properly randomized and controlled clinical trials can differentiate be­
tween the effects of frailty vs. overly intensive BP-lowering treatment, 
but unfortunately, few BP-lowering trials have included a substantial 
proportion of frail patients. Second, there is no consensus on how to 
grade frailty in day-to-day clinical practice.606 Complex frailty scales ex­
ist for application in research,523,691 but unless they are electronically 
generated,692 they are typically not practical in routine clinical care. 
Nonetheless, the clinical frailty scale (Figure 21) is intuitive and easy 
to administer and has been validated against 5-year risk of death.596,693
Recommendation Table 22 — Recommendations for 
managing hypertension in pregnancy (see Evidence 
Tables 38–40)
Recommendations
Classa
Levelb
In women with gestational hypertension, starting 
drug treatment is recommended for those with 
confirmed office systolic BP ≥140 mmHg or diastolic 
BP ≥90 mmHg.661
I
B
In pregnant women with chronic hypertension, 
starting drug treatment is recommended for those 
with confirmed office systolic BP ≥140 mmHg or 
diastolic BP ≥90 mmHg.88,660,661,678
I
B
Continued
In women with chronic and gestational hypertension, 
it is recommended to lower BP below 140/90 mmHg 
but not below 80 mmHg for diastolic BP.
I
C
Dihydropyridine CCBs (preferably extended-release 
nifedipine), labetalol, and methyldopa are 
recommended first-line BP-lowering medications for 
treating hypertension in pregnancy.
I
C
In consultation with an obstetrician, low- to 
moderate-intensity exercise is recommended in all 
pregnant women without contraindications to 
reduce the risk of gestational hypertension and 
pre-eclampsia.654,655
I
B
Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg 
in pregnancy can indicate an emergency, and 
immediate hospitalization should be considered.
IIa
C
HBPM and ABPM should be considered to exclude 
white-coat and masked hypertension, which are 
more common in pregnancy.679
IIa
C
RAS blockers are not recommended during 
pregnancy.680,681
III
B
© ESC 2024
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CCB, calcium channel 
blocker; HBPM, home blood pressure monitoring; RAS, renin–angiotensin system. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3971


<!-- PAGE 61 -->

### Page 61

9.3.2. Randomized controlled trials of blood pressure 
lowering in frail older patients
Few adults aged ≥85 years have been included in trials.131 In addition, 
generalizing data from RCTs to very frail patients may not be pos­
sible.692,694–697 However, the currently available evidence from RCTs 
has not demonstrated weakening of the benefits of BP-lowering treat­
ment (i.e. no effect modification) among frailer patients enrolled in 
these trials, although these participants likely had no more than mild 
frailty (see Supplementary data online).523,694,698
In the absence of robust randomized evidence, several observational 
studies have suggested that lowering BP might not be warranted or 
even be harmful in patients with significant frailty or multimorbidity, 
particularly when BP is not very high. For instance, a systematic review 
and meta-analysis of non-randomized studies that investigated 
associations between BP and risk of mortality in older patients found 
evidence for interaction by frailty status, suggesting that lowering BP 
might be harmful in this patient group.699 However, as noted above 
and in Section 9.8, these observational J-curve findings are unreliable 
when guiding clinical care, as unidentified biases potentially confound 
the results. For instance, in addition to reverse causality, stiffness of 
the large arteries is associated with both low diastolic BP and increased 
mortality.697 In addition, absolute CVD risk increases with age, indicat­
ing that fewer older than younger patients with hypertension may need 
to be treated to prevent one adverse health outcome.700
Therefore, 
given 
the 
totality 
of 
evidence 
from 
clinical 
trials,523,694,701,702 very old and frail patients with hypertension should 
not be denied the potential benefits of BP-lowering treatment down to 
a target of 120–129/70–79 mmHg. However, personalized decisionVery fit
1
People who are robust, 
active, energetic and 
motivated. These people 
commonly exercise regularly. They are among 
the fittest for their age.
Follow BP-lowering 
treatment guidelines as per 
younger cohorts, ensuring 
treatment is tolerated
Evidence for benefit in CV 
event reduction not as 
strong for people with 
moderate-to-severe frailty 
with functional impairment 
(poorly represented in 
clinical trials)
Evidence for benefits in 
reducing CVD events with 
more intensive treatment of 
BP
Exercise caution and clinical 
judgement in beginning and 
intensifying BP-lowering 
treatment, employing a 
shared decision-making 
approach
Low-dose combination 
therapy to achieve
BP control is reasonable
Single drug therapy may be reasonable in this cohort 
when initiating or maintaining 
BP-lowering treatment
ABPM if possible and 
regular review important, 
particularly if change in 
frailty
Monitor for symptomatic 
OH, asymptomatic OH 
with falls, poor treatment 
tolerance, or medication 
side effects. Use clinical 
judgement and APBM/HBPM to guide deprescribing 
or medication adjustment 
where appropriate
Well
2
People who have no active 
disease symptoms but are 
less fit than category I. 
Often, they exercise or are 
very active occasionally, e.g, 
seasonally.
Managing well
3
People whose medical 
problems are well 
controlled, but are not 
regularly active beyond 
routine walking.
Vulnerable
4
While not dependent on 
others for daily help, often 
symptoms limit activities. A 
common complaint is 
being "slowed up", and/or 
being tired during the day.
Mildly frail
5
These people often have more 
evident slowing, and need help 
in high order IADLs (finances, 
transportation, heavy 
housework, medications). 
Typically, mild frailty progressively impairs shopping and 
walking outside alone, meal 
preparation and housework.
Moderately frail
6
People need help with all outside activities and with 
keeping house. Inside, they 
often have problems with 
stairs and need help with 
bathing and might need 
minimal assistance cueing 
(prompting), standing by 
with dressing.
Severely frail
7
Completely dependent for 
personal care, from 
whatever cause (physical 
or cognitive). Even so, they 
seem stable and not at high risk of dying (within 
~6 months).
Very severely frail
8
Completely dependent,
approaching the end of life. 
Typically, they could not recover even from a 
minor illness.
Terminally ill
9
Approaching the end of 
life. This category applies 
to people with a life 
expectancy <6 months, 
who are not otherwise 
evidently frail.
Clinical Frailty
Scale 1–5
Clinical Frailty
Scale 6–9
Figure 21 Frailty assessment in the management of blood pressure. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CV, cardio­
vascular; CVD, cardiovascular disease; HBPM, home blood pressure monitoring; IADLs, independent activities of daily living; OH, orthostatic hypoten­
sion. Adapted from Rockwood et al.693


<!-- PAGE 62 -->

### Page 62

making should be a priority in the very old and frail. Together with man­
agement of BP, a major consideration should also be whether reversible 
causes of frailty can be addressed,609 e.g. by treating underlying co­
morbidities or undergoing supervised muscle-strengthening physiother­
apy or supervised exercise and co-ordination and balance training.703
9.3.3. Starting blood pressure-lowering treatment in 
very old or frail patients
All patients must be fully informed about the benefits and risks of start­
ing BP-lowering treatment, so that their preference is considered. 
Among 34 hypertension guidelines, 18 recommended 150 mmHg as 
the systolic goal in frailer and/or older patients, but four endorsed sys­
tolic targets <130 mmHg or <120 mmHg.704 Treatment can be started 
with a long-acting dihydropyridine calcium channel antagonist.596,705
To achieve BP control, an ACE inhibitor, or if contraindicated, an 
ARB, can also be used. Thereafter, low-dose thiazides or thiazide-like 
diuretics are preferred unless there is a specific contraindication, such 
as gout, orthostatic hypotension, or disturbed micturition (including 
micturition syncope).596,705 Beta-blockers are less desirable as they 
reduce heart rate, cause fatigue, and increase the systolic pulse wave 
amplitude, which is insufficiently buffered in stiff central elastic arteries. 
Vasodilating beta-blockers and direct vasodilators (e.g. hydralazine and 
minoxidil) are associated with increased risk of orthostasis. Though 
data are conflicting,706 alpha-blockers are also considered less desirable 
as they appear to be associated with an increased risk of orthostasis and 
falls in very old patients (aged ≥85 years).707,708 Alpha-1 blockers, such 
as doxazosin, prazosin, terazosin (also used to treat prostate symp­
toms), are particularly prone to causing orthostasis.98 Once the appro­
priate combination is found, a combination tablet with variable 
composition of two agents may optimize adherence. Starting with com­
bination therapy is not advised in most very old and/or frail patients, un­
less BP is very high.
9.3.4. Maintaining blood pressure lowering in very old 
or frail patients
If very old and frail patients tolerate BP-lowering treatment well, there 
is no automatic need to deprescribe or discontinue treatment; how­
ever, this should be kept under review. In the case of progressive frailty, 
systolic BP tends to drop,709 such that deprescription of a BP-lowering 
drug might become necessary. To identify candidate drugs for depre­
scribing, a patient’s current medications should be reviewed to identify 
BP-lowering drugs that may have become contraindicated due to con­
comitant prescriptions or newly developed comorbidities.705 To help 
guide deprescription of BP-lowering agents, ABPM can be used to de­
tect orthostatic hypotension or a highly variable BP not buffered by 
autonomic nervous reflexes.687,688
9.4. Isolated systolic and diastolic 
hypertension
9.4.1. Definition of isolated systolic hypertension
Isolated systolic hypertension is typically defined as systolic BP of 
≥140 mmHg with a diastolic BP of <90 mmHg. While isolated systolic 
hypertension is uncommon in younger patients,713 it is the most common 
type of hypertension in older patients; >80% of untreated patients with 
hypertension aged >60 years have isolated systolic hypertension.714
9.4.2. Isolated systolic hypertension, risk factors, and 
ageing
Systolic BP increases with age in men and women until the eighth dec­
ade of life, while diastolic BP gradually increases up until the fifth or sixth 
decade of life, after which it either plateaus or decreases. As a result, the 
pulse pressure (the difference between the systolic and diastolic BP) 
gradually widens from middle age.34 These BP changes are related to 
increased aortic stiffening with age.715,716
Since most older patients with hypertension have isolated systolic 
hypertension, and since with advancing age, risk of CVD events is driven 
by systolic rather than diastolic BP,717 management of isolated systolic 
hypertension in older adults is broadly in line with that of combined 
systolic-diastolic hypertension seen in younger adults.718 Early isolated 
Recommendation Table 23 — Recommendations for 
managing hypertension in patients who are very old or 
frail (see Evidence Table 41)
Recommendations
Classa
Levelb
It is recommended that treatment of elevated BP and 
hypertension among older patients aged <85 years 
who are not moderately to severely frail follows the 
same guidelines as for younger people, provided 
BP-lowering treatment is well tolerated.131,523,524
I
A
Continued
It is recommended to maintain BP-lowering drug 
treatment lifelong, even beyond the age of 85 years, if 
well tolerated.523–525
I
A
Because the benefit in reducing CVD outcomes is 
uncertain in these settings, and noting that close 
monitoring of treatment tolerance is advised, 
BP-lowering treatment should only be considered 
from ≥140/90 mmHg among persons meeting the 
following criteria: pre-treatment symptomatic 
orthostatic hypotension, age ≥85 years, clinically 
significant moderate-to-severe frailty, and/or limited 
predicted lifespan (<3 years).131,524,526,527
IIa
B
As the safety and efficacy of BP treatment is less 
certain in individuals with moderate or severe frailty, 
clinicians should consider screening older adults for 
frailty using validated clinical tests; frail patients’ 
health priorities and a shared-decision approach 
should be considered when deciding on BP 
treatments and targets.523,524,613,710
IIa
C
When initiating BP-lowering treatment for patients 
aged ≥85 years, and/or with moderate-to-severe 
frailty (at any age), long-acting dihydropyridine CCBs 
or RAS inhibitors should be considered, followed if 
necessary by low-dose diuretic if tolerated, but 
preferably not a beta-blocker (unless compelling 
indications exist) or an alpha-blocker.711
IIa
B
If BP drops with progressing frailty, deprescription of 
BP-lowering medications (and other drugs that can 
reduce BP, such as sedatives and prostate-specific 
alpha-blockers) may be considered.712
IIb
C
© ESC 2024
BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; RAS, 
renin–angiotensin system. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3973


<!-- PAGE 63 -->

### Page 63

systolic hypertension studies used systolic BP treatment targets of 160 or 
150 mmHg.718 However, results from the SPRINT and the Strategy of 
Blood Pressure Intervention in Elderly Hypertensive Patients (STEP) trials 
(mean BP at study entry of 140/78 mmHg and 146/82 mmHg, respective­
ly, indicating that many of the patients had isolated systolic hypertension) 
confirm that lower systolic BP targets are effective in reducing CVD 
events 
in 
patients 
with 
isolated 
systolic 
hypertension 
(see 
Supplementary data online).135,136
Since relative risk reduction by BP-lowering treatment is homoge­
neous in any age group, whereas absolute risk reduction is larger 
with advancing age,131 therapeutic inertia in older patients with isolated 
systolic hypertension should be avoided (see Section 9.3). As noted earl­
ier, beta-blockers should be avoided in patients with isolated systolic 
hypertension or more generally with arterial stiffness, as they increase 
stroke volume (given the lower heart rate).218
9.4.3. Isolated systolic hypertension in young adults
In young adults (<40 years old), the presence of isolated systolic hyper­
tension poses different pathophysiological and clinical considerations. In 
young patients with isolated systolic hypertension, arterial stiffness713
and relative risk of CVD events624 appear to be similar to those without 
isolated systolic hypertension and lower than young adults with com­
bined systolic-diastolic hypertension and isolated diastolic hypertension. 
Indeed, younger patients with isolated systolic hypertension appear to 
comprise a heterogeneous group.719 For these reasons, it might be rea­
sonable to assess central BP and arterial stiffness in these individuals, as 
recommended by other scientific societies.720,721 Out-of-office BP meas­
urement is recommended to exclude white-coat hypertension, which is 
often associated with isolated systolic hypertension in the young.634
9.4.4. Isolated diastolic hypertension
Isolated diastolic hypertension is defined as a systolic BP of <140 mmHg 
with a diastolic BP of ≥90 mmHg. The isolated diastolic hypertension 
phenotype is more commonly seen in younger adults and, particularly, 
younger adults with obesity or other metabolic derangements.722,723 In 
older adults with this phenotype, consideration should be given to 
whether the diastolic BP was accurately measured.724
Patients with isolated diastolic hypertension appear to have a slightly 
increased relative risk for CVD of 5%–30%.548,723,725 However, be­
cause patients with isolated diastolic hypertension are younger, they 
tend to have few events, and very large samples are required to 
show this association. Furthermore, because the absolute risk for 
CVD among these individuals is low (typically <10% over 10 years), it 
is less clear if isolated diastolic hypertension should prompt initiation 
of BP-lowering medication, particularly among persons in whom base­
line systolic BP is already at the target of 120–129 mmHg.723
Irrespective, patients with isolated diastolic hypertension should be fol­
lowed up, as they are at increased risk for systolic hypertension.723
Finally, it is also worth noting that when a patient achieves a target 
systolic BP of 120–129 mmHg with BP-lowering treatment, there is lit­
tle to no high-quality trial evidence that further intensifying BP-lowering 
medication to achieve both systolic BP of <120 mmHg and also diastol­
ic BP of <70 mmHg improves CVD prognosis.547,723
9.5. Orthostatic hypotension with supine 
hypertension
Patients with orthostatic hypotension need not be hypotensive and in­
deed, many have supine elevated BP or supine hypertension. 
Furthermore, many patients with orthostatic hypotension are asymp­
tomatic. Orthostatic hypotension is present in around 10% of all adults 
with hypertension and is defined as a drop in BP of ≥20/10 mmHg after 
rising from either a sitting or lying position to a standing position (see 
Section 5.5.3).97,99 Assessment for orthostatic hypotension should be 
timed to occur at 1 and/or 3 min after standing. Because seated to 
standing assessment can lead to under-detection of orthostatic hypo­
tension, it is preferable, where possible, to test for orthostatic hypoten­
sion using a supine (lying) to standing assessment (see Section 5).56,98,726
Assessing for orthostatic hypotension is important in managing adults 
with elevated BP or hypertension for several reasons. First, findings of trials 
linking more intensive BP control to improved outcomes may not gener­
alize to patients with orthostatic hypotension, particularly when it is severe 
in magnitude (standing systolic BP < 110 mmHg97) and/or symptomatic. 
Second, orthostatic hypotension may be associated with symptoms that 
may limit the patient’s tolerability of more intensive BP-lowering 
approaches. Third, orthostatic hypotension may be associated with an in­
creased risk of adverse effects commonly co-attributed to pharmacological 
BP lowering (such as hospitalizations for hypotension).727 Fourth, ortho­
static hypotension is associated with increased risk for CVD.728
However, the frequency of orthostatic hypotension is not increased 
in the more intensive BP-lowering arms of randomized trials compared 
with the less intensive BP-lowering arms.726,727,729,730 As such, and in 
contrast to common belief, it does not appear that more intensive 
treatment of BP (which almost always requires more BP-lowering 
medication) worsens orthostatic hypotension. In contrast, there is 
some evidence that more intensive treatment of hypertension may ac­
tually reduce the risk of orthostatic hypotension.730,731
The aetiology of orthostatic hypotension may be considered as 
neurogenic or non-neurogenic, with the latter being far more com­
mon.99 Patients with orthostatic hypotension may have underlying neu­
rodegenerative diseases, diabetes, B12 deficiency,732 renal failure, 
dehydration, prolonged recumbency, deconditioning, and triggering 
medications (like alpha-blockers, beta-blockers, diuretics, nitrates, anti­
depressants, and antipsychotics). Of note, ACE inhibitors, ARBs, and 
dihydropyridine CCBs are examples of BP-lowering medications that 
appear to have less impact on orthostatic hypotension, and their ad­
verse impact, if any, on orthostatic hypotension typically occurs in 
the first 2 weeks or so after starting or intensifying treatment.733
Managing patients with supine hypertension and orthostatic hypoten­
sion is a common clinical conundrum. More detailed reviews on this topic 
are available elsewhere.98,99 The approach to managing orthostatic hypo­
tension should be non-pharmacological at first. Patients with orthostatic 
hypotension should be asked to change position slowly, maintain ad­
equate hydration, and avoid alcohol and large meals. Compression stock­
ings, crossing legs while standing, and abdominal binders may also help and 
should be trialled.734,735 Abdominal heating pads and a head-up bed pos­
ition can reduce supine (typically nocturnal) hypertension, which may re­
duce nocturnal diuresis and daytime orthostatic hypotension.736
The treatment of orthostatic hypotension among those with supine 
hypertension is not to automatically down-titrate BP-lowering medica­
tions. Rather, reversible causes should be sought and treated (including 
discontinuation of offending medications), and patients requiring 
BP-lowering medication should be switched to BP-lowering medications 
that are less likely to cause orthostatic hypotension. When symptoms are 
disabling and the above interventions do not help, particularly in neuro­
genic orthostatic hypotension, the best evidence exists for midodrine 
to reverse orthostatic hypotension, and this may be given in conjunction 
with ongoing BP-lowering medications when supine hypertension ex­
ists.99 An alternative option to midodrine is droxidopa, though this is 
less readily available. Specialist referral is prudent when persons with su­
pine hypertension are prescribed these orthostatic hypotension treat­
ments, as these agents can increase supine BP more than standing BP.


<!-- PAGE 64 -->

### Page 64

9.6. Diabetes
9.6.1. Diabetes and elevated blood pressure/ 
hypertension
Patients with diabetes (both type 1 and type 2) often have elevated BP 
or hypertension, and are about twice as likely to suffer a major CVD 
event over the medium to long term compared with those without dia­
betes.737 Diabetes is also a major cause of microvascular events, such as 
retinopathy and nephropathy.738,739 Although the risk of CVD in pa­
tients with diabetes varies by screening and diagnostic methods,740,741
as well as with the presence of other CVD risk factors,740,742 on aver­
age, patients with diabetes are at ≥10% 10-year risk for CVD. 
However, formal risk estimation with the use of SCORE2-Diabetes 
among type 2 diabetes mellitus patients should be considered if they 
are aged <60 years (see Section 6).164,739
9.6.2. J-shaped curve of blood pressure and risk of 
cardiovascular disease in patients with diabetes
Evidence on the BP threshold and target for treatment in patients with 
diabetes has been subject to debate. Reports of a J-shaped association 
between BP and risk of CVD in diabetes,743 and the lack of a clear bene­
fit of treatment on cardiac outcomes at lower BP in some 
meta-analyses,744–746 has led to some cautious recommendations for 
intensive treatment in this patient population.
An individual patient data meta-analysis by the Blood Pressure 
Lowering Treatment Trialists’ Collaboration tested treatment effects 
in 103 325 patients with diabetes and provided evidence against 
effect modification by categories of baseline BP down to a systolic BP 
of 120 mmHg.445 BP reduction in patients with diabetes is expected 
to reduce the risk of diabetes-associated complications including retin­
opathy, vasculopathy, and nephropathy (albuminuria and end-stage re­
nal disease), which adds weight to the importance of reducing BP in 
these patients (see Supplementary data online).745–747 This task force 
also considered the fact that a proportion of patients with diabetes 
have orthostatic hypotension due to diabetic neuropathy,748 which 
might affect the tolerability of BP lowering.
9.6.3. Managing blood pressure in diabetes
We recommend that all patients with diabetes are offered pharmaco­
logical BP-lowering treatment with a BP target of 120–129/70–79 mmHg, 
if feasible and tolerated.136,146,445,747,749–752 The task force further sees no 
strong evidence for a differential BP treatment targets in patients with dia­
betes and those without.136,146,445,746,747 While the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) trial reported a null primary 
endpoint for more intensive BP targets in diabetes, stroke was marginally re­
duced.137Furthermore, extended follow-up of ACCORD,750as well as ana­
lyses of intensive BP reduction in those randomized to the standard 
glycaemic arm,749 provide evidence suggesting benefit consistent with the 
SPRINT, STEP, and Effects of intensive Systolic blood Pressure lowering 
treatment in reducing RIsk of vascular evenTs (ESPRIT) trials.136,146,545
Overall, all major BP-lowering medication classes are effective in preventing 
CVD in people with or without diabetes. Of note, however, albuminuria is 
more common in diabetes and, for this reason, ACE inhibitors and ARBs 
have potential advantages that may warrant consideration for BP-lowering 
in patients with diabetes (see Supplementary data online, Table S10).753
Evidence for modifying BP-lowering treatment in patients with 
pre-diabetes is somewhat limited. Furthermore, the relative effect of BP 
lowering is relatively consistent across different categories of BMI as a 
measure of obesity.754,755 It is also noteworthy that elevated BP itself 
may increase the risk of diabetes,755 emphasizing the potential role of BP 
lowering in preventing diabetes in addition to preventing CVD. Among 
the major classes of BP-lowering drugs, ACE inhibitors and ARBs are effect­
ive in preventing new-onset diabetes and can be considered in patients at 
risk of diabetes and who are indicated for BP-lowering therapy.164,755
9.7. Chronic kidney disease
9.7.1. Relationship between hypertension and chronic 
kidney disease
Approximately 850 million people worldwide have CKD, with >80% of 
them hypertensive, and the prevalence is expected to rise to 1.56 billion 
Recommendation Table 24 — Recommendations for 
managing hypertension in patients with orthostatic 
hypotension
Recommendation
Classa
Levelb
Before starting or intensifying BP-lowering 
medication, it is recommended to test for orthostatic 
hypotension, by first having the patient sit or lie for 5  
min and then measuring BP 1 and/or 3 min after 
standing.97,99
I
B
It is recommended to pursue non-pharmacological 
approaches as the first-line treatment of orthostatic 
hypotension among persons with supine 
hypertension. For such patients, it is also 
recommended to switch BP-lowering medications 
that worsen orthostatic hypotension to an 
alternative BP-lowering therapy and not to simply 
de-intensify therapy.726,727,729,730
I
A
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 25 — Recommendations for 
managing hypertension in patients with diabetes
Recommendations
Classa
Levelb
In most adults with elevated BP and diabetes, after a 
maximum of 3 months of lifestyle intervention, BP 
lowering with pharmacological treatment is 
recommended for those with confirmed office BP 
≥130/80 mmHg to reduce CVD risk.445,749
I
A
BP-lowering drug treatment is recommended for 
people with pre-diabetes or obesity when confirmed 
office BP is ≥140/90 mmHg or when office BP is 
130–139/80–89 mmHg and the patient is at 
predicted 10-year risk of CVD ≥10% or with 
high-risk conditions, despite a maximum of 3 months 
of lifestyle therapy.445
I
A
In persons with diabetes who are receiving 
BP-lowering drugs, it is recommended to target 
systolic BP to 120–129 mmHg, if 
tolerated.136,146,445,747,749–752
I
A
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3975


<!-- PAGE 65 -->

### Page 65

by 2025.756–759 The pathogeneses of hypertension and CKD are closely 
entwined.760 Resistant hypertension, masked hypertension, HMOD, 
and higher night-time BP are common in patients with CKD.761 CVD 
is one of the largest contributors to mortality in patients with CKD, 
with hypertension being a major risk factor.760,762
For the purposes of these guidelines, adults with moderate-to-severe 
CKD and elevated BP are at sufficiently high risk to be considered for 
BP-lowering drug therapy as outlined in Section 8 and the Central 
Illustration (Figure 19). We use Kidney Disease: Improving Global 
Outcomes (KDIGO) categories to define CKD-based risk, and our def­
inition of moderate-to-severe CKD comprises persons with an eGFR of 
<60 mL/min/1.73 m2 and/or albuminuria of ≥30 mg/g (≥3 mg/mmol).19
For persons with mild CKD and elevated BP, a CVD risk assessment 
should be conducted before deciding on BP-lowering treatment.
9.7.2. Blood pressure lowering in chronic kidney 
disease
BP lowering in patients with CKD is associated with beneficial effect on 
CVD events and mortality.275,763–766 BP lowering reduces progression 
of CKD and the incidence of end-stage renal disease, but this tends to 
be only in those with significant proteinuria at baseline.766,767
9.7.3. Managing blood pressure in chronic kidney 
disease
Patients with CKD should receive lifestyle advice, especially regarding 
reducing sodium intake. Dietary potassium supplementation recom­
mendations are provided in Section 8, with caution required among per­
sons with moderate-to-severe CKD. While exercise appears to have 
little effect on improving BP in patients with CKD768 or patients on dia­
lysis,769 those with CKD on ACE inhibitor monotherapy have protec­
tion against adverse kidney outcomes, CVD events, cardiovascular 
death, and all-cause death.770,771 Both ACE inhibitors and ARBs reduce 
the risk of CVD events and kidney failure compared with placebo; how­
ever, ACE inhibitors appear to do so with higher probability than 
ARBs.772,773 Patients with CKD usually require combination therapy, 
and this should be initiated as a combination of a RAS inhibitor and a 
CCB or diuretic. In patients with eGFR < 30 mL/min/1.73 m2, an ad­
equately up-titrated loop diuretic is necessary to define resistant hyper­
tension. Chlorthalidone, typically added to a loop diuretic, also effectively 
lowers BP and reduces microalbuminuria in patients with resistant hyper­
tension with stage 4 CKD (eGFR of 15–30 mL/min/1.73 m2).774 The 
combination of an ACE inhibitor and an ARB is not recommended in 
CKD or any other BP-treatment scenario.
9.7.4. Blood pressure targets in chronic kidney 
disease
Evidence regarding BP targets in patients with CKD is complex and con­
troversial. The 2021 KDIGO Guideline suggested that adults with ele­
vated BP and CKD be treated to a target systolic BP of <120 mmHg, 
when tolerated, using standardized office BP measurement (Class of 
Recommendation IIb).19 This suggestion was based, in part, on the 
SPRINT trial.545 It should be noted that patients with 24 h urine protein 
excretion ≥ 1 g/day or eGFR < 20 mL/min/1.73 m2 were excluded 
from SPRINT. In patients with CKD, after a median follow-up of 3.3  
years, the hazard ratio for the primary composite cardiovascular out­
come was 0.81 (95% CI 0.63–1.05) and for all-cause death it was 
0.72 (95% CI 0.53–0.99). Although intensive BP lowering in SPRINT re­
sulted in greater early decline in eGFR, there was no evidence that this 
reduction in eGFR attenuated the beneficial effects of the SPRINT 
intervention on CVD events or death.775
Several systematic reviews have examined the benefit of intensive BP 
control in patients with CKD (see Supplementary data online). Some 
have shown no benefit of intensive BP control on renal out­
comes,764,767 while others showed lower mortality in intensively trea­
ted vs. non-intensively treated patients.275 Highlighting the beneficial 
effects of SGLT2 inhibitors in persons with CKD776,777 and finerenone 
in persons with CKD and diabetes460–462,778 is relevant, though these 
drugs are not currently marketed for BP-lowering effects alone.
9.8. Cardiac disease
9.8.1. Blood pressure thresholds and targets in 
patients with cardiac disease
Recommended BP thresholds for initiating BP-lowering therapy and re­
commended BP targets in patients receiving therapy are provided in 
Sections 6 and 8. All patients with a history of CVD (including coronary 
artery disease) are at increased risk of recurrent CVD. As such, these 
patients are recommended to be treated with BP-lowering therapy 
for confirmed baseline BP of ≥130/80 mmHg and the recommended 
treatment target BP of 120–129/70–79 mmHg, provided treatment is 
tolerated (see Sections 6 and 8). As stated in Section 8, it should be re­
membered that a systolic BP of 120 mmHg (especially by out-of-office 
assessment) is likely the optimal point in the target range recommended 
in these guidelines. In addition to considering patients with known CVD 
at sufficiently high risk for more intensive BP treatment targets, the 
Recommendation Table 26 — Recommendations for 
managing hypertension in patients with chronic kidney 
disease
Recommendations
Classa
Levelb
In patients with diabetic or non-diabetic 
moderate-to-severe CKD and confirmed BP ≥130/ 
80 mmHg, lifestyle optimization and BP-lowering 
medication are recommended to reduce CVD risk, 
provided such treatment is well tolerated.275,766
I
A
In adults with moderate-to-severe CKD who are 
receiving BP-lowering drugs and who have eGFR 
>30 mL/min/1.73 m2, it is recommended to target 
systolic BP to 120–129 mmHg, if tolerated. 
Individualized BP targets are recommended for those 
with lower eGFR or renal transplantation.274,779
I
A
In hypertensive patients with CKD and eGFR >20  
mL/min/1.73 m2, SGLT2 inhibitors are 
recommended to improve outcomes in the context 
of their modest BP-lowering properties.776,777
I
A
ACE inhibitors or ARBs are more effective at 
reducing albuminuria than other BP-lowering agents 
and should be considered as part of the treatment 
strategy for patients with hypertension and 
microalbuminuria or proteinuria.780–782
IIa
B
© ESC 2024
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood 
pressure; CKD, chronic kidney disease, eGFR, estimated glomerular filtration rate; 
SGLT2, sodium–glucose co-transporter 2. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 66 -->

### Page 66

task force considers patients with both severe valvular heart disease 
and symptomatic heart failure to also be at sufficiently high risk. We 
also note that, whether used for angina control or BP control, a beta- 
blocker should not be combined with a non-dihydropyridine CCB.
9.8.2. Coronary artery disease with particular 
reference to the blood pressure J-curve
Important considerations in patients with coronary artery disease are: 
(i) the BP J-curve (an observation suggesting that over-intensive BP low­
ering may increase CVD risk in some patients), and (ii) compelling indi­
cations for specific classes of BP-lowering medications.
The J-curve phenomenon describes increased risk for CVD observed 
among patients with the lowest and highest BP in the dataset, with the 
best CVD outcome rates typically observed among those with BP in the 
normal range (e.g. systolic BP of 100–120 mmHg and diastolic BP of 
60–80 mmHg). For this reason, the J-curve is sometimes also called 
the U-curve, with both terms typically used interchangeably.697,783,784
However, observational data do not consistently demonstrate a BP 
J-curve with CVD risk.697 It is more commonly observed among pa­
tients with established clinical CVD, such as those with coronary artery 
disease, or in secondary prevention cohorts.785,786 Furthermore, the 
J-curve is more commonly observed when analysing diastolic BP values 
vs. systolic BP values, though it has been described for both.114,697 This 
stronger relationship with diastolic BP has informed the hypothesis that 
the J-curve may be caused by reduced perfusion of major organs at low 
BP, which is particularly operative for diastolic BP in the coronary vas­
culature when considering ischaemic heart disease events (since coron­
ary blood flow is largely confined to diastole).786,787
If excessive lowering of BP causes CVD events, this needs to be 
addressed in treatment recommendations provided by BP manage­
ment guidelines. The 2018 ESC/ESH Guidelines on the management 
of arterial hypertension introduced, for the first time, lower bounds 
of BP-lowering treatment targets, implying that treatment be 
de-intensified for patients with on-treatment BP below these bounds 
(i.e. <120 mmHg systolic or <70 mmHg diastolic).1 The 2023 ESH docu­
ment also makes this argument.788
However, since 2018, compelling evidence has demonstrated that 
the BP J-curve evident in observational datasets is highly unlikely to re­
flect a causal process and can instead be attributed to residual con­
founding and/or reverse causation.33,114,115,546,697,789–793
Accordingly, while low BP can indicate a high-risk state, particularly 
among older adults and those with comorbidities, there is no evidence 
that this is a causal phenomenon. Indeed, if there is another indication 
for BP-lowering therapy (e.g. in a patient with wide pulse pressure and a 
baseline systolic BP of >140 mmHg but diastolic BP of <60 mmHg), the 
evidence suggests that such therapy should be provided if tolerated to 
reduce CVD risk.
There is a limit to how low BP can be treated without potentially tip­
ping the scales in favour of CVD harm vs. CVD benefit. However, it is 
not clear what that limit is and how much it differs based on comorbid­
ities. Currently, the data do not suggest that risk for CVD can be caus­
ally increased by treating any patient to the recommended intensive 
BP target outlined in these guidelines of as low as 120/70 mmHg. 
We also do not recommend stopping or de-intensifying BP-lowering 
medication among asymptomatic patients with on-treatment BP of 
<120/70 mmHg. It should be recognized, though, that there are no ro­
bust data demonstrating that an on-treatment systolic BP of <90 mmHg 
or an on-treatment diastolic BP of <50 mmHg is safe from a CVD 
perspective and there is clear potential for harm. Furthermore, it 
must be emphasized that the above discussion of the BP J-curve relates 
solely to CVD risk and does not consider the known non-CVD side ef­
fects of BP-lowering drugs, like, e.g. orthostatic hypotension, syncope, 
and renal injury. We do know that patients treated to a more intensive 
BP target of 120/70 mmHg are at increased risk for these side effects,550
which is why these guidelines stress that this more intensive target 
should only be pursued among those in whom treatment is being toler­
ated (Section 8).
The second consideration in managing BP in patients with coronary 
artery disease is the recommended use of BP-lowering medications 
with compelling indications based on outcomes trials that demon­
strated CVD outcomes benefits in the setting of coronary artery dis­
ease. These recommendations are provided in the recommendation 
table below.
9.8.3. Valvular heart disease
Most patients with both severe heart valve disease and heart failure, de­
fined by the 2021 ESC/European Association for Cardio-Thoracic 
Surgery (EACTS) Guidelines for the management of valvular heart dis­
ease,794 can be considered at increased risk of CVD. Accordingly, it is 
recommended they are treated with BP-lowering therapy for con­
firmed baseline BP of >130/80 mmHg, and their recommended target 
of treatment is BP of 120–129/70–79 mmHg, provided treatment is tol­
erated. Persons with mild-to-moderate heart valve disease should have 
a CVD risk assessment prior to deciding their BP-lowering treatment 
threshold and target.
Vasodilating ARBs/ACE inhibitors are preferable over vasodilating di­
hydropyridine CCBs because of the link between valvular heart disease 
and subsequent heart failure and given the stronger efficacy evidence 
for ARBs/ACE inhibitors in the setting of heart failure once mani­
fested.795 In aortic valve stenosis, concomitant hypertension influences 
both the aortic root, the aortic valve, and the left ventricular structure 
and function.796 In this subgroup, treatment preferably with ARBs/ACE 
inhibitors should be considered. A beta-blocker may be added if BP re­
mains >140/90 mmHg.796,797
9.8.4. Heart failure
Patients with symptomatic heart failure are at increased risk of CVD. 
Therefore, it is recommended that these patients are treated with 
BP-lowering therapy for confirmed baseline BP of >130/80 mmHg and 
their recommended treatment target is BP of 120–129/70–79 mmHg, 
provided treatment is tolerated and with out-of-office confirm­
ation of on-treatment BP. Of note, many patients with systolic 
heart failure on maximal heart failure therapies have BP of 
<120/70 mmHg, and we do not recommend de-intensifying such 
treatment unless indicated by symptomatic side effects. Besides 
referencing the new evidence for ARNi and SGLT2 inhibitor ther­
apies,795 our 2024 recommendations for heart failure are largely 
unchanged from the 2018 ESC/ESH Guidelines on the management 
of arterial hypertension. Non-dihydropyridine CCBs should not be 
used in heart failure. Frailty and hypotension risk should be as­
sessed in older heart failure patients being considered for ARNi 
and SGLT2 inhibitor therapies, and older patients should be closely 
followed to ensure they are tolerating such treatments. For more 
information on the management of heart failure, we direct readers 
to the latest ESC Guidelines for the diagnosis and treatment of 
acute and chronic heart failure.798
ESC Guidelines                                                                                                                                                                                          3977


<!-- PAGE 67 -->

### Page 67

9.8.5. Heart rhythm disease (including AF)
Not all patients with heart rhythm disease, including those with AF, 
are at increased risk for CVD and, as such, the management of BP 
among patients with heart rhythm disease should be the same as for 
the general adult population.443 However, there is a close relationship 
between increased BP and AF risk, hence, ensuring good BP control is 
important.801,802 Management of heart rhythm disorders should follow 
recommendations in guidelines specific to these conditions.803
9.9. Chronic cerebrovascular disease  
and/or cognitive impairment
9.9.1. Role of hypertension in chronic cerebrovascular 
disease
Hypertension is a risk factor for chronic cerebrovascular disease 
through its direct effects on brain structure and microvasculature. 
This manifests as transient ischaemic attack (TIA) and stroke in 
the acute setting, but chronic hypertension can lead to covert stroke 
and white-matter ischaemic change over time, resulting in cognitive 
decline and progressive vascular dementia.804–808 Hypertension is 
also associated with increased risk of Alzheimer’s disease,809 and 
is a risk factor for developing AF, heart failure, and CKD, all of which 
are associated with increased risk of developing cognitive impair­
ment and dementia.810–813 For the purposes of these guidelines, 
adults with a history of stroke or TIA and elevated BP are consid­
ered at sufficiently high risk to be considered for BP-lowering 
drug therapy as outlined in Section 8 and the Central Illustration 
(Figure 19).
9.9.2. Treatment in patients with history of prior 
stroke or transient ischaemic attack
In patients with a prior history of TIA and ischaemic stroke, 
BP-lowering treatment reduces the risk of any recurrent stroke by 
20%.814–817 The aetiology of stroke can affect the degree of risk reduc­
tion with pharmacological treatment, with greater reductions observed 
for intracerebral haemorrhage and lacunar ischaemic stroke syn­
dromes.818–820
Most prior guidelines recommend an intensive BP target in patients 
with a prior history of stroke, typically using combination treatment 
(ACE inhibitor/ARB plus either a calcium channel antagonist or a thia­
zide/thiazide-like diuretic), with therapy commencing immediately after 
TIA and within a few days of ischaemic stroke (see Supplementary data 
online and see Section 10.3 for acute BP management during hospital­
ization for stroke).814,815,821–824
Regimens containing an ACE inhibitor and thiazide/thiazide-like diur­
etic may be superior to beta-blockers in terms of stroke risk reduc­
tion.825,826 Regarding intensive BP control after stroke, typically 
targeting a systolic BP of <130 mmHg, individual trials were somewhat 
inconclusive, but a meta-analysis showed a reduced risk of recurrent 
stroke of 22% in the intensive treatment group randomized to a target 
systolic BP as low as 120 mmHg.543,824,827,828 Caveats to this recom­
mendation would be for frail patients, who have a much higher rate 
of stroke and recurrent stroke than the general population, and who 
are more sensitive to adverse effects of BP-lowering agents (see 
Section 9.3).596,606,607,829
9.9.3. Treatment in patients with chronic 
cerebrovascular disease and cognitive impairment
Treatment of hypertension represents a key mechanism for reducing 
the global burden of dementia at the population level.830
Epidemiological studies have reported associations between mid-life 
hypertension and development of cognitive decline in later life, with, 
e.g. mid-life hypertension increasing relative risk of lifetime dementia 
by 20%–54%.831–837 In one observational meta-analysis, an increased 
risk for dementia emerged with systolic BP of >130 mmHg.831
Evidence for lowering BP to reduce the risk of dementia is limited 
due to heterogeneity in populations studied, cognitive testing methods 
used, and the varied use of dementia or cognitive impairment or both as 
a primary outcome.838,839 Findings from individual studies have mixed 
results (see Supplementary data online).264,839–843 Studies on effects 
of BP-lowering treatment on white-matter intensities concluded that 
patients in the intensive-control arm had less white-matter intensity ac­
cumulation than in the standard-treatment arm.841,844 Studies in which 
people with stroke and TIA were included reported a reduced risk of 
dementia and cognitive decline for the active-treatment group, but a 
mixed signal for dementia alone.841,845 However, individual studies 
Recommendation Table 27 — Recommendations for 
managing hypertension in patients with cardiac disease
Recommendations
Classa
Levelb
In patients with a history of myocardial infarction 
who require BP-lowering treatment, beta-blockers 
and RAS blockers are recommended as part of that 
treatment.538
I
A
In patients with symptomatic angina who require 
BP-lowering treatment, beta-blockers and/or CCBs 
are recommended as part of that treatment.538
I
A
In patients with symptomatic HFrEF/HFmrEF, the 
following treatments with BP-lowering effects are 
recommended to improve outcomes: ACE inhibitors 
(or ARBs if ACE inhibitors are not tolerated) or 
ARNi, beta-blockers, MRAs, and SGLT2 
inhibitors.795
I
A
In hypertensive patients with symptomatic HFpEF, 
SGLT2 inhibitors are recommended to improve 
outcomes in addition to their modest BP-lowering 
properties.795
I
A
In patients with a history of aortic valve stenosis and/ 
or regurgitation who require BP-lowering treatment, 
RAS blockers should be considered as part of that 
treatment.794,796
IIa
C
In patients with a history of moderate-to-severe 
mitral valve regurgitation who require BP-lowering 
treatment, RAS blockers should be considered as 
part of that treatment.794
IIa
C
In patients with symptomatic HFpEF who have BP 
above target, ARBs and/or MRAs may be considered 
to reduce heart failure hospitalizations and reduce 
BP.795,799,800
IIb
B
© ESC 2024
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNi, 
angiotensin receptor–neprilysin inhibitor; BP, blood pressure; CCB, calcium channel 
blocker; HFpEF, heart failure with preserved ejection fraction; HF(m)rEF, heart failure 
with (mildly) reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; 
RAS, renin–angiotensin system; SGLT2, sodium–glucose co-transporter 2. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 68 -->

### Page 68

may have been under-powered and more recent meta-analyses do 
convincingly support efficacy in reducing dementia with BP-lowering 
treatment.610,611 Indeed, these meta-analyses reported a reduced 
risk of incident dementia or cognitive impairment with BP lowering 
of 7%–13%.610,611 While one trial suggested superiority of long-acting 
CCBs,264 it is unclear if any first-line BP-lowering agent is preferable for 
preventing dementia and cognitive impairment.846,847
The role of competing risk mechanisms including orthostatic hypo­
tension848 and BP variability849 may be important factors in treatment 
decisions for people with frailty, multimorbidity, and/or chronic cere­
brovascular disease.
9.10. Aortopathy
9.10.1. Coarctation of the aorta
Aortic coarctation is associated with CVD in the long term, even follow­
ing early surgical or percutaneous treatment. The most common com­
plications are associated with hypertension, which is common in aortic 
coarctation. When aortic coarctation is not treated, patients often de­
velop severe hypertension and HMOD (especially LVH and left ventricu­
lar dysfunction, aortopathy, and cerebrovascular complications).850–852
No formal RCTs to define optimal medical treatment of hypertension 
in aortic coarctation have been conducted, therefore, patients not suit­
able for, or having undergone, intervention should be treated for hyper­
tension following the core algorithm for the general population.
9.10.2. Bicuspid aortic valve-related aortopathy
Bicuspid aortic valve is the most common congenital heart disease and is 
sometimes associated with aortopathy or aortic coarctation. Bicuspid aor­
tic valve disease is associated with an increased risk of valve malfunction 
and adverse aortic events.853,854 This risk is exacerbated by hypertension.
Beyond aortic dilation and aneurysm formation, bicuspid aortic valve 
disease is also a risk factor for aortic dissection and rupture.855 Blood 
pressure should be carefully monitored and controlled.856
9.10.3. Preventing aortic dilation and dissection in 
high-risk patients
A modest dilatation of the ascending aorta or aortic root is often asso­
ciated with chronic hypertension and HMOD. An additional cause of 
aortopathy (bicuspid valve, coarctation, Marfan or other syndromes) 
should be considered in more severe cases.857 Patients with aortic dila­
tation should have their BP optimally controlled following the core al­
gorithm for the general hypertension population.
In patients with Marfan syndrome, prophylactic use of ARBs, ACE inhi­
bitors, or beta-blockers may reduce complications or progression of aortic 
dilation.857–860 More information is available in the 2024 ESC Guidelines 
for the management of peripheral arterial and aortic diseases.861
9.11. Different ethnic groups
Influx and settlement of migrant populations in Europe have contribu­
ted to regional population growth and changes in its composition.862
Ethnic minority populations are disproportionally affected by hyperten­
sion and hypertension-mediated complications, compared with histor­
ically native Europeans, with data suggesting migrant women are 
particularly vulnerable.536,863 In particular, hypertension is more preva­
lent in those of African descent.863,864 The predominant group of 
European black ethnicity originates from sub-Saharan Africa,863 but 
specific studies on the management and control of hypertension in 
this population are lacking, and data are often extrapolated from studies 
in the African American population.864 This assumption requires cau­
tion, as differences likely exist between these populations in terms of 
CVD risk, economic, and sociological status,865,866 as well as responses 
to BP-lowering drugs.867
Black patients have a greater prevalence of low-renin, salt-sensitive 
hypertension and may be more predisposed to HMOD than white pa­
tients, possibly in part due to increased vascular stiffness.864,868,869 Salt 
restriction, thiazide or thiazide-like diuretics, and CCBs appear particu­
larly useful in black patients with hypertension, whereas RAS blocker 
monotherapy may be less effective.870–873 If combination therapy is 
needed, in a recent RCT conducted in sub-Saharan African countries, 
amlodipine plus either hydrochlorothiazide or perindopril proved to 
be equally effective and superior, respectively, to hydrochlorothiazide 
plus perindopril.874 When RAS blockers are used in combination ther­
apy, ARBs may be preferable to ACE inhibitors, as angioedema appears 
more common with ACE inhibitors in black patients.
Despite some recent progress,875 data on hypertension epidemi­
ology and management in European immigrant patients are still 
lacking.863,875–877
9.12. Nocturnal hypertension
9.12.1. Definition
Nocturnal hypertension is defined as night-time BP of >120 mmHg systol­
ic and/or >70 mmHg diastolic by 24 h ABPM. Nocturnal hypertension can 
occur as day–night sustained hypertension or isolated nocturnal hyperten­
sion (daytime BP < 135/85 mmHg on 24 h ABPM). Physiologically, BP is 
Recommendation Table 28 — Recommendations for 
managing hypertension in patients with chronic cere­
brovascular disease and cognitive impairment
Recommendations
Classa
Levelb
It is recommended that the BP-lowering drug 
treatment strategy for preventing recurrent stroke 
should comprise a RAS blocker plus a CCB or a 
thiazide-like diuretic.820,823,825,826
I
A
In patients with confirmed BP ≥130/80 mmHg with a 
history of TIA or stroke a systolic BP target of 120– 
129 mmHg is recommended to reduce CVD 
outcomes, provided treatment is tolerated.824,827,828
I
A
© ESC 2024
BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; RAS, 
renin–angiotensin system; TIA, transient ischaemic attack. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 29 — Recommendations for 
managing hypertension in different ethnic groups
Recommendation
Classa
Levelb
In black patients from Sub-Saharan Africa who 
require BP-lowering treatment, combination therapy 
including a CCB combined with either a thiazide 
diuretic or a RAS blocker should be considered.874
IIa
B
© ESC 2024
BP, blood pressure; CCB, calcium channel blocker; RAS, renin–angiotensin system. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3979


<!-- PAGE 69 -->

### Page 69

expected to decrease during sleep by 10%–20% relative to daytime BP.878
Night-time dipping patterns are classified into four groups:879,880
• Inverse dipping (riser): nocturnal increase in BP (night-to-day ra­
tio of >1.0).
• Non-dipper: reduced night-time BP dip of <10% (or night-to-day 
ratio of >0.9 and ≤1.0).
• Normal dipping: fall in night-time BP of >10% and <20% (or 
night-to-day ratio of 0.8 to 0.9).
• Extreme dipping: marked fall in night-time BP of >20% (or 
night-to-day ratio of <0.8).
Patients with nocturnal hypertension may be dippers or non-dippers. 
Of note, the long-term reproducibility of dipping patterns appears to 
be low.881,882
9.12.2. Epidemiology
Nocturnal hypertension has been observed in up to half of patients with 
hypertension,883–886 and is associated with increased HMOD,883 im­
paired renal function, and diabetes mellitus.887 Nocturnal hypertension 
appears to be more prevalent in black888–890 and Asian891,892 popula­
tions. Masked uncontrolled hypertension, which occurs in 30% of 
patients treated for hypertension, is more often due to poorly con­
trolled nocturnal BP than daytime BP on ABPM.893
Environmental factors, including sleep duration and higher humid­
ity,894 nocturia,895 OSAS,896 obesity, high salt intake in salt-sensitive pa­
tients,897 orthostatic hypotension, autonomic dysfunction, CKD,898–900
diabetic neuropathy/diabetes,901 and old age62 are associated with non- 
dipping. Moreover, nocturnal hypertension and absent night-time dip­
ping pattern are more common in secondary hypertension.902,903
9.12.3. Night-time blood pressure as a cardiovascular 
disease risk factor
Nocturnal hypertension is a risk factor for adverse CVD events,904
cerebrovascular disease, including stroke,905 and cardiovascular mor­
tality.891,906,907 Night-time BP may provide more prognostic infor­
mation than daytime BP, perhaps as it is less dependent on physical 
activities. Non-dipping908–910 and reverse dipping (nocturnal rise in 
BP) may also be associated with increased CVD risk.62,910–913 A noc­
turnal rise in BP is associated with an increased risk of dementia and 
Alzheimer’s disease in older men.914 There is also some evidence that 
extreme dipping, particularly in untreated patients, is associated with 
an increased risk for CVD events.35,886
9.12.4. Treatment of nocturnal hypertension
There is no reliable evidence that BP-lowering medication should be 
routinely dosed at bedtime. The diurnal timing of drug administration 
is discussed in Section 8.3.4. In patients with secondary hypertension, 
the underlying cause (OSAS, primary aldosteronism) should be treated 
as discussed in Section 9.14.
9.13. Resistant hypertension
9.13.1. Definition of resistant hypertension
Resistant hypertension is defined as BP remaining above goal despite 
three or more BP-lowering drugs of different classes at maximally tol­
erated doses, of which one is a diuretic (Table 11).915 Resistant hyper­
tension should be managed at specialized centres with the expertise 
and resources to exclude pseudo-resistant hypertension (adherence 
testing) and causes of secondary hypertension.916
9.13.2. Non-pharmacological interventions
The Treating Resistant Hypertension Using Lifestyle Modification to 
Promote Health (TRIUMPH) trial demonstrated significant clinic and 
ambulatory BP reductions in patients with resistant hypertension par­
ticipating in a 4-month lifestyle intervention comprising diet and exercise 
interventions delivered within a cardiac rehabilitation programme.917
9.13.3. Pharmacological interventions
BP-lowering treatment of resistant hypertension with single-pill combi­
nations is recommended to reduce the pill burden, thereby increasing 
drug adherence and persistence.492
As resistant hypertension often, and especially in CKD,918 represents a 
state of salt retention and volume expansion secondary to relative aldos­
terone excess,516,919,920 BP control may be improved by switching hydro­
chlorothiazide 
to 
long-acting 
thiazide-like 
diuretics, 
such 
as 
chlorthalidone.921,922 However, a recent trial of chlorthalidone vs. 
hydrochlorothiazide—which probably included a sizeable proportion of 
adults with resistant hypertension—did not demonstrate any difference 
in systolic BP or CVD outcomes between the two medications. In the sub­
group of patients with prior CVD, there was a strong trend of benefit with 
chlorthalidone on CVD outcomes.447 Of note, the risk of hypokalaemia 
was higher in the chlorthalidone group than in the hydrochlorothiazide 
group.447 In patients with eGFR < 30 mL/min/1.73 m2, an adequately up- 
titrated loop diuretic is necessary to define resistant hypertension.
Most patients with resistant hypertension require the addition of 
non-first-line BP-lowering drugs (Figure 22). Of these, low-dose spir­
onolactone (25–50 mg daily) should be considered first.459,515,923–925
In patients with resistant hypertension and type 2 diabetes, spironolac­
tone (25–50 mg daily) reduced BP and albuminuria.926 The use of spirono­
lactone can be precluded by limited tolerability due to anti-androgenic side 
effects resulting in breast tenderness or gynaecomastia (in about 6%), im­
potence in men, and menstrual irregularities in women.927 The efficacy and 
safety of spironolactone for treating resistant hypertension have not yet 
been established in patients with significant renal impairment. Moreover, 
spironolactone, especially in addition to RAS inhibitors, increases the risk 
of hyperkalaemia.927,928 Therefore, spironolactone should be restricted 
to patients with an eGFR of ≥30 mL/min/1.73 m2 and a plasma potassium 
concentration of ≤4.5 mmol/L.459 Steroidal MRAs are contraindicated in 
patients with an eGFR of <30 mL/min/1.73 m2. Serum electrolytes and kid­
ney function should be monitored soon after initiation and frequently 
thereafter. In patients with resistant hypertension and CKD (eGFR of 
25–45 mL/min/1.73 m2), the oral potassium binder patiromer enabled 
more patients to continue treatment with spironolactone.929
If spironolactone is not tolerated due to anti-androgen side ef­
fects, eplerenone may be used. If eplerenone is used, higher doses 
(i.e. 50–200 mg daily) and twice-daily dosing may be necessary to 
achieve a BP-lowering effect.503 Of note, eplerenone is not licensed 
for hypertension treatment in many countries.
When not already prescribed for a compelling indication, beta- 
blockers should be considered in the treatment of resistant hyperten­
sion, though their BP-lowering effects appear to be less potent than 
spironolactone in the setting of resistant hypertension.459
Amiloride and clonidine have data suggesting they are as effective as 
spironolactone for BP lowering, though they lack outcomes data. 
A non-exhaustive list of additional medications sometimes used for 
BP-lowering purposes includes other centrally acting BP-lowering med­
ications (e.g. methyldopa), hydralazine, aliskiren, minoxidil, triamterene, 
and loop diuretics (Figure 22).515,516 As noted earlier, minoxidil use is 
often limited by side effects.


<!-- PAGE 70 -->

### Page 70

9.13.4. Devices for blood pressure lowering
Several devices have been investigated for treating resistant hyper­
tension. Of these, the most evidence is available for catheter-based 
renal denervation. As discussed in Section 8.6.1, several randomized, 
sham-controlled trials have been published, demonstrating a 
BP-lowering efficacy over 24 h for radiofrequency and ultrasound 
renal denervation in a broad spectrum of hypertension, including re­
sistant hypertension.568,585 Other devices are still under investiga­
tion and are not recommended for routine use in clinical practice 
(Section 8.6.2).
Intensification of pharmacotherapy
If BP remains uncontrolled
Renal denervation
Interventional therapy
Shared risk-benefit discussion and multidisciplinary assessment
Beta-blocker (if not already recommended for a compelling indication)
Spironolactone
If spironolactone is not tolerated: eplerenone
True treatment-resistant hypertension
Office BP 140/90 mmHg despite 3 or more BP-lowering medications at maximally tolerated doses, including a diuretic
Referral to hypertension centre should be considered
Treatment optimization of BP-lowering medications (ideally three-drug SPC)
Exclusion of secondary and pseudo-resistant hypertension
Alpha blockers
Centrally acting
BP-lowering drugs
K+ sparing diuretics
Others
 (Class IIa)
 (Class IIa)
 (Class IIb)
 (Class IIa)
 (Class IIa)
Figure 22 Management of resistant hypertension. BP, blood pressure; K+, potassium; SPC, single-pill combination.  
Recommendation Table 30 — Recommendations for 
treating resistant hypertension (see Evidence Tables 42 
and 43)
Recommendations
Classa
Levelb
In patients with resistant hypertension and 
uncontrolled BP despite use of first-line BP lowering 
therapies, the addition of spironolactone to existing 
treatment should be considered.459,515
IIa
B
Continued
ESC Guidelines                                                                                                                                                                                          3981


<!-- PAGE 71 -->

### Page 71

9.14. Management of specific causes 
of secondary hypertension
9.14.1. General considerations
These guidelines will describe only the general principles of managing 
the most common forms of secondary hypertension. For the rarer 
forms of secondary hypertension, patients should be referred to specia­
lized hypertension centres.
By definition, secondary hypertension should be, for the most part, 
cured when the underlying cause has been unambiguously identified 
and removed. However, in clinical practice, this is not always the case. 
Vascular remodelling, a common feature of a delayed diagnosis of sec­
ondary hypertension, affects renal function and can account for residual 
high BP in some patients with secondary hypertension. The rate of cure is 
higher when the diagnosis is made early in the course of the disease. Most 
common forms of secondary hypertension are listed in Table 13.
9.14.2. Primary aldosteronism
Primary aldosteronism (Conn syndrome) is the most common form of 
secondary hypertension. The management of primary aldosteronism 
depends on its subtype, particularly on adrenal lesions being unilateral 
or bilateral, because the unilateral forms are amenable to surgical treat­
ment while the latter require lifelong medical treatment. In sporadic 
forms, unilateral primary aldosteronism is distinguished from bilateral 
primary aldosteronism by adrenal vein sampling or functional imaging 
with radiolabelled tracers.930–932 In the much less common familial 
forms (necessitating a family history be taken), genetic testing for germ­
line mutations is necessary.933
For unilateral primary aldosteronism, surgical removal of the offending 
adrenal gland is typically considered, unless the patient is older or has co­
morbidities of concern. Surgery is not an option for bilateral primary 
aldosteronism. Medical treatment is currently based on MRAs. Among 
MRAs, spironolactone is the most widely available. The effective dose, 
usually 50–100 mg once daily, can be titrated up to 300–400 mg once 
daily, if necessary. Eplerenone is also used and, despite being less potent 
than spironolactone and requiring twice-daily administration, it has the ad­
vantage of causing less gynaecomastia and erectile dysfunction in men.934
Newer agents, such as the non-steroidal MRAs finerenone and 
exarenone, and the aldosterone synthase inhibitor baxdrostat, which low­
er BP in resistant hypertension,326,474 are also being tested for treating pri­
mary aldosteronism. Of the familial forms, only glucocorticoid-remediable 
primary aldosteronism, now reclassified as familial hyperaldosteronism 
type 1, can be corrected with dexamethasone,935 usually with low doses 
that are free of glucocorticoid effects and can be safely used during preg­
nancy.936 For detailed information, readers are referred to the latest pri­
mary aldosteronism guidelines.328,329
9.14.3. Renovascular hypertension
Patients with RVH should receive medical therapy to reduce BP in the 
first instance. Percutaneous transluminal renal angioplasty (PTRA) 
without stenting is the treatment of choice for fibromuscular dysplasia, 
and can restore renal perfusion pressure and lower BP.937 When this is 
not feasible, RAS blockers are the drugs of choice for treatment, but 
they require careful monitoring of renal function over time, as they 
can cause acute renal failure in those with tight bilateral stenoses or a 
stenosed solitary functioning kidney. Possible involvement of the ca­
rotid, coronary, and other major arteries, possibly leading to dissection 
if BP is not controlled, should also be considered, as fibromuscular dys­
plasia is now recognized as a systemic disease affecting multiple vascular 
beds.
Patients with significant atherosclerotic renal artery stenosis are at 
very high risk of CVD and renal events. It is recommended that 
PTRA and stenting are performed in experienced centres due to the 
high risk of restenosis. Unfortunately, though these studies did not sole­
ly recruit patients with true significant atherosclerotic RVH, publication 
of some null trials938,939 have decreased the enthusiasm for investigat­
ing atherosclerotic renal artery stenosis. This could result in more un­
controlled hypertension, recurrent flash pulmonary oedema (Pickering 
syndrome), and worsening renal function ultimately leading to end- 
stage renal disease.940
In patients with resistant hypertension in whom 
spironolactone is not effective or tolerated, 
treatment with eplerenone instead of 
spironolactone,503 or the addition of a beta-blocker if 
not already indicated459 and, next, a centrally acting 
BP-lowering medication,515 an alpha-blocker,515
hydralazine, or a potassium-sparing diuretic516
should be considered.
IIa
B
To reduce BP, and if performed at a medium-to-high 
volume centre, catheter-based renal denervation 
may be considered for resistant hypertension 
patients who have BP that is uncontrolled despite a 
three BP-lowering drug combination, and who 
express a preference to undergo renal denervation 
after a shared risk-benefit discussion and 
multidisciplinary assessment.564,566–568,586–590
IIb
B
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 31 — Recommendations for 
managing hypertension in patients with renovascular 
hypertension (see Evidence Tables 44 and 45)
Recommendations
Classa
Levelb
Renal artery angioplasty without stenting should be 
considered for patients with hypertension and 
haemodynamically significant renal artery stenosis 
due to fibromuscular dysplasia.941
IIa
C
Renal artery angioplasty and stenting may be 
considered in patients with haemodynamically 
significant, atherosclerotic, renal artery stenosis 
(stenosis of 70%–99%, or 50%–69% with 
post-stenotic dilatation and/or significant 
trans-stenotic pressure gradient) with: 
• Recurrent heart failure, unstable angina, or sudden 
onset flash pulmonary oedema despite maximally 
tolerated medical therapy;
• Resistant hypertension;
• Hypertension with unexplained unilaterally small 
kidney or CKD;
• Bilateral renal artery stenosis or unilateral renal 
artery stenosis in a solitary viable kidney.942,943
IIb
C
Continued


<!-- PAGE 72 -->

### Page 72

9.14.4. Phaeochromocytoma/paraganglioma
Phaeochromocytomas are rare adrenal tumours that secrete catecho­
lamines and are present in <0.2% of patients with hypertension. A small 
percentage (<10%) of catecholamine-producing tumours are extra- 
adrenal and are derived from sympathetic and non-sympathetic nerves. 
More than 35% of the non-syndromic PPGLs are due to germline mu­
tations.338 These mutations should be screened for because, when 
found, they can drive management of the proband and the family and 
also inform the choice of functional imaging. Moreover, some germline 
mutations, such as those involving succinate dehydrogenase B, carry a 
risk of malignant adrenal tumours.301,336
Sympathetic PPGLs are usually secreting and present with chron­
ic, episodic, or labile hypertension. Adrenergic crises cause hyper­
tensive emergencies and should be treated with an intravenous 
(i.v.) alpha-1-blocker, such as phentolamine, doxazosin or terazosin, 
or labetalol. When given i.v. (1–2 mg/kg) twice weekly as a bolus over 
1 min followed by a continuous infusion, labetalol also has alpha- 
blocker properties and has the advantage of allowing titration of 
the infusion based on the BP response, and avoids tachycardia via 
beta-blockade.
Identifying a single tumour mandates surgical excision after ad­
equate pharmacological preparation, because secreting PPGLs can 
cause fatal events with no warning. Administering doxazosin or ter­
azosin, followed by a beta-blocker, usually controls BP and adrener­
gic crises. As PPGLs are associated with a redistribution of volume 
from the periphery to the cardiopulmonary system,944 patients 
with PPGLs have peripheral hypovolaemia that exposes them to 
the risk of profound hypotension, particularly right after tumour ex­
cision. Therefore, adequate fluid administration should be carefully 
managed.
9.14.5. Obstructive sleep apnoea syndrome
The management of this prevalent condition should be driven by the 
result of a polysomnography study, which should provide the value 
of the AHI (the average number of episodes per hour) and the sleep 
position in which apnoeic–hypopnoeic episodes occur. For mild 
OSAS (AHI < 15), weight loss and advice on sleep hygiene are usu­
ally sufficient. For moderate (AHI of 15–30) and severe (AHI > 30) 
OSAS, continuous positive airway pressure (CPAP) is indicated 
and usually improves BP control and helps to resolve resistant 
hypertension. If CPAP is not tolerated, the site of upper airway ob­
struction should be determined by an Ear, Nose, and Throat evalu­
ation with drug-induced sleep endoscopy as a potential step to 
corrective surgery.
9.14.6. Drug-induced hypertension
Over-the-counter medications, prescribed drugs, and drug abuse (rec­
reational substances and misuse of drugs) can cause hypertension 
(Supplementary data online, Table S4).
9.14.6.1. Anticancer drug-induced hypertension
Growing evidence indicates that, while contemporary anticancer and 
anti-angiogenic drugs improve cancer survival, they can also cause hyper­
tension (Supplementary data online, Table S4). This is especially evident 
in patients treated with vascular endothelial growth factor inhibitors, in 
whom BP increases in 80%–90%.945 Tyrosine kinase inhibitors and pro­
teasome inhibitors also increase BP, as do adjuvant therapies (corticos­
teroids, calcineurin inhibitors, non-steroidal anti-inflammatory drugs, and 
anti-androgen hormone therapy). Hypertension caused by anticancer 
drugs is often dose limiting and may be reversible after therapy interrup­
tion or discontinuation. Evidence-based clinical trials specifically addres­
sing patients who develop hypertension due to cancer therapy are 
lacking. It is recommended that management of hypertension in these pa­
tients follows that for the general population.945,946 Managing these com­
plex patients requires multidisciplinary healthcare involving oncologists, 
hypertension specialists, cardiologists, and nephrologists,945,946 as high­
lighted in the 2022 ESC Guidelines on cardio-oncology.946
9.14.7. Other forms of secondary hypertension
Other forms of secondary hypertension, such as genetic causes of 
hypertension (Liddle’s syndrome, glucocorticoid-remediable aldoster­
onism), excess liquorice, Cushing’s syndrome, thyroid disease, hyper­
parathyroidism, aortic coarctation, and acromegaly are rare. Affected 
patients should be referred to specialized centres for treatment.
10. Acute and short-term lowering 
of blood pressure
10.1. Acute blood pressure management in 
hypertensive emergencies
10.1.1. Definition and characteristics of hypertensive 
emergencies
Hypertensive emergency is defined as BP of ≥180/110 mmHg (see 
Figure 10) associated with acute HMOD, often in the presence of 
symptoms. Hypertensive emergencies are potentially life-threatening 
and require immediate and careful intervention to reduce BP, often 
with i.v. therapy.
Symptoms of hypertensive emergency depend on the organs affected 
but may include headache, visual disturbances, chest pain, shortness of 
breath, dizziness, and other neurological deficits. In patients with hyper­
tensive encephalopathy, somnolence, lethargy, tonic–clonic seizures, and 
cortical blindness may precede a loss of consciousness; however, focal 
neurological lesions are rare and should raise the suspicion of stroke.
As outlined in Section 7, we define HMOD among patients with 
chronically elevated BP or hypertension as the presence of specific car­
diac, vascular, and renal alterations.31,159 However, in the setting of 
hypertensive emergency, more acute manifestations of organ damage 
are relevant for management.
Acute manifestations of organ damage include:
• Patients with severe acute hypertension associated with other clinical 
conditions likely to require urgent reduction in BP, e.g. acute onset of 
aortic dissection, myocardial ischaemia, eclampsia, or heart failure.
In patients with an indication to renal artery 
revascularization and technically unfeasible, or failed, 
renal artery angioplasty and stenting, open surgical 
revascularization may be considered.
IIb
C
Renal artery angioplasty is not recommended in 
patients without confirmed haemodynamically 
significant renal artery stenosis.c 938,939
III
A
© ESC 2024
CKD, chronic kidney disease. 
aClass of recommendation. 
bLevel of evidence. 
cA haemodynamically relevant stenosis is usually defined by a luminal narrowing of >70% or 
50%–70% with post-stenotic dilatation.
ESC Guidelines                                                                                                                                                                                          3983


<!-- PAGE 73 -->

### Page 73

• Malignant hypertension, defined as extreme BP elevations and acute 
microvascular damage (microangiopathy) affecting various organs.947
The hallmark of this condition is small-artery fibrinoid necrosis in the kid­
neys, retina, and brain. The acute microangiopathy is typically character­
ized clinically by retinopathy (flame haemorrhages, cotton wool spots, 
and/or papilloedema). Other manifestations of microangiopathy include 
disseminated intravascular coagulation, encephalopathy (in about 15% of 
cases), acute heart failure, and acute deterioration in renal function.
• Patients with sudden severe hypertension due to phaeochromocyto­
ma, which can result in severe acute organ damage.
The term ‘hypertension urgency’ describes severe hypertension in pa­
tients without clinical evidence of acute organ damage. While these pa­
tients require BP reduction, they do not usually require admission to 
hospital, and BP reduction is best achieved with oral medication accord­
ing to the drug treatment algorithm presented in Section 8. However, 
these patients may require more urgent outpatient review to ensure 
that their BP is controlled.
Acute and severe increases in BP can sometimes be precipitated by 
sympathomimetics such as methamphetamine or cocaine, when cau­
tion around beta-blocker use is also needed. Many patients in an emer­
gency department with acute pain or distress may have acutely elevated 
BP that will normalize when the pain and distress are relieved, rather 
than requiring any specific intervention to lower BP.
A diagnostic work-up is necessary for patients with a suspected 
hypertensive emergency (see Supplementary data online, Table S12).
10.1.2. Acute management of hypertensive 
emergencies
Key considerations in defining treatment are: 
(1) Establishing the affected target organ(s) and whether they require 
any specific interventions other than BP lowering.
(2) Determining whether there is a precipitating cause for the acute 
rise in BP and/or another concomitant health condition present 
that might affect the treatment plan (e.g. pregnancy).
(3) The recommended timing and magnitude of BP lowering required 
for safe BP reduction.
These considerations will inform the type of BP-lowering treatment re­
quired. Regarding BP-lowering drugs, i.v. treatment using a short half- 
life drug is typically ideal to allow careful titration of the BP response 
to treatment. This requires a higher dependency clinical area with facil­
ities for continuous or near-continuous haemodynamic monitoring. 
Recommended drug treatments for specific hypertensive emergencies 
are provided in the Supplementary data online, Table S13.
Rapid and uncontrolled or excessive BP lowering is not recommended 
in hypertensive emergency as this can lead to further complications. 
Although i.v. drug administration is recommended for most hypertensive 
emergencies, oral therapy with ACE inhibitors, ARBs, or beta-blockers 
(shorter-acting formulations like captopril or metoprolol) can also be ef­
fective. However, low initial doses should be used because these patients 
can be very sensitive to these agents, and treatment should take place in 
hospital. Further comprehensive details on the clinical management of 
hypertensive emergencies are available elsewhere.242
10.1.3. Prognosis and follow-up
The survival of patients with hypertensive emergencies has improved 
over the past few decades, but these patients remain at high risk and 
should be screened for secondary hypertension.
10.2. Acute blood pressure management in 
acute intracerebral haemorrhage
In acute intracerebral haemorrhage, an increased BP is common and is 
associated with a greater risk of haematoma expansion and death, and a 
worse prognosis for neurological recovery. In trials testing immediate 
BP lowering (within <6 h) to a systolic target of <140 mmHg, the 
achieved systolic BP in the intervention group was typically 140–160  
mmHg and was reported to reduce the risk of haematoma expan­
sion.948,949 Excessive acute drops in systolic BP (>70 mmHg) may be 
associated with acute renal injury and early neurological deterioration 
and should be avoided.950,951
10.3. Acute blood pressure management in 
acute ischaemic stroke
The beneficial effects of BP reduction in acute ischaemic stroke remain un­
clear. In patients not receiving i.v. thrombolysis or mechanical thrombec­
tomy, there is no evidence for actively lowering BP unless it is extremely 
high (e.g. >220/120 mmHg). If BP is extremely high, an initial moderate 
relative reduction of 10%–15% over a period of hours may be consid­
ered.952 The reason for a more conservative approach to acute BP man­
agement is that cerebral autoregulation may be impaired in acute stroke, 
and maintaining cerebral perfusion relies on systemic BP.
In contrast, patients who are treated with i.v. thrombolysis or mechan­
ical thrombectomy (or both) should have more proactive management of 
severe hypertension, because they have an increased risk of reperfusion 
injury and intracranial haemorrhage. In patients undergoing treatment 
with i.v. thrombolysis, BP should be lowered to <185/110 mmHg prior 
to thrombolysis and then maintained at <180/105 mmHg over the 
following 24 h.953 In patients undergoing treatment with mechanical 
thrombectomy (with or without i.v. thrombolysis) there is limited 
evidence from clinical trials, but BP should also be lowered to 
<180/105 mmHg prior to thrombectomy and maintained over the 
next 24 h.953,954 Therefore, patients with acute ischaemic stroke and a 
BP of <180/105 mmHg in the first 72 h after stroke do not seem to bene­
fit from the introduction or reintroduction of BP-lowering medication.955
For stable patients who remain hypertensive (≥140/90 mmHg) ≥3 days 
after an acute ischaemic stroke, initiation or reintroduction of 
BP-lowering medication is recommended.
Recommendation Table 32 — Recommendations for 
acutely managing blood pressure in patients with intra­
cerebral haemorrhage or acute ischaemic stroke
Recommendations
Classa
Levelb
For patients with ischaemic stroke or TIA and an 
indication for BP lowering, it is recommended that 
BP-lowering therapy be commenced before hospital 
discharge.819,820,823
I
B
In patients with acute ischaemic stroke, early BP lowering with BP-lowering 
therapy should be considered in the first 24 h in the following settings:
• In patients who are eligible for re-perfusion 
therapy with intravenous thrombolysis or 
mechanical thrombectomy, BP should be carefully 
lowered and maintained at <180/105 mmHg for at 
least the first 24 h after treatment.956–960
IIa
B
Continued


<!-- PAGE 74 -->

### Page 74

10.4. Acute blood pressure management in 
pre-eclampsia and severe hypertension in 
pregnancy
10.4.1. Pre-eclampsia
Pre-eclampsia is discussed in Section 9. Here we focus on its management 
in the acute setting. Pre-eclampsia is cured by delivery. Most international 
societies, including the ESC, recommend an intensive approach to BP 
lowering in pre-eclampsia.89,964,965 In women with pre-eclampsia and se­
vere hypertension, immediately reducing systolic BP to <160 mmHg and 
diastolic BP to <105 mmHg using i.v. labetalol or nicardipine (with admin­
istration of magnesium sulfate if appropriate and consideration of deliv­
ery if appropriate) was recommended in the 2018 ESC/ESH Guidelines 
on the management of arterial hypertension and the 2022 ESC 
Guidelines for management of cardiovascular disease in pregnancy.1,89
The objective of treatment is to lower BP within 150–180 min.
Magnesium sulfate [4 g i.v. over 5 min, then 1 g/h i.v.; or 5 g intramus­
cularly (i.m.) into each buttock, then 5 g i.m. every 4 h] is recommended 
for eclampsia treatment but also for women with pre-eclampsia who 
have severe hypertension and proteinuria or hypertension and neuro­
logical symptoms or signs.966 There is a risk of hypotension when mag­
nesium is given concomitantly with nifedipine.967 If BP control is not 
achieved by 360 min despite two medications, consulting critical care 
is recommended for intensive care unit admission, stabilization, and de­
livery (if appropriate).966 Since plasma volume is reduced in pre- 
eclampsia, diuretic therapy should be avoided.
10.4.2. Severe acute hypertension in pregnancy
Severe hypertension in pregnancy (without pre-eclampsia) may neces­
sitate acute BP-lowering therapies. Severe hypertension in pregnancy is 
defined in general as systolic BP of >160 mmHg and diastolic BP of 
>110 mmHg and is associated with adverse maternal and peri-natal 
outcomes independent of pre-eclampsia and potentially of the same 
magnitude as eclampsia itself.89,968
There are differences in rate of BP control between i.v. labetalol and 
i.v. hydralazine in severe hypertension in pregnancy.969 While evidence 
is conflicting,667,668 hydralazine may be associated with more peri-natal 
adverse events than other drugs.970 Nifedipine seems to provide lower 
BP with lower rates of neonatal complications than labetalol.971
10.5. Peri-operative acute management of 
elevated blood pressure
Details are provided in the ESC Guidelines on cardiovascular assessment 
and management of patients undergoing non-cardiac surgery.972
Peri-operative hypertension, hypotension, and BP variability are associated 
with haemodynamic instability and poor clinical outcomes for patients 
undergoing surgery.973 Pre-operative risk assessment for BP management, 
therefore, should involve assessing for underlying end-organ damage and 
comorbidities.974 Postponing necessary non-cardiac surgery is not usually 
warranted for patients with minor or moderate elevations in BP, as they 
are not at higher CVD risk.130,975
Avoiding large fluctuations in BP in the peri-operative course is im­
portant, and planning a strategy for a patient should account for the 
baseline office BP.974–977
There is insufficient evidence for reduced or increased peri- 
operative BP targets compared to usual care BP targets to lower 
peri-operative events.978 No specific measure of BP appears better 
than any other for predicting risk of peri-operative events.975
10.5.1. Blood pressure-lowering drugs in the 
peri-operative phase
Routine initiation of a beta-blocker peri-operatively is not necessary.979
Pre-operative initiation of beta-blockers in advance of high-risk, 
non-cardiac surgery may be considered in patients who have 
known coronary artery disease or myocardial ischaemia980 or 
two or more significantly elevated clinical risk factors in order to 
reduce the incidence of peri-operative myocardial infarction.979
Peri-operative continuation of beta-blockers is recommended for 
patients currently taking beta-blockers.981
Some studies suggest that continued use of ACE inhibitors is asso­
ciated with a higher risk of peri-operative hypotension and subsequent 
end-organ damage including kidney injury, myocardial infarction, and 
stroke.982 In the Prospective Randomized Evaluation of Preoperative 
Angiotensin-Converting Enzyme Inhibition (PREOP-ACEI) trial, transient 
pre-operative interruption of ACE inhibitor therapy was associated with 
a decreased risk of intra-operative hypotension.983 A subsequent system­
atic review also showed a decreased risk of intra-operative hypotension 
with withholding ACE inhibitors/ARBs before surgery, but no association 
• In patients with ischaemic stroke not receiving 
re-perfusion treatment and BP of ≥220/110  
mmHg, BP should be carefully lowered by 
approximately 15% during the first 24 h after 
stroke onset.956–960
IIa
C
In patients with intracerebral haemorrhage, 
immediate BP lowering (within 6 h of symptom 
onset) should be considered to a systolic target 140– 
160 mmHg to prevent haematoma expansion and 
improve functional outcome.948,949
IIa
A
In patients with intracerebral haemorrhage 
presenting with systolic BP ≥220 mmHg, acute 
reduction in systolic BP >70 mmHg from initial levels 
within 1 h of commencing treatment is not 
recommended.950,951,960–963
III
B
© ESC 2024
BP, blood pressure; TIA, transient ischaemic attack. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 33 — Recommendations for 
acutely managing blood pressure in patients with severe 
hypertension in pregnancy and pre-eclampsia (see 
Evidence Table 46)
Recommendation
Classa
Levelb
In pre-eclampsia or eclampsia with hypertensive 
crisis, drug treatment with i.v. labetalol or nicardipine 
and magnesium is recommended.971
I
C
In pre-eclampsia or eclampsia associated with 
pulmonary oedema, nitroglycerin given as an i.v. 
infusion is recommended.242
I
C
In severe hypertension in pregnancy: 
• drug treatment with i.v. labetalol, oral methyldopa, 
or oral nifedipine is recommended. Intravenous 
hydralazine is a second-line option.666–668,969,971
I
C
© ESC 2024
i.v., intravenous. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3985


<!-- PAGE 75 -->

### Page 75

with decreased mortality or CVD outcomes.984 On the other hand, vigi­
lance is needed because withholding ACE inhibitors has also been shown 
to increase post-operative hypertension.985 In patients with heart failure, 
loop diuretics can be continued in patients prone to volume overload.986
CCBs are generally considered safe pre-operatively.
11. Patient-centred care 
in hypertension
11.1. Definition
Patient-centred care is defined as an attitude of the healthcare profes­
sional that closely aligns with the patient’s preferences and needs.987
In the patient-centred approach (Figure 23), patients are viewed as ac­
tive participants in health services, who work as partners alongside 
healthcare professionals. A patient-centred approach is associated 
with higher satisfaction rates, better adherence to recommendations 
and prescriptions, and better treatment, particularly in the manage­
ment of chronic illness, such as hypertension.988 While there is limited 
evidence for the efficacy and effectiveness of specific shared decision- 
making intervention strategies in hypertension care,989 it is viewed as 
an ethical imperative in healthcare practice and health policy, and in 
clinical guidelines.130
11.2. Communicating consequences of 
treatment
In line with patient-centred care, it is important to assess whether patients 
understand their hypertension-related risk, the rationale for any hyperten­
sion treatment, the benefits and harms of hypertension treatment, and 
that the treatment plan is also centrally guided by what matters most to 
the patient. Risk communication is challenging, and providers need to be 
led by the individual’s preferences when presenting more detailed numeric 
and visual representations of risk and the likely benefits and harms of 
hypertension treatment. Socio-demographic differences in healthcare 
need to be considered in patient–provider communication.990,991
Standard approaches to communicate consequences of treatment 
can involve 10-year risk of a CVD event with SCORE2 or 
SCORE2-OP. Alternatively, individual risk and risk reduction can be 
communicated in terms of ‘risk age’ or ‘heart age’ (Section 7.3).
P
a t
i e
n t
Lifestyle
(inclusive of health behaviour and social context)
Medications
Multidisciplinary medical team
Self-care
Family
Figure 23 Patient-centred care.


<!-- PAGE 76 -->

### Page 76

11.3. Self-measuring and monitoring
Self-care refers to individual responsibility for healthy lifestyle beha­
viours, as well as the actions required to cope with health condi­
tions.996,997
In the context of hypertension, it also includes 
self-management and self-measurement of BP.
Self-management includes lifestyle behaviour (diet, exercise, smoking, 
alcohol), co-management of medical treatments, and support for adher­
ing to prescribed medication.998 Self-monitoring allows high BP to be de­
tected early,999 and enables patients to co-manage medications with 
their healthcare provider.1000,1001 Suitably validated and correctly used 
digital devices have the potential to support co-management,1002,1003
and facilitate remote monitoring of BP.76,81,1004
11.4. Facilitating medication adherence 
and persistence
Adherence (Figure 24) to BP-lowering drug regimens in clinical practice 
is almost always lower than seen in clinical trials.1007 Most apparent 
treatment-resistant hypertension is accounted for by non- 
adherence.1008 Adherence should always be assessed with a no-blame 
approach. Various methods are available to assess adherence and, along 
with details on barriers to adherence, are described in the 
Supplementary data online and Table S14.1009
Adherence may also be facilitated by an optimal therapeutic regi­
men, which can be achieved by medication reviews carried out at 
appropriate intervals. Several factors should be considered: (i) identify­
ing drug-related adverse events and appropriate dosing levels, (ii) using 
long-acting drugs that require once-daily dosing (preferably drugs that 
are long-acting due to pharmacokinetic properties rather than galenic 
formulation), (iii) avoiding complex dosing schedules, (iv) using single- 
pill combinations whenever feasible, (v) taking into account the financial 
capacity of the patient to pay for a given regimen in the longer term, if 
relevant, or other pertinent aspects of the local or national healthcare 
systems, and (vi) enlisting support of a family member or other social 
support to facilitate medication adherence and persistence (see 
Supplementary data online, Table S15).1010
While there have been advancements in digital tools to support self- 
management of chronic illness including hypertension, there is little 
efficacy evidence evaluating these interventions. Therefore, it is prema­
ture to make recommendations about specific digital tools.
11.5. Multidisciplinary management
A collaborative approach to managing hypertension, using team-based 
care among physicians, nurses, pharmacists, dietitians, and physiothera­
pists, 
offers 
significant 
benefits 
over 
physician-only 
care. 
Multidisciplinary care is intended to be collaborative and complemen­
tary to regular medical care1011 and is associated with lower systolic 
and diastolic BP227,229,1012,1013
and improved outcomes.230,1014
Task-shifting away from physicians is necessary to meet the huge 
need for the management of elevated BP and hypertension in the popu­
lation.1015 Prescribing remains a physician duty, but prescribing can be 
conducted under collaborative practice agreements with the multidis­
ciplinary team in many countries.
Further details on patient-centred care in hypertension is provided in 
the Supplementary data online.
Recommendation Table 34 — Recommendations for 
communicating 
consequences 
of 
treatment 
(see 
Evidence Table 47)
Recommendation
Classa
Levelb
An informed discussion about CVD risk and 
treatment benefits tailored to the needs of a patient 
is recommended as part of hypertension 
management.992
I
C
Motivational interviewing should be considered for 
patients with hypertension at hospitals and 
community health centres to assist patients in 
controlling their BP and to enhance treatment 
adherence.993,994
IIa
B
Physician–patient web communications are an 
effective tool that should be considered in primary 
care, including reporting on home BP readings.995
IIa
C
© ESC 2024
BP, blood pressure; CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 35 — Recommendations for 
self-measuring and monitoring blood pressure (see 
Evidence Table 48)
Recommendations
Classa
Levelb
Home BP measurement for managing hypertension 
by using self-monitored BP is recommended to 
achieve better BP control.
I
B
Self-measurement, when properly performed, is 
recommended due to positive effects on the 
acceptance of a diagnosis of hypertension, patient 
empowerment, and adherence to treatment.1001
I
C
Enhanced self-monitoring of BP using a device paired 
with a connected smartphone application may be 
considered, though evidence to date suggests that 
this may be no more effective than standard 
self-monitoring.1005,1006
IIb
B
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 36 — Recommendations for 
multi/interdisciplinary blood pressure management 
(see Evidence Table 49)
Recommendation
Classa
Levelb
Multidisciplinary approaches in the management of 
patients with elevated BP and hypertension, including 
appropriate and safe task-shifting away from 
physicians, are recommended to improve BP 
control.227,229,230,1012–1014,1016
I
A
© ESC 2024
BP, blood pressure. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3987


<!-- PAGE 77 -->

### Page 77

### 12 Key messages

(1) Given the demographic transition and the worldwide ageing of 
populations, the number of individuals with elevated BP or hyper­
tension is increasing worldwide.
(2) The trajectory of BP control appears to be worsening in North 
America, in some (but not all) European countries, and elsewhere 
around the world.
(3) The risk for CVD attributable to BP is on a continuous log-linear 
exposure variable scale, not a binary scale of normotension vs. 
hypertension.
(4) BP-lowering drugs can reduce CVD risk even among individuals 
not traditionally classified as hypertensive. Accordingly, a new 
BP category called ‘elevated BP’ is introduced. Elevated BP is de­
fined as an office systolic BP of 120–139 mmHg or diastolic BP of 
70–89 mmHg. Hypertension remains defined as office BP of 
≥140/90 mmHg.
(5) Hypertension in women is under-studied in basic, clinical, and popu­
lation research.
(6) HMOD suggests long-standing or severe hypertension and is 
associated with increased CVD risk.
(7) Absolute CVD risk must be considered when assessing and man­
aging elevated BP.
(8) Despite the growing number of hypertension guidelines, the rates 
of diagnosis, treatment, and control of hypertension (and elevated 
BP) remain suboptimal. A major factor underlying this is poor 
e.g. affordability of medications and lack of social support to manage medications
Socio-economic factors e.g. experience of side-effects and challenges of polypharmacy
(treatment burden)
Therapy-related factors e.g. beliefs about hypertension and related medications, persistence of medication taking habits and emotional distress
Patient-related factors e.g. hypertension is a disease without an illness (asymptomatic)
and often one among many morbidities
Condition-related factors e.g. clarity and consistency of communication with patient,
quality of ongoing relationship with healthcare providers
Health system/healthcare team factors
Figure 24 The five dimensions of adherence (WHO, 2003) applied to hypertension.


<!-- PAGE 78 -->

### Page 78

implementation of evidence-based guidelines in real-world clinical 
practice.
(9) One of the most important changes in the 2024 Guidelines is the 
focus on evidence related to CVD outcomes of BP-lowering in­
terventions rather than BP lowering alone.
(10) Irrespective of the threshold BP above which BP-lowering treat­
ment (lifestyle or pharmacological or other treatment) is re­
commended, the on-treatment BP target is 120–129/70–79  
mmHg for all adults, provided this treatment is well tolerated. 
There are several important exceptions to these targets and in­
dividualized decision-making is always the most important 
priority.
13. Gaps in the evidence
(1) Drivers of worsening trajectories of BP control in women and 
men.
(2) Need for sex-specific data on epidemiology, risk factors, and 
pathophysiology of hypertension. Need for more prospective 
studies to assess women’s and men’s specific CVD risk factors 
pertinent to adults with elevated BP and hypertension, due to bio­
logical and socio-cultural conditions. This includes sex-specific 
weighting of traditional risk factors, as well as inclusion of sex- 
dependent, non-traditional, vascular risk factors such as stress, 
socio-economic conditions, and others.1017,1018 We are also lack­
ing data on sex-specific hormonal and genetic mechanisms and 
pathophysiology in the human.1019 Another important area in 
need of investigation is a better understanding of the role of gen­
der in the management of elevated BP and hypertension (including 
gender-driven barriers in accessing medical care and adherence).
(3) More widespread validation of home BP measuring devices. 
Validation protocols for cuffless BP measurement devices have 
just recently been proposed and need to be tested.
(4) Clinical effectiveness of HMOD in directing intensity of care and 
personalized approaches in managing elevated BP and hypertension.
(5) Best practice to screen and manage primary aldosteronism.
(6) Clinical benefits of treating low CVD-risk individuals with elevated 
BP and further data strengthening the use of BP-lowering 
medication among high-risk persons with baseline systolic BP 
of 120–129 mmHg.
(7) Need for more data on the sex-specific optimal dosing, effects, 
and adverse effects of BP-lowering drugs,1020 in particular from 
specifically planned prospective randomized trials.
(8) More consideration for overall CVD outcomes of BP-lowering 
interventions.
(9) More European data (RCTs, real life) about the beneficial effect of 
treating patients with elevated BP and hypertension with polypills 
(inclusive of non-BP lowering medications).
(10) CVD outcomes-based data on MRAs as add-on therapy solely for 
resistant hypertension.
(11) Trials on the BP-lowering effects of newer antidiabetic drugs 
(such as SGLT2 inhibitors and GLP-1 receptor agonists) or drugs 
that now have indications for other conditions, such as finerenone 
or sacubitril-valsartan.
(12) Beneficial BP and CVD effects of increasing dietary potassium in­
take and other lifestyle interventions. Studies to disentangle the 
effect of sodium reduction vs. the effect of potassium supplemen­
tation on BP control and CVD outcomes.
(13) RCTs comparing single-pill combination therapy with fixed doses 
vs. multiple monotherapies and their effects on CVD outcomes.
(14) Cardiovascular outcomes trials of renal denervation.
(15) BP-lowering treatment RCTs on different ethnic and migrant 
groups established in Europe.
(16) Pharmacological BP management in young adults (aged <40 years) 
and better data on the efficacy of a life-course approach for the 
drug management of BP.1021
(17) CVD outcomes in moderately to severely frail and/or very elderly 
persons where BP medications have been deprescribed, and the 
impact of competing risks.
(18) Management of renal artery disease with haemodynamically stable 
but severe stenosis (i.e. without high-risk features).
(19) Need for clinical trials on managing hypertension in patients trea­
ted with anticancer drugs or anti-rejection drugs in recipients of 
an allograft transplant.
(20) Hypertension management in the setting of climate changes, glo­
bal warming, air and other forms of pollution, pandemics, war 
zones, and in the context of drug restrictions experienced in 
some low-to-middle-income countries.
(21) Need to improve implementation of guidelines by healthcare 
providers.
(22) How to develop sustainable hypertension care at the intersection 
of growing numbers of patients and limited resources.
(23) Treat-to-target trials specifically testing BP-lowering drugs among 
drug-naïve persons with baseline BP of 120–129 mmHg and in­
creased CVD risk.
14. ‘What to do’ and ‘what not to 
do’ messages from the guidelines
A selected sample of the main messages from these guidelines are pro­
vided in Table 15.
Table 15 What to do and what not to do
Recommendations
Class
Level
5. Measuring blood pressure
It is recommended to measure BP using a validated and calibrated device, to enforce the correct measurement technique, and to apply a 
consistent approach to BP measurement for each patient.
I
B
All adult patients (≥18 years or older) are recommended to have their office and/or out-of-office BP measured on an opportunistic basis and 
recorded in their medical file, and be told what their current BP is.
I
C
Continued
ESC Guidelines                                                                                                                                                                                          3989


<!-- PAGE 79 -->

### Page 79

Out-of-office BP measurement is recommended for diagnostic purposes, particularly because it can detect both white-coat hypertension and 
masked hypertension. Where out-of-office measurements are not logistically and/or economically feasible, then it is recommended that the 
diagnosis be confirmed with a repeat office BP measurement using the correct standardized measurement technique.
I
B
It is recommended that office BP should be measured in both arms at least at the first visit, because a between-arm systolic BP difference of 
>10 mmHg is associated with an increased CVD risk and may indicate arterial stenosis.
I
B
If a between-arm difference of >10 mmHg in systolic BP is recorded, then it is recommended that all subsequent BP readings use the arm with 
the higher BP reading.
I
B
Out-of-office BP measurement is recommended for ongoing management to quantify the effects of treatment and guide BP-lowering 
medication titration, and/or identify possible causes of side effects (e.g. symptomatic hypotension). Where out-of-office measurements are 
not logistically and/or economically feasible then ongoing management is recommended to be based on repeated office BP measurements 
using the correct standardized measurement technique.
I
B
It is recommended that all patients undergoing BP measurement also undergo pulse palpation at rest to determine heart rate and arrhythmias 
such as AF.
I
C
6. Definition and classification of elevated blood pressure and hypertension
It is recommended that BP be categorized as non-elevated BP, elevated BP, and hypertension to aid treatment decisions.
I
B
It is recommended to use a risk-based approach in the treatment of elevated BP, and individuals with moderate or severe CKD, established 
CVD, HMOD, diabetes mellitus, or familial hypercholesterolaemia are considered at increased risk for CVD events.
I
B
SCORE2 is recommended for assessing 10-year risk of fatal and non-fatal CVD among individuals aged 40–69 years with elevated BP who are 
not already considered at increased risk due to moderate or severe CKD, established CVD, HMOD, diabetes mellitus, or familial 
hypercholesterolaemia.
I
B
SCORE2-OP is recommended for assessing the 10-year risk of fatal and non-fatal CVD among individuals aged ≥70 years with elevated BP 
who are not already considered at increased risk due to moderate or severe CKD, established CVD, HMOD, diabetes mellitus, or familial 
hypercholesterolaemia.
I
B
It is recommended that, irrespective of age, individuals with elevated BP and a SCORE2 or SCORE2-OP CVD risk of ≥10% be considered at 
increased risk for CVD for the purposes of risk-based management of their elevated BP.
I
B
7. Diagnosing hypertension and investigating underlying causes
In individuals with increased CVD risk where their screening office BP is 120–139/70–89 mmHg, it is recommended to measure BP 
out-of-office, using ABPM and/or HBPM or, if not logistically feasible, make repeated office BP measurements on more than one visit.
I
B
Where screening office BP is 140–159/90–99 mmHg, it is recommended that the diagnosis of hypertension should be based on out-of-office 
BP measurement with ABPM and/or HBPM. If these measurements are not logistically or economically feasible, then diagnosis can be made on 
repeated office BP measurements on more than one visit.
I
B
Where screening BP is ≥160/100 mmHg: 
• It is recommended that BP 160–179/100–109 mmHg is confirmed as soon as possible (e.g. within 1 month) preferably by either home or 
ambulatory BP measurements.
• It is recommended when BP is ≥180/110 mmHg that hypertensive emergency be excluded.
I
C
It is recommended to measure serum creatinine, eGFR, and urine ACR in all patients with hypertension.
I
A
If moderate-to-severe CKD is diagnosed, it is recommended to repeat measurements of serum creatinine, eGFR, and urine ACR at least 
annually.
I
C
A 12-lead ECG is recommended for all patients with hypertension.
I
B
Echocardiography is recommended in patients with hypertension and ECG abnormalities, or signs or symptoms of cardiac disease.
I
B
Fundoscopy is recommended if BP >180/110 mmHg in the work-up of hypertensive emergency and malignant hypertension, as well as in 
hypertensive patients with diabetes.
I
C
Routine genetic testing for patients with hypertension is not recommended.
III
C
It is recommended that patients with hypertension presenting with suggestive signs, symptoms, or medical history of secondary hypertension 
are appropriately screened for secondary hypertension.
I
B
8. Preventing and treating elevated blood pressure
Restriction of sodium to approximately 2 g per day is recommended where possible in all adults with elevated BP and hypertension [this is 
equivalent to about 5 g of salt (sodium chloride) per day or about a teaspoon or less].
I
A
Moderate-intensity aerobic exercise of ≥150 min/week [moderate aerobic exercise (≥30 min, 5–7 days/week) or alternatively 75 min of 
vigorous exercise per week over 3 days] is recommended and should be complemented with low- or moderate-intensity dynamic or 
isometric resistance training (2–3 times/week) to reduce BP and CVD risk.
I
A
It is recommended to aim for a stable and healthy BMI (20–25 kg/m2) and waist circumference values (<94 cm in men and <80 cm in women) 
to reduce BP and CVD risk.
I
A
Continued


<!-- PAGE 80 -->

### Page 80

Adopting a healthy and balanced diet such as the Mediterranean or DASH diets is recommended to help reduce BP and CVD risk.
I
A
Men and women are recommended to drink less alcohol than the upper limit, which is about 100 g/week of pure alcohol. How this translates 
into number of drinks depends on portion size (the standards of which differ per country), but most drinks contain 8–14 g of alcohol per drink. 
Preferably, it is recommended to avoid alcohol consumption to achieve best health outcomes.
I
B
It is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy intake. It is 
also recommended to discourage consumption of sugar-sweetened beverages, such as soft drinks and fruit juices, starting at young age.
I
B
It is recommended to stop tobacco smoking, initiate supportive care, and refer to smoking cessation programmes, as tobacco use strongly and 
independently causes CVD, CVD events, and all-cause mortality.
I
A
Among all BP-lowering drugs, ACE inhibitors, ARBs, dihydropyridine CCBs, and diuretics (thiazides and thiazide-like drugs such as 
chlorthalidone and indapamide) have demonstrated the most effective reduction of BP and CVD events, and are therefore recommended as 
first-line treatments to lower BP.
I
A
It is recommended that beta-blockers are combined with any of the other major BP-lowering drug classes when there are other compelling 
indications for their use, e.g. angina, post-myocardial infarction, HFrEF, or for heart rate control.
I
A
It is recommended to take medications at the most convenient time of day for the patient to establish a habitual pattern of medication taking 
to improve adherence.
I
B
Given trial evidence for more effective BP control vs. monotherapy, combination BP-lowering treatment is recommended for most patients 
with confirmed hypertension (BP ≥140/90 mmHg) as initial therapy. Preferred combinations are a RAS blocker (either an ACE inhibitor or an 
ARB) with a dihydropyridine CCB or diuretic. Exceptions to consider include patients aged ≥85 years, symptomatic orthostatic hypotension, 
moderate-to-severe frailty, and those with elevated BP (systolic BP 120–139 mmHg or diastolic BP 70–89 mmHg) with a concomitant 
indication for treatment.
I
B
In patients receiving combination BP-lowering treatment, fixed-dose single-pill combination treatment is recommended.
I
B
If BP is not controlled with a two-drug combination, increasing to a three-drug combination is recommended, usually a RAS blocker with a 
dihydropyridine CCB and a thiazide/thiazide-like diuretic, and preferably in a single-pill combination.
I
B
Combining two RAS blockers (ACE inhibitor and an ARB) is not recommended.
III
A
In adults with elevated BP and low/medium CVD risk (<10% over 10 years), BP lowering with lifestyle measures is recommended and can 
reduce the risk of CVD.
I
B
In adults with elevated BP and sufficiently high CVD risk, after 3 months of lifestyle intervention, BP lowering with pharmacological treatment 
is recommended for those with confirmed BP ≥130/80 mmHg to reduce CVD risk.
I
A
It is recommended that in hypertensive patients with confirmed BP ≥140/90 mmHg, irrespective of CVD risk, lifestyle measures and 
pharmacological BP-lowering treatment is initiated promptly to reduce CVD risk.
I
A
It is recommended to maintain BP-lowering drug treatment lifelong, even beyond the age of 85 years, if well tolerated.
I
A
8. Preventing and treating elevated blood pressure (blood pressure targets)
To reduce CVD risk, it is recommended that treated systolic BP values in most adults be targeted to 120–129 mmHg, provided the treatment 
is well tolerated.
I
A
In cases where BP-lowering treatment is poorly tolerated and achieving a target systolic of 120–129 mmHg is not possible, it is recommended 
to target a systolic BP level that is ‘as low as reasonably achievable’ (ALARA principle).
I
A
8. Preventing and treating elevated blood pressure (renal denervation)
Due to a lack of adequately powered outcomes trials demonstrating its safety and CVD benefits, renal denervation is not recommended as a 
first-line BP-lowering intervention for hypertension.
III
C
Renal denervation is not recommended for treating hypertension in patients with moderate-to-severely impaired renal function (eGFR <40  
mL/min/1.73 m2) or secondary causes of hypertension, until further evidence becomes available.
III
C
9. Managing specific patient groups or circumstances
Young adults
Comprehensive screening for the main causes of secondary hypertension is recommended in adults diagnosed with hypertension before the 
age of 40 years, except for obese young adults where it is recommended to start with an obstructive sleep apnoea evaluation.
I
B
Hypertension in pregnancy
In women with gestational hypertension, starting drug treatment is recommended for those with confirmed office systolic BP ≥140 mmHg or 
diastolic BP ≥90 mmHg.
I
B
In pregnant women with chronic hypertension, starting drug treatment is recommended for those with confirmed office systolic BP ≥140  
mmHg or diastolic BP ≥90 mmHg.
I
B
In women with chronic and gestational hypertension, it is recommended to lower BP below 140/90 mmHg but not below 80 mmHg for 
diastolic BP.
I
C
Continued
ESC Guidelines                                                                                                                                                                                          3991


<!-- PAGE 81 -->

### Page 81

Dihydropyridine CCBs (preferably extended-release nifedipine), labetalol, and methyldopa are recommended first-line BP-lowering 
medications for treating hypertension in pregnancy.
I
C
In consultation with an obstetrician, low- to moderate-intensity exercise is recommended in all pregnant women without contraindications to 
reduce the risk of gestational hypertension and pre-eclampsia.
I
B
RAS blockers are not recommended during pregnancy.
III
B
Very old and frail patients; orthostatic hypotension
It is recommended that treatment of elevated BP and hypertension among older patients aged <85 years who are not moderately to severely 
frail follows the same guidelines as for younger people, provided BP-lowering treatment is well tolerated.
I
A
It is recommended to maintain BP-lowering drug treatment lifelong, even beyond the age of 85 years, if well tolerated.
I
A
Before starting or intensifying BP-lowering medication, it is recommended to test for orthostatic hypotension, by first having the patient sit or 
lie for 5 min and then measuring BP 1 and/or 3 min after standing.
I
B
It is recommended to pursue non-pharmacological approaches as the first-line treatment of orthostatic hypotension among persons with 
supine hypertension. For such patients, it is also recommended to switch BP-lowering medications that worsen orthostatic hypotension to an 
alternative BP-lowering therapy and not to simply de-intensify therapy.
I
A
Diabetes
In most adults with elevated BP and diabetes, after a maximum of 3 months of lifestyle intervention, BP lowering with pharmacological 
treatment is recommended for those with confirmed BP ≥130/80 mmHg to reduce CVD risk.
I
A
BP-lowering drug treatment is recommended for people with pre-diabetes or obesity when confirmed office BP is ≥140/90 mmHg or when 
office BP is 130–139/80–89 mmHg and the patient is at predicted 10-year risk of CVD ≥10% or with high-risk conditions, despite a maximum 
of 3 months of lifestyle therapy.
I
A
In persons with diabetes who are receiving BP-lowering drugs, it is recommended to target systolic BP to 120–129 mmHg, if tolerated.
I
A
Chronic kidney disease
In patients with diabetic or non-diabetic moderate-to-severe CKD and confirmed BP ≥130/80 mmHg, lifestyle optimization and BP-lowering 
medication are recommended to reduce CVD risk, provided such treatment is well tolerated.
I
A
In adults with moderate-to-severe CKD who are receiving BP-lowering drugs and who have eGFR >30 mL/min/1.73 m2, it is recommended to 
target systolic BP to 120–129 mmHg, if tolerated. Individualized BP targets are recommended for those with lower eGFR or renal 
transplantation.
I
A
In hypertensive patients with CKD and eGFR >20 mL/min/1.73 m2, SGLT2 inhibitors are recommended to improve outcomes in the context 
of their modest BP-lowering properties.
I
A
Cardiac disease
In patients with a history of myocardial infarction who require BP-lowering treatment, beta-blockers and RAS blockers are recommended as 
part of that treatment.
I
A
In patients with symptomatic angina who require BP-lowering treatment, beta-blockers and/or CCBs are recommended as part of that 
treatment.
I
A
In patients with symptomatic HFrEF/HFmrEF, the following treatments with BP-lowering effects are recommended to improve outcomes: 
ACE inhibitors (or ARBs if ACE inhibitors are not tolerated) or ARNi, beta-blockers, MRAs, and SGLT2 inhibitors.
I
A
In hypertensive patients with symptomatic HFpEF, SGLT2 inhibitors are recommended to improve outcomes in the context of their modest 
BP-lowering properties.
I
A
Other conditions
It is recommended that the BP-lowering drug treatment strategy for preventing stroke should comprise a RAS blocker plus a CCB or a 
thiazide-like diuretic.
I
A
In patients with confirmed BP ≥130/80 mmHg with a history of TIA or stroke a systolic BP target 120–129 mmHg is recommended to reduce 
CVD outcomes, provided treatment is tolerated.
I
A
Renal artery angioplasty is not recommended in patients without confirmed haemodynamically significant renal artery stenosis.
III
A
10. Acute and short-term lowering of blood pressure
Intracerebral haemorrhage or acute ischaemic stroke
For patients with ischaemic stroke or TIA and an indication for BP lowering, it is recommended that BP lowering therapy should be 
commenced before hospital discharge.
I
B
In patients with intracerebral haemorrhage presenting with systolic BP ≥220 mmHg, acute reduction in systolic BP >70 mmHg from initial 
levels within 1 h of commencing treatment is not recommended.
III
B
Continued


<!-- PAGE 82 -->

### Page 82

### 15 Evidence tables

Evidence tables are available at European Heart Journal online.
16. Data availability statement
No new data were generated or analysed in support of this research.
17. Author information
Author/task force Member Affiliations: Cian P. McCarthy, 
Cardiovascular Division Massachusetts General Hospital and Harvard 
Medical School Boston, MA, United States of America; Rosa Maria 
Bruno, PARCC, Université Paris Cité, Inserm, Paris, France, and 
Pharmacology & Hypertension, AP-HP, Hôpital Européen Georges 
Pompidou, Paris, France; Sofie Brouwers, Cardiovascular Center 
Aalst, Department of Cardiology, OLV Clinic Aalst, Aalst, Belgium, 
and Department of Experimental Pharmacology, Faculty of Medicine 
and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium; Michelle 
D. Canavan, School of Medicine, College of Medicine, Nursing and 
Health Sciences, University of Galway, Galway, Ireland, and 
Department of Geriatric Medicine, University Hospital Galway, Saolta 
Hospitals Group, Galway, Ireland; Claudio Ceconi, Motusmed 
Clinic, 
Brescia, 
Italy; 
Ruxandra 
Maria 
Christodorescu, 
Department V Internal Medicine, University of Medicine and 
Pharmacy V Babes, Timisoara, Romania, and Research Center, 
Institute of Cardiovascular Diseases, Timisoara, Romania; Stella 
S. Daskalopoulou, Medicine Research Institute of the McGill 
University Health Centre, McGill University, Montreal, Canada; 
Charles J. Ferro, Department of Renal Medicine, University 
Hospitals Birmingham, Birmingham, United Kingdom, and Institute of 
Cardiovascular Sciences University of Birmingham, Birmingham, 
United Kingdom; Eva Gerdts, Department of Clinical Science, 
University of Bergen, Bergen, Norway, and Department of Heart 
Disease, Haukeland University Hospital, Bergen, Norway; Henner 
Hanssen, Department Sport, Exercise and Health, Medical Faculty, 
University of Basel, Basel, Switzerland; Julie Harris (United 
Kingdom), ESC Patient Forum, Sophia Antipolis, France; Lucas 
Lauder, Department of cardiology, University hospital Basel, Basel, 
Switzerland, and Department of internal medicine III, Cardiology, 
Angiology, and Intensive Care Medicine, Saarland university medical 
center, Homburg, Germany; Richard J. McManus, Nuffield 
Department of Primary Care Health Sciences, University of Oxford, 
Oxford, United Kingdom; Gerard J. Molloy, School of Psychology, 
University of Galway, Galway, Ireland; Kazem Rahimi, Deep 
Medicine, Nuffield Department of Women’s and Reproductive 
Health, University of Oxford, Oxford, United Kingdom; Vera 
Regitz-Zagrosek, Charite, University Medicine Berlin, Gender in 
Medicine, Berlin, Germany; Gian Paolo Rossi, Department of 
Medicine, DIMED, University of Padua, Padua, Italy; Else Charlotte 
Sandset, Department of Neurology, Oslo University Hospital, Oslo, 
Norway, The Norwegian Air Ambulance Foundation, Oslo, Norway, 
and Institute of Clinical Medicine University of Oslo, Oslo, Norway; 
Bart Scheenaerts (Belgium), ESC Patient Forum, Sophia Antipolis, 
France; Jan A. Staessen, Non-Profit Research Association Alliance 
for the Promotion of Preventive Medicine, Mechelen, Belgium, and 
Biomedical Research Group, Faculty of Medicine, University of 
Leuven, Leuven, Belgium; Izabella Uchmanowicz, Department of 
Nursing and Obstetrics, Faculty of Health Sciences, Wroclaw Medical 
University, Wroclaw, Poland; and Maurizio Volterrani, Exercise 
Science and Medicine San Raffaele Open University, Rome, Italy, and 
Cardiopulmonary Department, IRCCS San Raffaele, Rome, Italy.
18. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Ana Abreu (CPG Review Co-ordinator) 
(Portugal), Michael Hecht Olsen (CPG Review Co-ordinator) 
(Denmark), Marco Ambrosetti (Italy), Emmanuel Androulakis (United 
Kingdom), Lia Evi Bang (Denmark), Jesper Nørgaard Bech (Denmark), 
Michael A. Borger (Germany), Pierre Boutouyrie (France), Luís 
Bronze (Portugal), Sergio Buccheri (Sweden), Regina Dalmau (Spain), 
Maria Carmen De Pablo Zarzosa (Spain), Christian Delles (United 
Severe hypertension in pregnancy and pre-eclampsia
In pre-eclampsia or eclampsia with hypertensive crisis, drug treatment with i.v. labetalol or nicardipine and magnesium is recommended.
I
C
In pre-eclampsia or eclampsia associated with pulmonary oedema, nitroglycerin given as an i.v. infusion is recommended.
I
C
In severe hypertension in pregnancy: 
• drug treatment with i.v. labetalol, oral methyldopa, or oral nifedipine is recommended. Intravenous hydralazine is a second-line option.
I
C
11. Patient-centred care in hypertension
An informed discussion about CVD risk and treatment benefits tailored to the needs of a patient is recommended as part of hypertension 
management.
I
C
Home BP measurement for managing hypertension by using self-monitored BP is recommended to achieve better BP control.
I
B
Self-measurement, when properly performed, is recommended due to positive effects on the acceptance of a diagnosis of hypertension, 
patient empowerment, and adherence to treatment.
I
C
Multidisciplinary approaches in the management of patients with elevated BP and hypertension, including appropriate and safe task-shifting 
away from physicians are recommended to improve BP control.
I
A
© ESC 2024
ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ACR, albumin:creatinine ratio; AF, atrial fibrillation; ALARA, as low as reasonably achievable; ARB, 
angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; 
CVD, cardiovascular disease; DASH, Dietary Approaches to Stop Hypertension; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ESC, European Society of 
Cardiology; HBPM, home blood pressure monitoring; HFpEF, heart failure with preserved ejection fraction; HF(m)rEF, heart failure with (mildly) reduced ejection fraction; HMOD, 
hypertension-mediated organ damage; i.v., intravenous; MRA, mineralocorticoid receptor antagonist; RAS, renin–angiotensin system; SCORE2, Systematic COronary Risk Evaluation 2; 
SCORE2-OP, Systematic COronary Risk Evaluation 2-Older Persons; SGLT2, sodium–glucose co-transporter 2; TIA, transient ischaemic attack.
ESC Guidelines                                                                                                                                                                                          3993


<!-- PAGE 83 -->

### Page 83

Kingdom), Maria Manuela Fiuza (Portugal), Rahima Gabulova 
(Azerbaijan), Bjørn Olav Haugen (Norway), Christian Heiss (United 
Kingdom), Borja Ibanez (Spain), Stefan James (Sweden), Vikas Kapil 
(United Kingdom), Meral Kayikçioglu (Turkey), Lars Køber 
(Denmark), Konstantinos C. Koskinas (Switzerland), Emanuela Teresa 
Locati (Italy), Sharon MacDonald (United Kingdom), Anastasia 
S. Mihailidou (Australia), Borislava Mihaylova (United Kingdom), 
Richard Mindham (United Kingdom) Martin Bodtker Mortensen 
(Denmark), Sandor Nardai (Hungary), Lis Neubeck (United 
Kingdom), Jens Cosedis Nielsen (Denmark), Peter M. Nilsson 
(Sweden), Agnes A. Pasquet (Belgium), Mónica Mendes Pedro 
(Portugal), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), 
Ernst Rietzschel (Belgium), Bianca Rocca (Italy), Xavier Rossello 
(Spain), Jean-Paul Schmid (Switzerland), Eduard Shantsila (United 
Kingdom), Isabella Sudano (Switzerland), Ana Teresa Timóteo 
(Portugal), Georgios Tsivgoulis (Greece), Andrea Ungar (Italy), Ilonca 
Vaartjes (Netherlands), Frank Visseren (Netherlands), Heinz Voeller 
(Germany), Christiaan Vrints (Belgium), Adam Witkowski (Poland), 
Maria-Christina Zennaro (France), and Katja Zeppenfeld (Netherlands).
ESC National Cardiac Societies actively involved in the 
review process of the 2024 ESC Guidelines for the manage­
ment of elevated blood pressure and hypertension:
Albania: Albanian Society of Cardiology, Naltin Shuka; Algeria: 
Algerian Society of Cardiology, Nadia Laredj; Austria: Austrian 
Society of Cardiology, Noemi Pavo; Azerbaijan: Azerbaijan Society 
of Cardiology, Ulvi Mirzoyev; Belgium: Belgian Society of 
Cardiology, Philippe van de Borne; Bosnia and Herzegovina: 
Association of Cardiologists of Bosnia and Herzegovina, Šekib 
Sokolović; Bulgaria: Bulgarian Society of Cardiology, Arman 
Postadzhiyan; Croatia: Croatian Cardiac Society, Jure Samardzic; 
Cyprus: Cyprus Society of Cardiology, Petros Agathangelou; 
Czechia: Czech Society of Cardiology, Jiri Widimsky; Denmark: 
Danish Society of Cardiology, Michael Hecht Olsen; Egypt: Egyptian 
Society of Cardiology, Wael M. El-Kilany; Estonia: Estonian Society 
of Cardiology, Priit Pauklin; Finland: Finnish Cardiac Society, Jari 
A. Laukkanen; France: French Society of Cardiology, Romain 
Boulestreau; Georgia: Georgian Society of Cardiology, Bezhan 
Tsinamdzgvrishvili; Germany: German Cardiac Society, Ulrich 
Kintscher; Greece: Hellenic Society of Cardiology, Maria Marketou; 
Hungary: Hungarian Society of Cardiology, Dénes Páll; Iceland: 
Icelandic Society of Cardiology, Þórdís Jóna Hrafnkelsdóttir; Ireland: 
Irish Cardiac Society, Eamon Dolan; Israel: Israel Heart Society, 
Talya Wolak; Italy: Italian Federation of Cardiology, Grzegorz Bilo; 
Kazakhstan: Association of Cardiologists of Kazakhstan, Meiramgul 
Kapsimetovna Tundybayeva; Kyrgyzstan: Kyrgyz Society of 
Cardiology, Erkin Mirrakhimov, Latvia: Latvian Society of 
Cardiology, Karlis Trusinskis; Lebanon: Lebanese Society of 
Cardiology, Ghassan Kiwan; Libya: Libyan Cardiac Society, Omar 
Msalem; Lithuania: Lithuanian Society of Cardiology, Jolita 
Badarienė; Luxembourg: Luxembourg Society of Cardiology, 
Cristiana-Astra Banu; Malta: Maltese Cardiac Society, Matthew 
Mercieca Balbi; Moldova (Republic of): Moldavian Society of 
Cardiology, Alexandru Caraus; Montenegro: Montenegro Society 
of Cardiology, Aneta Boskovic; Morocco: Moroccan Society of 
Cardiology, Najat Mouine; Netherlands: Netherlands Society of 
Cardiology, Tom Vromen; North Macedonia: National Society of 
Cardiology of North Macedonia, Marijan Bosevski; Norway: 
Norwegian Society of Cardiology, Helga B. Midtbø; Poland: Polish 
Cardiac Society, Adrian Doroszko; Portugal: Portuguese Society of 
Cardiology, Hélder Dores; Romania: Romanian Society of 
Cardiology, Elisabeta Badila; San Marino: San Marino Society of 
Cardiology, Roberto Bini; Serbia: Cardiology Society of Serbia, 
Dragan Vojislav Simić; Slovenia: Slovenian Society of Cardiology, 
Zlatko Fras; Spain: Spanish Society of Cardiology, Pilar Mazón; 
Sweden: Swedish Society of Cardiology, Jonas Spaak; Switzerland: 
Swiss Society of Cardiology, Thilo Burkard; Syrian Arab Republic: 
Syrian Cardiovascular Association, Elias Barakat; Tunisia: Tunisian 
Society of Cardiology and Cardiovascular Surgery, Salem Abdessalem; 
Türkiye: Turkish Society of Cardiology, Yilmaz Gunes; Ukraine: 
Ukrainian Association of Cardiology, Yurij M. Sirenko; United 
Kingdom of Great Britain and Northern Ireland: British 
Cardiovascular Society, Adrian J. B. Brady; and Uzbekistan: Association 
of Cardiologists of Uzbekistan, Gulnoz Abdusattarovna Khamidullaeva.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
